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ABSTRACT
Metalloproteins requiring one or more metal ions for normal function make up 30 % of
all known proteins, and many critical biological pathways contain at least one metallo-enzyme.
Di-nuclear metallo-proteins constitute a large class of these proteins yet we currently lack
effective methods of inhibiting these enzymes for the development of new medical therapies,
particularly for the discovery of new antibiotics. Our work has focused on developing novel
functionalities that selectively interact with di-nuclear catalytic centers, and we are targeting
three separate di-zinc-metallo-enzymes that are unique to bacteria and play key roles in their
growth and development. These enzymes are DapE, AiiA, and NDM-1. DapE is involved in
biosynthesis of lysine and meso-diaminopimelic acid, essential precursors in the production of
bacterial cell walls. AiiA is a di-Zn-dependent lactonase involved in bacterial cell-cell
communication, and NDM-1 is a di-metallo-beta-lactamase capable of deactivating the most
commonly administered antibiotics, gaining international attention for this enzyme as a
clinically-relevant pharmaceutical target, yet drug development efforts have proven ineffective
due to a lack of effective inhibitors.
As part of our ongoing studies to functionally annotate the Gcn5-related Nacetyltransferase (GNAT) PA4794 from Pseudomonas aeruginosa with unknown functions, we
have used PA4794 as a model system for exploring efficient formation of bisubstrate complexes
to enhance our success rate in obtaining co-crystal structures of GNATs with ligands bound in
their acceptor sites. We have synthesized and tested substrate analogs of the previously identified
xxvi

N-phenylacetyl glycine lysine (NPAcGK) enabling two separate three-dimensional structures of
PA4794 with NPAcGK analog-derived bisubstrates formed through direct reaction with CoA—
the first through direct alkylation with a reactive substrate, and the second through X-ray induced
radical-mediated process. We have also performed docking and molecular dynamics simulations
of the reverse reaction pathway from the NPAcGK product back to formation of the tetrahedral
intermediate/transition state to complement our structural work and to explore the key ligandprotein interactions within the active site of PA4794, guiding mutant synthesis and kinetics to
explore the role of key residues in the active site.
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CHAPTER ONE
INTRODUCTION TO METALLOENZYMES
Overview
The metallome, described as the collection of transcriptome, proteome, and metabolome,
is the assemblage of biological macromolecules that share the common characteristic of
complexing metal ions into their protein tertiary structure to fulfill a given biological task.1, 2 The
themes expressed in this work can be, in large part, applied over the entire metallome. However,
the focus of this work pertains to the interaction of metals with proteins, referred to as the
metalloproteome.
Metalloproteins include any protein that is coordinated to a metal ion cofactor.
Metalloproteins (MP) have fascinated chemists and biochemists since 1960, when John Kendrew
and coworkers reported the first X-ray crystal structure of sperm whale myoglobin (PDB ID:
1mbn) bound to a single iron atom (Figure 1).3
Much is now known about metalloproteins, including how metal clusters are assembled
and introduced into target proteins and which metal ions are commonly found in metalloproteins.
Moreover, it has been estimated that such proteins make up more than 30% of the known
proteome.4 In fact, the majority of biological pathways contain at least one metalloprotein that
requires one or more metals in order to express its given biological function. Although
metalloproteins are known to participate in a wide range of biological functions, when a
metalloprotein is involved in catalyzing a biochemical transformation we refer to the class of
1

2
2

proteins as metalloenzymes.

Figure 1. The 1960 crystal structure of Myoglobin (PDB ID: 1mbn). Depicted is the Myoglobin
ribbon structure consisting of an eight α-helical backbone domain (blue) that wrap around a
central heme-binding domain containing a heme group (green) coordinating a single iron atom
(rust-red). The Fe atom is flanked by His93 on one side and bound O2 which further interacts
with His64.
The field of metalloenzyme studies has made substantial progress toward the
understanding of these interesting molecules. We are much closer to understanding the
mechanisms by which metalloenzymes catalyze a vast array of complex chemical reactions as
well as how we can use traditional chemical techniques to manipulate the metalloenzymatic
functions. However, despite more than half a century of research by chemists, biochemists, and
cell biologists, there is still much to learn about metalloenzymes. The work described herein is
our contribution to the understanding of metalloproteins through the investigation of novel
methods of small molecules interacting with pharmaceutically relevant metalloenzymes, and in
understanding their mechanism of action through computational methods.
Naturally occurring metalloenzymes utilize trace micronutrients found in the cellular
microenvironment. These micronutrient metal cofactors play a crucial role as Lewis acids for
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the host metalloenzyme in their biological catalytic function. Metalloproteins are coordinated to
metal cofactors in the protien’s active site referred to as the metal center through interactions
with nitrogen, oxygen or sulfur atoms belonging to amino acids in the protien chain, or a through
a porphyrin ring incorporated into the protein as in the case of myoglobin.3 All amino acid
residues have been shown to have the ability to coordinate metal centers. These metal cofactors
are most commonly Mg+2, K+1, Ca+2, Na+1, Fe+2/+3, Mn+2, Co+2, and Zn+2 but can also be other
less common trace metals such as Cu+2, Ni+2, Se+2, W+4, Mo+4, etc., and even occasionally
uranium.5-7 Metalloenzymes have evolved to coordinate a particular metal cofactor to enable
finely tuned catalytic transformations.8
Metalloenzymes are considered amongst the most proficient catalysts in terms of their
activity, selectivity, and ability to operate under mild conditions.8 Additionally, metalloenzymes
can express more than one biological functions’ depending upon metal cofactor composition
while maintaining a conserved protein sequence to create a new metalloisoform. When the metal
cofactor of a metalloenzyme is changed, subtle changes in the metal coordination sphere
manifest themselves as altered biological functions. This phenomenon is referred to as metal
promiscuity, metal plasticity and/or metal moonlighting, allows this class of proteins to change
its purpose through simply swapping one metal for another.
An excellent example of such metal promiscuity was reported recently by a team of
researchers from Northwestern University who found that at the moment of egg fertilization by
the sperm, organelles in the germocyte cells release a significant amount of Zn+2 ions from
specialized vesicles, dramatically increasing the Zn+2 concentrations within the zygote. Upon the
Zn+2 ion concentration spike, the Cu+2 ions coordinated in membrane-bound metalloenzymes are
displaced by Zn+2 ions, turning off the enzyme’s original function, thus resulting in the entire
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surface of the zygote becoming impervious to other sperm cell entry. Understanding the
plasticity of metalloenzymes is an important factor when designing methods to manipulate and
utilize metalloenzymes toward therapeutic strategies.
Therefore, absolute metal ion concentrations are tightly regulated in biological systems
through a system of metal uptake and extrusion protein complexes which maintaine metallohomeostasis in the organism. A variety of metal transport molecules ranging in size from simple
peptides like glutathione, to large proteins like serum albumin, and compartmentalization that
create metal ion gradients across membranes all for the expressed purpose of maintaining
organism homeostasis.10-13 Taken together, metalloenzymes have evolved over most of Earth’s
geologic past to be ideal biological tools for the maintenance and proliferation of all life.4
Challenges in Targeting Di-metalloenzymes
Di-nuclear metalloenzymes constitute a large class of proteins in the metalloproteome yet
we currently lack effective methods of inhibiting these enzymes for the development of new
medical therapies, particularly for the discovery of new antibiotics. The research herein is
focused on the investigation of novel methods of interacting with di-metalloenzymes of
pharmaceutical relevance, such as unexplored metal-binding functional groups that selectively
interact with di-nuclear catalytic centers and also on unique in silico analytical techniques to
probe enzymatic structure/function relationships. The task of finding new inhibitor strategies that
selectively interact with di-metallo catalytic centers is a challenging proposition. Towards this
aim, we have targeted three separate di-nuclear metalloenzymes that are unique to bacteria and
play key roles in their growth and development.
Metal Promiscuity and the Presence of Multiple Isoforms.
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Metal promiscuity and the presence of multiple isoforms (closely-related enzymes)
within biological systems is a common feature among di-metalloenzymes that adds an additional
challenge to targeted inhibition. This is due to Zn1-Zn2 and Zn1-[M]2 enzyme variants
comprising essentially two separate targets that may possess differing active site geometries and
enzymatic functionalities.14-17 Multiple X-ray crystal structures of di-Zn-MP have shown a
common catalytic site geometry, with two Zn(II) atoms bound in the active site ~3.30 Å apart
and bridged by a catalytic water molecule. The coordination sphere of the catalytic Zn metals
adopts a distorted tetrahedral geometry in the active site. One metal ion, Zn1, is bound more
tightly than the second metal site which can exchange a second Zn (II) for an alternative metal
ion in vivo or can function with only one Zn(I).14
Recent studies indicate the active site metal composition of the di-metallopeptidase DapE
may regulate the enzyme’s roles between mDAP and lysine biosynthesis and aspartate peptidase
activity. Broder and Miller have investigated the promiscuity of DapE acting as an aspartyl
peptidase in the presence of different metals by activating DapE with MnCl2, which replaces the
weaker bound Zn2 metal in the active site, and have shown the enzyme to catalytically cleave the
amide bonds of small dipeptide molecules with the general formula of Asp-X, most notably AspSer, Asp-Gly, and Asp-Leu dipeptides (Figure 2). It is also important to mention that Asp-Pro
was found to have absolutely no detectable binding with Mn-activated DapE.14, 15 Their results
revealed that DapE’s catalytic activity as a peptidase is up to 15x greater when the enzyme is
bound to manganese and zinc instead of two zinc ions and that in the Zn/Mn isoform the native
substrate N-succinyl-L,L-diaminopimelic acid (L,L-SDAP) and dipeptide Asp-X substrates
compete against one another for active site binding.
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Figure 2. Effect of divalent cations on DapE_Mn-catalyzed hydrolysis of Asp-Leu. An activity
level of 100 % is 222 mol/min/mg. Divalent cations (as chloride salts) were present at 1 mM.15
B) Substrate specificity of DapE_Mn for aspartyl peptides with Asp-Leu activity at 100 %.15 C)
Structure Comparison of known DapE Substrates.14
The native substrate of the di-Zn isoform of DapE, L,L-SDAP shows similarity with the
Mn-activated dipeptide Asp-X specificity and most likely shares key protein/substrate
interactions.15 However, the subtle changes in active site geometries coupled with the differing
binding properties of zinc and manganese shed light on the challenge of targeting differing
Zn/Zn, Zn/-, and/or Zn/Mn isoforms in vivo with a single broad-spectrum inhibitor class.14
Conformational Dynamics.
Major protein conformational changes play a key role in enzymatic activity in this class
of enzymes. Metalloenzymes are not static structures but rather are dynamic entities that are in
constant motion, therefore, addressing the dynamic nature of the proteins is critical.18 Any
successful inhibitory interaction may involve simultaneous interaction with two separate metallocenters at once while altering the dynamic movements of the proteins macrostructure.
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Catalytic Center.
A crucial issue pertaining to the synthesis of novel inhibitor classes for MPs containing
dinuclear metal centers stems from the nature of the catalyst itself. The dinuclear metal catalytic
centers activate simple water molecules in the strongly basic and potently nucleophilic hydroxyl
form that can cleave peptides or labile functionalities. Any inhibitor selective enough to bind to
the active site of a dinuclear metal active site must also be chemically stable enough to survive
this environment.
Metalloenzymes in Focus
Antimicrobial therapy has saved millions of lives over the past 80 years, yet our arsenal
of effective antibiotics is increasingly diminished by the alarming rise of bacteria that are
resistant to all currently available antibiotics.19 Over two million people annually in the United
States acquire infections that are resistant to antibiotics, and at least 23,000 people die as a result,
according to a report issued by the Centers for Disease Control and Prevention.20 In the U.S.,
antibiotic resistance adds $20 billion in additional direct health care costs, with cost productivity
as high as an additional $35 billion annually.21 According to the Infectious Disease Society of
America, at least ten new synthetic antibacterial drugs need to enter the market by the year 2020
in order to maintain the current quality of healthcare.22
There is an urgent need for antibacterial agents with new cellular mechanisms of action,
yet the pharmaceutical industry shows little interest in antibiotic research and development even
though bacterial infections are a global medical problem.23 Since the discovery of penicillin in
1928, and the Golden Age of Discovery (Figure 3), antibiotics have been a major tool in fighting
infections and saving and extending the lives of millions globally.
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Figure 3. Timeline of antibiotic discovery through medicinal chemistry.
Yet, the emergence of drug resistance in bacteria is reversing the advancements of the
past nine decades, with the treatment choices for many bacterial infections becoming
increasingly limited, expensive, and, in some cases, nonexistent. The Centers for Disease Control
and Prevention has recently reported that there are now several strains of Staphylococcus aureus
that are resistant to all known antibiotics including vancomycin, underlying the need for research
of new antimicrobial targets with previously unexplored mechanisms of action. Thus, researchers
have the arduous challenge of developing new methods for combating the spread of infectious
bacterial diseases.
The study of MPs has become a growing area of research with the rise of antibiotic
resistance in bacteria and the persistent problem of metallo-β-lactamases (MBL) that deactivate
our most important antibiotics. The impending dilemma of how to manage antibiotic resistant
superbugs and the need to discover novel mechanisms of action to block bacterial proliferation
has sparked our interest in the study of bacterial metalloenzymes, such as N-succinyl-L,Ldiaminopimelic Acid Desuccinylase (DapE), New Delhi Metallo-β-lactamase-1 (NDM-1), and
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AHL-lactonase (AiiA/AidC) (Figure 4), each of which possesses the unique dinuclear metal
center motif. Our strategies and efforts for addressing this dilemma are thus presented herein.
Efforts in our lab to selectively target di-metal specific catalytic sites in metalloproteins
have already led to the discovery of separate compound classes that can target each of these three
enzymes. These include N-acetyl-5-halo-indoline-6-sulfonamide, N-Cbz-indoline-7-(N-acylsulfonamides), simplified N-succinyl- and N-glutamyl aryl sulfonamides, and a series of novel
sulfonyl azide-derived sulfonyl triazoles, sulfonyl amidines, sulfonyl imidates and N-acylsulfonamides that show potential as di-metalloenzyme inhibitors and a small series of
cyclobutanones that have been shown to function as tetrahedral trasitions state memtics at the
catalytic metal center. We have developed robust chemical methods for making these new
inhibitors, enabling preparation of analogs to optimize activity. Preliminary docking results
suggest that these novel compounds may function as inhibitors over a broad class of dimetalloenzymes.

Figure 4. Enzyme active sites for A) N-succinyl-L,L-diaminopimelic Acid Desuccinylase
(DapE), B) New Delhi Metallo-β-lactamase-1 (NDM-1), C) AHL-lactonase (AiiA/AidC).
N-succinyl-L,L-diaminopimelic Acid Desuccinylase (DapE).
The bacterial enzyme N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) offers
an excellent target for the development of new antibiotics.24 DapE is one of the crucial enzymes
in the meso-diaminopimelate (mDAP)/lysine biosynthetic pathway utilized by most bacteria,

some archaea, some fungi, some algae, and plants.

25-28
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The products of this pathway, mDAP and

lysine, are essential components for the synthesis of the peptidoglycan cell wall in Gramnegative and most Gram-positive bacteria, hence inhibitors of enzymes within this pathway
should provide a new class of antibiotics. Since there are no analogous pathways in mammals,
inhibitors of enzymes in the mDAP/lysine pathway should exert selective toxicity against
bacteria without mechanism-related toxicity in mammals. Furthermore, it has been shown that
deletion of the DapE gene that encodes the DapE enzyme is lethal to Helicobacter pylori and
Mycobacterium smegmatis29, 30 and only in the presence of mDAP supplemented media was the
H. pylori deletion mutant able to grow, and not in the presence of only lysine supplemented
medium. Therefore, DapE is essential for prokaryotic growth and proliferation but is absent in
mammals, thus providing a very attractive antibiotic target with a new mechanism of action.24
Therefore, it is important to study this enzyme in the mDAP/Lys pathway, and enhance
the structural and mechanistic understanding of DapE through crystallographic studies of wild
type and selected mutants. It is of equal importance to synthesize potent and ultimately
druggable inhibitors toward a new generation of antibiotics.
New Delhi Metallo-β-lactamase-1 (NDM-1).
Multidrug-resistant Mycobacterium tuberculosis, methicillin-resistant and vancomycinresistant Staphylococcus aureus, and blaNDM-1/blaKPC Klebsiella pneumoniae are significant
global threats.31 β-Lactam antibiotics penicillin, cephalosporin and carbapenems represent more
than 50 % of antibiotic usage worldwide, and are among the cheapest and most effective
antibacterial agents available, but growing resistance to these drugs is a major concern.17
Metallo-β-lactamases (MBLs) are a diverse set of enzymes that catalyze the hydrolysis
of a broad range of β-lactam drugs conferring resistance to the bacteria. New Delhi metallo-β-
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lactamase 1 (NDM-1), shown in Figure 5, is a zinc-dependent metallohydrolase belonging to the
B1 family found in bacteria that confers resistance to commonly administered antibiotics,
including penicillins, cephalosporins, and carbapenems.17, 32, 33

Figure 5. Crystal structure of NDM-1 (B-factor ribbon model) bound to the hydrolyzed form of
the common antibiotic meropenem seen in orange (PDB ID: 4EYL).
Horizontal gene transfer has enabled the blaNDM-1 gene encoding NDM-1 to spread
between species, facilitating the development of multi-drug resistant bacterial strains.17, 34
Bacteria carrying the blaNDM-1 gene have been found on all continents, and consequently, NDM1 has gained international attention as a clinically relevant pharmaceutical target.32, 35-54 Known
inhibitors of MBLs, such as thiol-containing inhibitors, are prone to oxidation and challenges
with selectivity due to the thiol moiety.55 As such, drug development efforts of NDM-1 have
proven ineffective due to a lack of effective inhibitors.
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AHL-lactonase (AiiA/AidC).
AiiA-related metalloenzymes utilize a di-Zn metallo center to catalyze the hydrolysis of
important N-acyl homoserine lactones (AHLs) important for cell-to-cell communication between
bacteria.56-59 Development of drug-like molecules that are capable of targeting metal centers in
AiiA and related enzymes are predicted to disrupt the quorum sensing/quenching mechanism
between bacterial communities and provide another chemical tool for studying these systems.
Since each species of bacteria has specific and unique molecules for quorum sensing, tailor-made
inhibitors may modulate the risk of specific bacterial proliferation.59 Our collaborative work with
Dr. Liu’s crystallography research group to target AiiA di-Zn-dependent lactonase with a small
series of α-amido cyclobutanones possessing a C6 and C10 hydrocarbon tails, synthesized using
chemistry pioneered in the Becker research lab, has resulted in co-crystal structures of our
inhibitors bound to the metallo active site of AiiA-cobalt (AiiA_Co). The electron density of the
C6 cyclobutanone co-crystal was not resolved enough to make an accurate atom placement.
Surprisingly, because the extra length of the C10 alkyl chain was able to interact with the
hydrophobic phenylalanine clamp region of AiiA adjacent to the active site,60 atomic placement
of the C10 alkyl chain and cyclobutanone functionality of N-(2-oxocyclobutyl)decanamide was
assigned. However, the determination of the co-crystalized cyclobutanone did not show the
presence of the trapped tetrahedral transition-state mimetic of cyclobutanone (Figure 6), as
hypothesized, but rather the ring-opened product 4-decanamideobutanoic acid. The ring-opened
product was synthesized and comfirmed by NMR.
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Figure 6. Modeled structure of AiiA_Co AHL metallo-lactonase bound to N-(2oxocyclobutyl)decanamide as the tetrahedral transitions state mimetic.
Follow-up experiments were performed to determine whether the presence of the
observed ring-opened product originated from enzymatic catalysis or radiation damage during
crystallographic data collection. A discontinuous assay experiment was performed in
conjunction with radical catalyzed organic reaction screening with AIBN, H2O2, and H2O2 in the
presence of various metal salts. A series of radical-mediated synthetic experiments, including an
X-ray exposure assay performed at Argonne National Laboratory, were also carried out to assay
the ability of the cyclobutanone to be opened under chemical means. These experiments are in
progress and the results will be disclosed in due course.

CHAPTER TWO
INSIGHT INTO LARGE CONFORMATIONAL CHANGES, SUBSTRATE AND
PRODUCTS BINDING AND RELEASE IN N-SUCCINYL-L,L-DIAMINOPIMELIC ACID
DESUCCINYLASE
DapE’s Structural Background
The dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) is a latestage dinuclear zinc(II) dependent M20 metallopeptidase in the lysine biosynthetic pathway.25-27
Most bacteria, plants, and algae use this pathway to synthesize mDAP and lysine from aspartic
acid through three related pathways that diverge after the production of L-tetrahydrodipicolinate
(Figure 7). In bacteria, lysine biosynthesis is required for protein synthesis and is also used in the
peptidoglycan layer of Gram-positive bacterial cell walls. The amino acid meso-diaminopimelate
(mDAP), is also an essential component of the peptidoglycan cell wall for Gram-negative
bacteria.
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Figure 7. Biosynthetic Pathways of meso-diaminopimelic acid and lysine in bacteria. DapE is
indicated in red.61
The gene responsible for encoding the bacterial metalloenzyme DapE have been
identified in many pathogenic Gram-positive and Gram-negative bacteria and purified from
multiple sources. Furthermore, it has been shown that deletion of the dapE gene that encodes
DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis29, 62 Only in the presence of
mDAP supplemented media was H. pylori able to grow, but not in the presence of Lys
supplemented medium. Therefore, DapE is essential for bacterial cell growth and proliferation
but is absent in mammals, thus providing a very attractive antibiotic target with a new
mechanism of action.24
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Much of the biochemical and structural work on DapE enzyme has come from studies
performed by our collaborators Dr. Richard Holz and Dr. Boguslaw Nocek on model organisms
Neisseria meningitidis (NmDapE) and Haemophilus influenzae (HiDapE). X-ray structures63 of
DapEs from NmDapE and HiDapE revealed almost identical homodimeric architectures, as
expected given a high degree (57 %) of sequence identity. HiDapE has an elongated shape as
shown in Figure 8.

Figure 8. A) Ribbon diagram of HiDapE dimer and monomer, B) di-zinc active site, C) monozinc active site.
Each subunit of the dimer consists of two functional domains: an α/β catalytic domain,
which houses the active site, and the dimerization domain attached to the catalytic domain via
flexible linkers. The catalytic domains are enclosed by several functionally important loops, most
notably loop V seen in Figure 9.
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Figure 9. The active site of WT-HiDapE showing loop V in orange. T325 resides on loop V
directly over the dinuclear active site.
The location and architecture of the active sites are strikingly similar to the dinuclear
active sites of other members of M20 and M28 family of dinuclear Zn(II)-dependent
metalloproteases such as the leucine aminopeptidase AAP from Aeromonas proteolytica and the
carboxypeptidase CPG2 from Pseudomonas sp strain-RS-16.64, 65 The active site of DapE (Figure
8B) contains two Zn(II) ions at a distance of ~3.3 Å. Each of the Zn(II) ions adopts a distorted
tetrahedral geometry and is coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2)
and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are bridged by
additional carboxylate groups (D100) on one side and water/hydroxide on the opposite side,
forming a (μ-aquo)(μ- carboxylato)dizinc(II) core with one terminal carboxylate and one
histidine residue at each metal site. By limiting the amount of divalent metal ions present during
crystallization our group obtained both the mono‐ and dinuclear forms of the active site. In the
active site of mono-Zn(DapE), Zn1 resides in a distorted tetrahedral geometry coordinated by the
carboxylate oxygens (OD1) of D100 and (OE1) of E163 as well as one nitrogen atom (NE2) of
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H67 and an oxygen atom provided by a water molecule.

Analysis of mono and dimethylated DapE structures and previously reported kinetic and
spectroscopic studies on DapE enzymes allowed a refined mechanism of the catalysis for DapE
enzymes to be proposed (Figure 10).63, 66-68 It was proposed that the first step in catalysis for
DapEs is likely recognition of the L,L-SDAP side chain by the cavity adjacent to Zn1. Next, the
peptide carbonyl oxygen of L,L-SDAP coordinates to Zn1, expanding its coordination number
from four to five, and activating the carbonyl for nucleophilic attack. Deprotonation of the metalbound water molecule by E134 to form a nucleophilic hydroxide moiety is consistent with the
postulated pKa of the zinc-bound water molecule.25 Once the zinc-bound hydroxide is formed, it
could attack the activated carbonyl carbon of the substrate, forming a η-1-μ-transition-state
complex. Steady-state kinetic experiments verified a metal-dependent mechanism, with a Km for
N-succinyl-l,l-diaminopimelic acid of 1.3 mM and a turnover number of 200 s-1 in the presence
of zinc. Solvent kinetic isotope effect studies yielded an inverse kinetic isotope effect, that was
explained by the attack of a zinc-bound hydroxide on the amide carbonyl.25 E134 may provide a
proton to the penultimate amino nitrogen, similar to that observed for AAP, returning it to its
ionized state and facilitating product release.
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Figure 10. Previously proposed mechanism of DapE (a) mono zinc DapE and (b) dizinc DapE.63
Once the products are released, the water molecule bridging the two metal ions is
replaced. In the absence of a second metal ion, the catalytic mechanism does not likely change
markedly as H349 is in position to assist in orienting the substrate properly in the active site
through the formation of a hydrogen bond with a carboxylate side chain of the substrate, thereby
stabilizing the transition-state intermediate reminiscent to proposals for the mono-metallated
forms of AAP and EcMetAP.69-71 In the presence of a dinuclear site, it was proposed that the
second metal ion coordinates either the peptide carbonyl oxygen in a bridging fashion or a
carboxylate side chain of the substrate.
Structural analysis of M20 metalloproteases showed that these enzymes exist either as
dimers with both catalytic and dimerization domains, or as monomers having a single catalytic
domain, yet the substrate specificity of these enzymes remains poorly understood. To understand
the specific role of each domain of DapE, truncated versions of DapE were previously
engineered that possessed only the catalytic domain, are monomeric in solution, and closely
resemble AAP (Figure 11). It was found that removal of the dimerization domain in DapE
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rendered the enzyme inactive, suggesting that the dimerization domain function is critical in
catalysis.72
A

B

Figure 11. Ribbon diagrams showing DapE’s truncated catalytic domain from Haemophilus
influenzae (Green) in comparison to Aminopeptidase from Aeromonas proteolytica (Teal).
It was concluded that the dimerization domain likely restricts the conformational freedom
of the active site and contributes several residues to the active site environment (H194, R179,
R258, T325) that are important for substrate recognition and binding. Recent molecular
dynamics studies of DapE by Mishra73 further confirmed the results, suggesting plasticity of the
architecture of DapE, and suggested that the enzyme undergoes significant conformational
changes upon SDAP binding. Additionally, Mishra proposed a list of residues (K175, R178,
N345, K350) involved in binding.73
The binding mode of the DapE inhibitor L-captopril was revealed by 1.8 Å resolution
complex structure of NmDapE with L-captopril showing clear electron density corresponding to
L-captopril inside a positively charged binding groove formed between the catalytic and the
dimerization domains (Figure 12).74 The structural work revealed that the sulfhydryl group of Lcaptopril bridges the two active site Zn(II) ions while displacing the bridging water molecule
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(Figure 12B) The carboxylate of the proline moiety of L-captopril forms a hydrogen bond with
N346 (ND2–O3, 3.0 Å) and the amide of G325 (N–O2, 2.9 Å). It also makes a strong hydrogen
bond with the hydroxyl of Y198 (OH–O3, 2.5 Å), which reaches over from the second subunit of
the dimer. The significant interaction with the residues from the opposite dimerization subunit
of the dimer was certainly unexpected and indicates that both domains play a functional role in
substrate binding. The O1 peptide carbonyl oxygen of L-captopril forms a hydrogen bond with a
well-ordered water molecule (2.8 Å) that is stabilized by its interaction with R179 (NH2–O, 3.1
Å) and P165 (2.6 Å). Thiols are commonly used as inhibitors of Zn(II) metalloproteins because
Zn(II) is a relatively soft acid and thiols are soft bases, however, organosulfur compounds have a
higher potential for drug-induced toxicity and off-target interactions.
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Figure 12. ZnZn_NmDapE complex with L-captopril. A) Ribbon diagram of NmDapE
homodimer, subunits in blue and orange; B) active site with L-captopril, key residues, and a
water molecule (red sphere).
Product Bound DapE
We have characterized a new crystal form of DapE that was grown in the presence of the
substrate (L,L-SDAP). This structure unveiled HiDapE with the significantly changed
dimensions 47 × 45 × 111 Å (Figure 13B), with the active sites completely enclosed and
inaccessible, and where the enzymatic reaction has occurred producing a remarkable productbound complex. An overlay of the product-bound HiDapE and apo-HiDapE structures reveals
large domain shifts, with the catalytic domains rotated approximately 50 degrees and moved
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closer to the dimerization domains by ~11 Å. These results show that HiDapE enzyme undergoes
dynamic modulation between the open and closed states, likely induced by substrate binding.
The overall movement is consistent with a hinge domain mechanism, which enables both
domains to interact with the substrate. The HiDapE product-bound structure reveals the
surprisingly flexible nature of DapE`s active site and identifies several new protein-ligand
interactions which have not been predicted either by docking attempts or molecular dynamics.75
The HiDapE-product structure shows that the active site can be divided into succinic acid and
diaminopimelic acid binding pockets and that both domains play a key role in recognition and
catalysis. Furthermore, this structure has enabled application of our new computational analysis
to explore the enzymatic mechanism.

Figure 13. Structures of dimetaleted HiDapE in ligand free form (A: open conformation) and
HiDapE product bound form (B: closed-conformation) (C). Active site of HiDapE showing
binding interactions of succinic acid and diaminopimelic acid.
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Experimental Procedures
Protein Expression, Purification, Crystallization, & Structure Determination.
Detail cloning, expression and purification of HiDapE enzyme was performed by our
collaborator Dr. Boguslaw Nocek at Argonne national laboratory according to the standard
protocol described previously.72 Specifically, prior to crystallization 50 mM N-succinyl-LL-2,6diaminoheptanedioate (SDAP) was added to HiDapE protein and equilibrated on ice for 30 min.
Almost three hundred commercially available conditions were used for screening by the sittingdrop vapor-diffusion method at 16 °C using a Mosquito liquid handling robot with 96 well
plates. Crystals grew in 10-different conditions within 3 weeks. The best crystals were obtained
using 400 nl of a precipitant solution (0.05 M HEPES pH 7.3, 10.7 % (w/v) PEG MME 2000,
and 8.6 % (w/v) PEG 2000) and 400 nl of 18 mg/ml solution of HiDapE. The crystals belonged
to the orthorombic space group I222 with unit cell parameters a =56.6 Å, b = 135.5 Å, c = 149.6
Å, and α = β = γ = 90°, and one molecule within the asymmetric unit.
The presence of Zn ions in the protein crystals of HiDapE was confirmed by the X-ray
florescence spectrum. Data was collected on the 19-ID beam line of the Structural Biology
Center at the Advanced Photon Source using SBC-Collect software at a wavelength of 0.9795 Å
from the single crystals and were processed using HKL3000. The structure of the complex of
HiDapE was determined by molecular replacement using the catalytic and dimerization domains
separately (PDB ID 4H2K and 3ISZ)63, 72 as search models. Analysis and validation of the
structures were performed with the aid of MOLPROBITY and COOT validation tools. Figures
were prepared using Pymol. The atomic coordinates and structure factor file for the complexed
structure of HiDapE have been deposited in the RCSB Protein Bank with PDB ID: (TBD).

25
Product-Based Transition-State Modeling (PDTSM).
We employed the HiDapE product-bound structure as a starting point to model in reverse
chronological time back through a model of the tetrahedral intermediate and further back to a
hypothetical model of the bound substrate and the catalytic water in the active site of DapE. This
method, which we refer to as “Product-Based Transition State Modeling” (PBTSM), is intended
to provide a hypothetical model of the substrate binding geometry before initiation of the
catalytic cycle. This modeling technique was performed using the Chemical Computing Group’s
Molecular Operating Environment (MOE).76 A step-by-step description of the PBTSM protocol
is outline in Figure 14 below, which hereafter will be referred to as Figure14-Step# in the
following text to refer to steps 1 through 7.
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Figure 14. PBTSM Protocol.
After upload of the crystallographic data of the product-bound structure, the system was
prepared using MOE’s utility Structure-Prep to correct problems encountered in crystallographic
data such as missing loops, empty residues, chain termini or breaks, missing disulfide bonds or
atom names, picking alternate conformations, and other potential artifacts.76 The model was then
solvated in a simple water box at pH of 7.4 (Figure 15A) which was treated with NaCl counter
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ions to balance the charge (Figure 15B). Periodic boundary conditions were enabled, and the
hydrogen bonding network of the model was optimized by automatic sampling different
tautomer/protomer states using Protonate3D.77 Protonate3D is employed to calculate optimal
protonation states, including titration, rotamer and “flips” using a large-scale combinatorial
search.78 A localized energy minimization was run on the solvated system using the MOE
function QuickPrep (Figure 15C) followed by a short global minimization to equilibrate the
system for further modeling. After structural preparation, solvation and energy optimization
using MOE, the product bound HiDapE molecular model is referred to as the model
Suc_DAP_DapE_PC (Figure 14-Step1).
A

B

C

Figure 15. A) Solvent Box of LLSDAP transition state intermediate DapE model. B) Solvate
Function. C) QuickPrep Function.
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Upon completion of system equilibration, product atom coordinates were used to model
the tetrahedral transition state intermediate of the substrate-catalytic hydroxyl bound structure.
This model was referred to as the LLSDAP-TS_DapE_PC model and reflects the moment just
after nucleophilic attack by the activated hydroxyl group at the amide carbonyl of the substrate
which forms the tetrahedral transition state intermediate but just before cleavage of the scissile
amide bond. The double bond of the succinyl carbonyl, proximal to di-Zn metal center, were
converted to a single bond using the Builder utility in MOE. The scissile amide bond was then
reformed by creating a bond between the ammonium nitrogen of DAP to the carbonyl carbon of
succinate atoms proximal to the metal cofactors. The results of the remodeling are the creation
of a distorted tetrahedral transition state intermediate of the substrate and catalytic hydroxyl
group possessing distorted bond distance/angles (Figure 14-Step2). It should be noted here that a
transition state by definition is an energy maximum whereas the tetrahedral intermediate is a
local energy minimum, yet given that formation of the tetrahedral intermediate is an endothermic
process, Hammond postulate states that the tetrahedral intermediate is a good approximation of
the transition state. In medicinal chemistry, a mimetic of the tetrahedral intermediate is a
transition state mimetic, and the language herein reflects this convention.
At this point, the hydrogen bonding network was manually optimized, and charge
adjustment of the tetrahedral atoms in the transition state was applied to the formal charges of the
ammonium nitrogen and the alkoxide oxygen associated with the amide carbonyl of the
substrate, resulting in a neutral and negative charge respectively. This was followed by
hydrogen bond network optimization of the important active site residues critical for catalysis
and transition state intermediate stabilization. These residues were manually adjusted so that
active site formal charges kept the overall net charge of the system balanced throughout the
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process and conservation of matter was strictly adhered to. In total, these minor, but critical
system adjustments most heavily affected the ionization states and hydrogen bonding motifs of
the general acid-base Glu134, the amide associated nitrogen and oxygen atoms, and the catalytic
water/hydroxyl group atoms. At this stage in the protocol, a localized minimization was
conducted to normalize the bond distances/angles of the L,L-SDAP-OH transition state
intermediate to reasonable values as well as balance the net charges of ligand/receptor system
(Figure 14-Step3).
Following preparation of the in silico generated substrate transition state intermediate
model, a relatively short 1.0 ns molecular dynamics equilibration was performed using an NPA
algorithm with a Amber12:EHT force field (Figure 16). The MD experiment was initiated with
parameters as followed: initial heating from 0 K to 300 K over 100 ps followed by equilibration
for 100 ps at 300 K, followed by a 700 ps production run, and finally a 100 ps cooling from 300
K to 0 K (Figure 14-Step4). After completion of the dynamics equilibration run, two major
changes were observed in the transition state intermediate bound model. The hydrogen bond
network strengthened, as indicated by swelling hydrogen bond and vdW contact-cylinder
representations between ligand and receptor, and an increase in atom distance of the catalytic Zn
metals from 3.3 Å to 3.97 Å was observed.

30

Figure 16. Molecular Dynamics Protocol Window in MOE.
Step 5 in the PBTSM protocol used the final transition state intermediate model from the
previous step to estimate the atomic coordinates of the catalytic hydroxyl group and native
substrate bound to the metal center of the product binding conformation of DapE. This
following model was referred to as the LLSDAP_OH_DapE_PC model and reflected the
moment just after deprotonation of the catalytic water by general acid-base Glu134 but just
before nucleophilic attack by the activated hydroxyl group at the amide carbonyl of the substrate.
MOE’s Builder utility was again utilized to first remove the bond between the tetrahedral carbon
center and the oxygen closest to the Zn ion and Glu134 followed by a ionization state adjustment
of the newly formed catalytic water/hydroxide oxygen to a negative ( O--C---X---OH to O--C
OH). Thus, the catalytic hydroxyl group, coordinated to the metallo-center, was modelled into
the system in the approximate area observed in other known crystal structures of DapE. Next, a
double bond was reestablished between the tetrahedral carbon center and the anionic oxygen of
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the transitional state ( O -C-NH to O=C-NH) to reform the amide carbonyl. Finally, a local
minimization with constraints was initiated to correct for distorted molecular bond angels and
distances resulting from the Builder manipulations (Figure 14-Step5).
After the in silico generated substrate and catalytic hydroxide model was prepared, a
second 1.0 ns molecular dynamics equilibration was performed using an NPA algorithm with a
Amber12:EHT force field. The MD experiment was initiated with parameters as followed:
initial system heating from 0 K to 300 K over 100 ps followed by an equilibration stage at 300 K
over 100 ps before an 800 ps production run at constant temperature. The dynamics experiment
was concluded with a final 100 ps cooling stage from 300 K to 0 K (Figure 14-Step6).
The last step in the PBTSM protocol was a continuation of the previously generated
model which was used to estimate the atomic coordinates of the catalytic water group and native
substrate bound to the metal center of the product binding conformation of DapE. This last
model was referred to as the LLSDAP_HOH_DapE_PC model and reflected the moment just
after substrate complexation to the metallo active site, displacement of the metal-bridging
catalytic water to a single Zn ion closest to the general acid-base Glu134 and subsequent
conformational closure of the active site by the dimerization domain thus forming the product
binding conformation of DapE. This model’s point in time also falls just before activation of the
catalytic water by Glu134 deprotonation. The final model was generated using Protonate3D
followed by QuickPrep to reoptimize the hydrogen bonding network and perform a localized
energy minimization before a final global energy minimization. The final steps in the PBTSM
modeling protocol results in deprotonation of the neutralized carboxylic acid side chain of
Glu134 along with a simultaneous protonation of the catalytic hydroxyl group (Figure 14-Step7).
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Molecular Dynamics for Analysis of Product Release.
Former undergraduate researcher Kaitlyn Lovato, in collaboration with Dr. Ken Olsen,
employed NAMD to gain insight into the structural dynamics of DapE. Using our previously
reported open conformation of DapE and guided by the newly-obtained structure of DapE with the
cleaved substrate products, L,L-DAP and succinate were modeled into both active sites of DapE
in Visual Molecular Dynamics (VMD). In a computer generated solvent box, a 50 ns molecular
dynamics (MD) experiment was run using NAMD. The reaction products did not move in the 50
ns experiment, so this was followed by a series of 8 steered molecular dynamics (SMD)
experiments, each of 40 ps duration (Figure 17). In these simulations, an additional unit vector
force was directed from one of the nitrogen atoms in L,L-SDAP out of the active site towards a
water molecule in the solvent box at different angles out the active site. One SMD simulation
resulted in succinate, which is deeper in the active site, moving out of the active site in addition to
the movement of L,L-DAP into the solvent. These SMD experiments provide insight into the
favorable and unfavorable exit trajectories for the DapE reaction products.

Frame 0
Frame 13
Frame 15
Frame 24
Frame 28
Figure #: A series of snapshots of one of the dimers of DapE from a 40 ps steered molecular dynamics
experiment.
total simulation
was 36of
frames
in VMD
a stride
of 100
Figure 17. The
A series
of snapshots
one visualized
of the dimers
ofwith
DapE
from
a 40frames
ps steered molecular

dynamics experiment. The total simulation was 36 frames visualized in VMD with a stride of 100
frames.
Results and Discussion
HiDapE in the Closed Conformation
In our previous studies, we reported the apo-structure of HiDapE, which revealed the
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structure of the DapE enzyme in the open conformation (DapE_OC). In this conformation, the
63

catalytic and dimerization domains adopt an extended conformation with dimensions 50 × 44 ×
121 Å. The active site clefts, which are located between the two domains in the center of the
catalytic domains that coordinate the metal ions, are broadly open. The open conformation
allows easy access to the di-zinc centers (Figure 13A). Addition of the substrate (SDAP) to the
protein prior to crystallization yielded a new crystal form that has not been observed previously.
In this crystal form, Dr. Nocek was able to capture the enzyme in the products-bound state, with
succinate and L,L-diaminopimelic acid as both products are clearly observed and modeled into
the Fo-Fc omit electron density map.
The 1.95 Å resolution product-bound structure unveiled the HiDapE enzyme in the
significantly changed conformation with the dimensions 47× 45 × 111 Å (Figure 13B) and close
comparison of the product-bound HiDapE (DapE_PC) structure to its previously determined
apo-HiDapE structure revealed a large domain movement of the catalytic domains. The overlay
of the open and closed conformations reveals that in the product bound-conformation the
catalytic domains rotated and shifted approximately 50 degrees and 11 Å (as measured at the
position of Zn atoms) relatively to the dimerization domain, effectively closing the access to the
active site. The extent of movement is shown in Figure 13A and 13B. These two states clearly
show that HiDapE enzyme undergoes dynamics modulation between the different catalytic states
presumably to bind and activate the substrate in the active site. The overall characteristic of the
closure movement is consistent with the hinge domain movement mechanism reported for
Allantoate Amidohydrolase from Escherichia coli, beta-alanine synthase from the yeast
Saccharomyces kluyveri, and the antibiotic resistance factor HmrA from methicillin-resistant
Staphylococcus aureus,79-81 which allows a twist and turn movement at the inter-domain linker.
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Succinic Acid & LL-Diaminopimelic Acid Binding Revealed.
The HiDapE product-bound structure unveiled the surprising flexible nature of DapE`s
active site and identified several new protein-ligand interactions which have not been predicted
either by docking attempts or molecular dynamics studies.75 The HiDapE-product complex show
that the active site can be segmented into two distinct binding pockets for succinic acid and for
diaminopimelic acid (Figure 18). The succinic acid binding pocket is postioned adjacent to the
Zn metal center as highlighted in the cyan box, in Figure 13C. The succinic acid is bound in such
way that one of the carboxylate moieties bridges between two Zn ions while simultaneously
interacting with the hydrogen bond donor His194.B located on the dimerization domain of the
opposing chain. The other carboxylate forms the salt bridge interaction with Arg178, and forms
H-bonding interactions with Tyr197.B also from the opposing dimerization domain.

Figure 18. Shown is a surface structure cross-section of the closed product conformation of
DapE with products succinate and DAP bound in the active site.
The interactions with diaminopimelic acid are shown in the yellow box in Figure 13C.
Similar to succinic acid, the diaminopimelic acid interacts with HiDapE through the interaction
of its carboxylate groups with the side chains of following residues: Ser181, Asn244.B,
Asn245.B, Ser290, Arg258. The results clearly show that residues supplied by both domains play
a key role in catalysis, and it is noteworthy that many of these residues are highly conserved in

35
DapE protein sequences.
Product-Based Transition-State Modeling Analysis
The structure of the catalytically-generated products of L,L-SDAP in the active site of
DapE reveals important protein-ligand interactions and implicates previously unidentified
residues in the stabilization of the L,L-SDAP tetrahedral intermediate/transition state complex of
DapE. We have employed the in silico modeling technique that we refer to as “Product-Based
Transition State Modeling” (PBTSM), to model hypothetical native substrate and the catalytic
water/hydroxide bound to DapE as well as the substrate transition state intermediate-bound DapE
model, and could also be applied to non-substrate studies in the future. This technique, described
in Figure 14, employed the product-bound crystal structure as a starting point to generate these
models in reverse chronology back through the substrate tetrahedral intermediate and two native
substrate-catalytic water/hydroxyl binding modes.
The atomic coordinates of the structurally prepared model of the original product bound
DapE crystal structure, Suc_DAP_DapE_PC were used to generate three additional DapE
molecular models of substrate species at key stages along the enzyme’s catalytic trajectory. That
being the LLSDAP_HOH_DapE_PC substrate bound with unactivated catalytic water model
(Figure 19D), LLSDAP_OH_DapE_PC substrate bound with activated catalytic hydroxide
model (Figure 19C), and the LLSDAP-TS_DapE_PC transition state intermediate bound model
after nucleophilic attack of the amide by the catalytic hydroxide (Figure 19B). The free energy of
binding was calculated by the Generalized Born Volume Integral Weighed Surface Area
(GBVI/WSA) ΔG method using MOE. The GBVI/WSA is a forcefield-based scoring function
which estimates the free energy of binding of the ligand from a given pose and is reported in
units of kcal/mol. It has been trained using the MMFF94x and AMBER99 forcefield on the 99

36
protein-ligand complexes of the solvated interaction energy (SIE) training set.
A

B

82, 83
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Figure 19. Model results as each stage of Product-Base Transition-State Modeling. A) Succinate
& DAP products bound to the closed conformation of DapE, generated from crystal structure
obtained from Dr. Nocek. B) L,L-SDAP transition state intermediate bound to the closed
conformation of DapE, generated through PBTSM. C) L,L-SDAP and activated cat. hydroxyl
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group bound to the closed conformation of DapE, generated through PBTSM. D) L,L-SDAP and
unactivated cat. water bound to the closed conformation of DapE, generated through PBTSM.
Atoms associated with succinate and DAP are colored cyan and yellow while protein chains A
and B are colored dark green and orange respectively.
In the GBVI/WSA method, the free energy of substrate binding to the DapE enzyme is
obtained as the sum of the contributions from average gain/loss of rotational and translational
entropy, Coulombic electrostatic free energy, the free energy of solvation, van der Waals
contributions to binding, and the free energy contribution of surface area, weighed by exposure
which penalizes exposed surface area, whereas the alpha and beta terms refer to constants which
are determined during training. This calculation is expressed in Eq. (1) below.
2

∆𝐺 ≈ 𝑐 + 𝛼 [3 (∆𝐸Coul + ∆𝐸sol ) + ∆𝐸vdW + 𝛽∆𝑆𝐴weighted ]

Eq. (1)

Binding Affinities found for all four molecular models in the PBTSM series are
summarized in Table 1. The free energy trends are in agreement with expected energy profile for
enzyme catalyzed hydrolysis.
Table 1. GBVI/WSA ΔG Binding Affinity Calculations for PBTSM-Generated Structures.
Model ID
Figure Ref. GBVI/WSA ΔG
LLSDAP_HOH_DapE_PC (Figure 19D) -21.58 kcal/mol
LLSDAP_OH_DapE_PC (Figure 19C) -20.68 kcal/mol
LLSDAP-TS_DapE_PC
(Figure 19B) -34.86 kcal/mol
Suc_DAP_DapE_PC
(Figure 19A) -30.79 kcal/mol
Super positioning of the models and analysis of the binding interaction reveals four main
ligand-enzyme interaction zones as described in Figure 20 below. These zones are the catalytic
metallo-center, the distal carboxylate of the succinyl subunit, the proximal carboxylate of the
DAP subunit, and the distal amino acid end of the DAP segment. These zones of substrateligand interaction work together to orient the scissile bond of the native substrate optimally over
the catalytic metal center while simultaneously creating Coulombic and van der Waals
interactions along the active site cleft between the opposing catalytic and dimerization domains.
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The interaction at this interface by the substrate functions as the glue that stabilizes the
interfacial interaction between the two opposing enzyme domains which keeps DapE in the
closed conformation.

Figure 20. Shown are four major zones of ligand-enzyme interaction as seen in LLSDAPTS_DapE_PC. A) Bond distance of transition state intermediate bound to metal center. Binding
analysis of transition state intermediate after molecular dynamics and minimization: B) Distal
carboxylate of succinyl segment, C) Proximal carboxylate of TS bound DAP segment, D) Distal
end of DAP segment.
Hypothetical Conformational Changes Drive Catalysis.
It has become clear that major conformational changes in the structure of DapE are a
critical component in the function of the enzyme. In the open conformation of DapE the metallo
active site is open to solvent and the dimerization domains of the opposing chain are situated
above. The initial open conformation of DapE, as seen in the previously reported crystal
structures 3IC1 & 5UEJ, facilitates an open binding site for the succinyl potion of the substrate
to fill the hydrophobic binding pocket with a positive charge at the bottom of the pocket while
the terminal mDAP carboxyl group can interact with the two arginine residues, Arg244 and
Arg258, located in or near the hinge region of DapE. The Colombic interactions formed by the
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distal end of the substrate also lie in close proximity to Tyr197.B and His194.B. Once
interactions are made with DAP by the opposing dimerization residues a contraction of the dimer
superstructure flexes and twists the hinge region. The enzyme conformational movement leads
directly to closure of substrate binding pocket by the dimerization domain residues and
orientation of the scissile peptide bond onto Zn1, displacement of the bridging catalytic water on
Zn2, deprotonation by general acid base Glu134 and subsequent catalytic hydrolysis of the
substrate. Upon catalytic turnover and cleavage of the scissile bond, the tethering interaction
between the two domains holding the active site closed is interrupted. The subsequent increase
in entropy leads to the release of the products and reformation of the open conformation of
DapE.
Substrate Specificity Regulates Formation of Transient Oxyanion Hole.
The concept of an oxyanion hole is a well-established enzyme characteristic in
biochemistry, specifically when referring to serine or serine-like hydrolase/peptidase enzymatic
functions. The oxyanion hole refers to a pocket in the active site of an enzyme that stabilizes the
tetrahedral transition state negative charge on a deprotonated oxygen or alkoxide. This residue
motif typically consists of backbone amides or positively charged side chain residues. This
functions to stabilize the transition state while lowering the activation energy necessary for the
reaction, and so promotes catalysis.84, 85
Analysis of the models described herein suggests a transient oxyanion hole that is utilized
by the enzyme to modulate both catalytic turnover and substrate specificity for DapE (Figure
21). One of the two H-bond donors of the transient oxyanion hole provided by His194 from the
dimerization domain and the other through a single Zn cofactor from the opposing catalytic
domain.
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Figure 21. Hypothesized transient oxyanion hole in the (A) catalytically active form, (B)
catalytically inactive form.
The concept of a transient oxyanion hole gating and its role in substrate specificity is, to
my knowledge, an unidentified enzymatic characteristic shared among many different dimetalloenzymes to regulate catalytic turnover. Information about substrate shape is incorporated
into an enzyme catalytic feedback loop which imparts a conformational response by the enzyme
to accommodate the substrate. As seen with many M20 metallopeptidase such as, Human
Carnosinase-2 (CN2) (Figure 22), Dug1p from Saccharomyces cerevisiae, Staphylococcus
aureus metallopeptidase (Sapep) and now DapE, enzymes possessing a high degree of substrate
specificity often require an equally high degree of conformation dynamics in the enzyme’s
macrostructure to facilitate catalytic turnover. If a potential substrate cannot activate the requisite
conformational change needed to create a full residue-metallocofactor oxyanion hole and thus
activate it for transitions-state stabilization, then catalytic turnover will not proceed.
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Figure 22. Trapped product bound conformation of Human Carnosinase-2 (CN2) (PDB I.D.
4RUH) trapped in the closed conformation by inhibitor bestatin interacting with metal center and
a highly-conserved histidine.
Conversely, in the notoriously un-specific metallo-β-lactamase NDM-1, catalytic
turnover is facilitated by a similar transient oxyanion hole that is formed by Asn220 and the Zn1
of the di-Zn system (Figure 23). However, the loop associated Asn220 is much smaller and is
conformationally stabilized closer to the metallo active site, thus leading to less specific
activation of the oxyanion components and leading to more flexible and promiscuous βlactamase activity.18, 47, 86-88
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Figure 23. NDM-1 active site cleft with a modeled meropenem transition state intermediate
bound at the metal center. Enzyme represented in B-factor with ribbon diagram shown as wire
except for the hairpin loop and binding loop I.18, 47, 86-88
Updated Catalytic Mechanism of DapE.
The product bound X-ray structures of DapE prompted us to reconsider the catalytic
mechanism previously proposed. The first step in the updated catalysis for DapE remains initial
recognition of the L,L-SDAP by the solvent accessible crescent-shaped cavity residues in the
open conformation. Subsequent induced conformational change in DapE’s structure induces
interfacial interaction between the catalytic and dimerization domains facilitating stabilization of
the substrate transition state interaction. During the conformational change, the peptide carbonyl
oxygen of L,L-SDAP coordinates to Zn1 which is followed by formation of an activated
transient oxyanion hole by alignment of His194.B from the dimerization domain. Strong
interactions made by the Zn and His194.B to the carbonyl oxygen leads to polarization of the
carbonyl oxygen and activation the carbonyl for nucleophilic attack at the carbon center.
Carbonyl coordination to Zn1 by L,L-SDAP simultaneously leads to displacement of the
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bridging catalytic water group onto Zn2. Movement of the catalytic water onto Zn2 brings it in
optimal proximity to the general acid base Glu134 where deprotonation of the metal-bound water
molecule by Glu134 forms the nucleophilic hydroxide moiety. This is consistent with the
postulated pKa of the zinc-bound water molecule.25 Once the zinc-bound hydroxide is formed, it
can attack the activated carbonyl carbon of the substrate, forming a transition-state complex.25
Solvent kinetic isotope effect studies yielded an inverse isotope effect that was explained by the
attack of a zinc-bound hydroxide on the amide carbonyl.25 As seen with similar M20
metalloenzymes such as AAP and elucidated further by PBTSM evidence described herein,
Glu134 then provides a proton to the penultimate amino nitrogen, returning it to its ionized state
thus facilitating product release.69 Once the products are released, a water molecule bridging the
two metal ions is replaced.
In the absence of a second metal ion, the catalytic mechanism does not likely change
markedly as H349 is in position to assist in orienting the substrate properly in the active site
through the formation of a hydrogen bond with a carboxylate side chain of the substrate, thereby
stabilizing the transition-state intermediate reminiscent to proposals for the mono-metalated
forms of AAP and the methionine aminopeptidase from E. coli.69-71 However, the product bound
crystallographic data presented here suggest that in the presence of a dinuclear site, the second
metal ion likely does not coordinate the proximal carboxylate side chain of the substrate’s DAP
subunit. More likely, the proximal carboxylate participates in bifurcated H-bonds with the side
chains of Arg258.A, Thr325.A and Asn245.B which is more reminiscent of what is known about
substrate binding in Metallo-Β-lactamase NMD-1.39, 89, 90
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Conclusions
We have presented a previously unidentified product bound crystal structure of DapE in
complex with products succinate and DAP which were generated through co-crystallization of
DapE with the native substrate L,L-SDAP. This new crystal structure shows clear
conformational changes in the overall enzyme structure that we believe to be critical in
structure/function relationship for DapE. The single turnover catalytic hydrolysis of the substrate
observed in the solid-state crystal structure of DapE allowed for modeling of key steps in the
mechanistic process that lead to the observed products bound in the active site by utilization of
the in silico modeling technique that we refer to as “Product-Based Transition-State Modeling”
(PBTSM). The results of these models, in combination with previously reported DapE crystal
structures and molecular dynamics publications, help to form a more complete story of how
DapE catalyzes the hydrolysis of L,L-SDAP. In summary, the results obtained from the studies
described herein have provided new insight into the structure and function of DapE enzymes and
additional insight into the catalytic mechanism of DapE. Determination and understanding of
substrate binding will be critical for the rational design of future selective DapE inhibitors that
may function as a new class of antimicrobial agents.
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CHAPTER THREE
SUBSTRATE ANALOG SYNTHESIS AND NINHYDRIN-BASED ENZYME ASSAY FOR
THE BACTERIAL ENZYME DIAMINOPIMELATE DESUCCINYLASE
Introduction
The sharp increase in mortality and morbidity due to rising general infections caused by
antibiotic-resistant bacteria underlines the need to discover previously unexplored enzymatic
mechanisms as novel antibiotic targets with the goal of developing new molecular leads. For
example, invasive methicillin-resistant Staphylococcus aureus (MRSA) is a serious and growing
health problem.91 Several newly discovered strains of MRSA show antibiotic resistance even to
vancomycin, which has been considered for decades as the standard for the treatment of systemic
infections.92 An attractive bacterial target is the dapE-encoded N-succinyl-L,L-diaminopimelic
acid desuccinylase (DapE, E.C. 3.5.1.18)) enzyme which is a member of the succinylase
pathway in bacteria that provides both lysine and m-DAP,24 since these metabolites are essential
in bacteria both for protein production and for bacterial peptidoglycan cell-wall synthesis. DapE
catalyzes the hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP) to succinate and L,Ldiaminopimelic acid (Scheme 1). Deletion of the dapE gene is lethal to Helicobacter pylori and
Mycobacterium smegmatis demonstrating the indispensable role of this bacterial enzyme in most
pathogenes.29, 62 Furthermore, lack of a similar pathway in humans suggests that selective
inhibition of DapE may be toxic to bacteria but not to human hosts, making it a promising
pathway to exploit for antibiotics with a new mechanism of action.24
47
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It had been demonstrated by Cosper et al. that DapE is a dinuclear metallohydrolase,
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but later it was shown with high-resolution X-ray crystal structures that functionally relevant
DapE enzymes may have either one or two zinc ions bound in the active site. These structures
have enabled further refinement of a mechanistic hypothesis of peptide bond cleavage by DapE
enzymes which have facilitated inhibitor identification.63 A small, focused screen of compounds
containing zinc-binding groups identified the thiol-containing ACE inhibitor captopril as a low
micromolar competitive inhibitor of DapE from Haemophilus influenza (IC50 = 3.3 μM) along
with several other small molecule inhibitors including 3-mercaptobenzoic acid (IC50 = 35 μM),
phenylboronic acid (IC50 = 107 μM) and 2-thiopheneboronic acid (IC50 = 92 μM).93 A highresolution (1.8 Å) X-ray crystal structure of captopril bound to DapE from Neisseria meningitidis
revealed a thiolate-bridged dinuclear Zn(II) active site complex and provided a model for in
silico approaches to identify potential inhibitors of DapE.94
Scheme 1. Conversion of SDAP substrate by DapE.

SDAP (1a) and analogs N6-methyl SDAP (1b), N6,N6-dimethyl-SDAP (1c), and N6-acetylSDAP (1d) with corresponding hydrolysis products succinate (2) and L,L-diaminopimelic acid
derivatives (3a-d).
Gelb first isolated the DapE enzyme from Escherichia coli and characterized it with its
natural substrate SDAP, which exhibited a Km value of 0.4 mM and a turnover rate of 16,000
min-1, as well as several substrate analogs.95 Further work on substrate analogs was taken up by
Holz, in addition to investigating the differences in activities of the zinc and cobalt metal
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isozymes of DapE, and it was revealed that DapE is inactive toward the substrate analog lacking
the free N6-amino group.96 Several assays have been developed for examining inhibitors of
DapE. The original assay97 for DapE took advantage of the fact that DAP reacts somewhat faster
with ninhydrin than with SDAP, but this assay suffered from a lack of reproducibility. Gelb then
developed two new assays for DapE. The first employed 14C-labeled SDAP followed by
scintillation counting of liberated 14C-succinate. The second was a coupled assay utilizing
porcine succinate thiokinase and inositol triphosphate to convert liberated succinate to succinylCoA and inositol diphosphate. The inositol diphosphate was then detected by its reaction with
phosphoenolpyruvate to yield liberated pyruvate, itself being detected spectrophotometrically
using lactate dehydrogenase. Finally, in our own earlier work, inhibitors of DapE were assayed
against zinc-reconstituted DapE by monitoring amide bond cleavage of L,L-SDAP at 225 nm
utilizing L,L-SDAP as a substrate (225 nm = 304 M-1cm-1).93 All of these assays suffered
serious limitations. The original ninhydrin assay employing native or racemic SDAP, as noted,
had very poor reproducibility. The 14C-labeled substrate assay required working with
radioactivity with extra safety protocols and waste disposal issues. We employed Gelb’s coupled
assay with some success, but found it to be technically troublesome and therefore unreliable.
Finally, the assay measuring cleavage of the simple amide bond of the substrate at 225 nm is
simple and reliable, but precludes the testing of inhibitors that absorb strongly in the ultraviolet
region, thus ruling out testing of many preferred medicinal chemistry leads and analogs.
The desire for a robust and higher throughput assay for supporting our medicinal
chemistry efforts toward the discovery of DapE inhibitors as new antibiotics led us to consider
developing a new assay. Gelb’s and Holz’s work demonstrated strict structural requirements for
the substrate in order to be cleaved by the enzyme: The free amino group of SDAP is important
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for substrate recognition as SDAP lacking the basic 6-amino group (at the non-succinylated end)
was hydrolyzed at only 0.036 % of the rate of the natural SDAP substrate.95. Recognizing the
ease and reliability of a ninhydrin-based assay to detect the release of the primary amino group
upon cleavage of the succinate amide, we explored whether we could block the reactivity of the
free amino group of the substrate to prevent interference caused by its reaction with ninhydrin.
We prepared both N6-acetylated and N6-methylated derivatives of SDAP, and deprioritized the
contemplated N,N-dimethyl SDAP analog based on molecular docking and modeling.

Figure 24. Generic diagram of Ninhydrin Assay implementation.
DapE Molecular Modeling to Assess Mono- Vs. Dimethyl-SDAP Analogs.
Ligand models of L,L-SDAP, mono-methyl-L,L-SDAP and di-methyl-L,L-SDAP were
built using the Molecular Operating Environment (MOE) computational suite’s Builder utility
followed by minimization in the gas phase using the force field MMFF94X. An X-ray crystal
structure of the product-bound DapE crystal structure in the closed conformation was obtained.98
Following receptor preparation, molecular docking was performed using ligand conformation
databases. Docking poses of the substrate SDAP (1a) and analogs 1b and 1c were assessed as
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judged by their similarity to the product binding interactions seen in the original product-bound
crystal structure. The three ligand/enzyme models were then solvated in a simple water box at
pH of 7.4. The system atoms were then optimized with a short, localized molecular minimization
process. Molecular Dynamics parameters were set to globally minimize the protein, ligand and
solvent atoms with a typical heating and cooling protocol. Simulation results were then
minimized once again before the final binding poses were obtained for comparison. The final
solvated and minimized substrate-bound DapE models are shown in Figure 25a-c.
A

B

C

Figure 25. Minimized substrate/analogs docked and modeled in the DapE active site; A) native
substrate L,L-SDAP (yellow), B) monomethyl-LL-SAP (brown), C) dimethyl-L,L-SDAP
(turquoise). Note*Chain A (catalytic domain, green), Chain B (dimerization domain, purple).
As seen in Figure 25, the docked and modeled endogenous substrate SDAP amide
carbonyl is bound to one of the zinc atoms while the amide N-H acts as an H-bond donor to the
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backbone carbonyl of Thr325.A. The proximal carboxylate participates in bifurcated H-bonds
with the side chains of Arg258.A, Thr325.A and Asn245.B. The free primary amino group acts
as an H-bond donor to the backbone carbonyl of Ala136.A and a water molecule, which in turn
participates in H-bond donation to the backbone carbonyl of Glu135.A and to the side chain
carbonyl of Asn245.B. The terminal carboxylate of the pimelic acid moiety is H-bonded to the
N-H of Asn244.B, the side chain hydroxyl of Ser181.A, and Ser290.A, and a water molecule,
which in turn H-bond donates to the side chain hydroxyls of Thr183.A and Thr325.A. We
observe by comparing the enzyme-substrate interactions in the crystal-bound L,L-SDAP
product(s) and the docked & modeled L,L-SDAP structures, that the substrate links the catalytic
domain of chain A to the dimerization/cap domain of chain B. We propose that the presence of
the substrate induces a conformational change in the enzyme structure that facilitates catalytic
activation within the active site, and without the substrate the enzyme remains in the open,
inactive conformation. In effect, the substrate is the conduit that links the catalytic domain of
chain A to the dimerization/cap domain of chain B. The interactions of the monomethyl-L,LSDAP analog 1b are identical to those of the endogenous substrate, except for the added methyl
group on the primary amino group that eliminates the H-bond interaction to the backbone
carbonyl of Ala-136.A. The presence of the N-methyl group also leads to perturbations of the
water interaction at the ammonium N-H. However, H-bond bridging between the backbone
carbonyl of Glu135.A and the side chain carbonyl of Asn245.B by the ammonium N-H(s) are
maintained, while the N-methyl forms a new hydrophobic interaction with the adjacent alanine136.A residue. In contrast, the dimethyl-L,L-SDAP dimethyl substrate 1c is quite distinct from
the natural L,L-SDAP substrate’s binding due to the presence of the two additional methyl
groups. Loss of the interfacial domain interaction between the backbone carbonyl of Glu135.A
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and the side chain carbonyl of Asn245.B by the ammonium N-H species, due to interference of
the additional methyl groups, appear to be the key difference to the endogenous L,L-SDAP
substrate binding mode. The additional bulk of the two methyl groups also leads to the
migration of the N-H bond from the ammonium species of the potential substrate from Glu135.A
to the backbone carbonyl of Glu134.A. Significantly, Glu134 (E134) is proposed to act as the
general acid/base during the hydrolysis reaction catalyzed by DapE99 and this residue is shifted
further away from the active site. Thus, it is concluded that the mono-methyl-L,L-SDAP
substrate analog 1b retains overall similar binding to the endogenous L,L-SDAP 1a, while the
dimethyl-L,L-SDAP analog 1c would likely suffer loss of significant binding interactions due to
the presence of the second methyl group. N-Acetyl-SDAP analog 1d was found not to act as a
substrate.
Synthetic Protocol
The mixture of N-succinyl-N6-acetyl-L,L/D,D-diaminopimelic acid (1d) was prepared by
exposing a mixture of L,L/D,D- N-succinyl-diaminopimelic acid, previously synthesized by
Dinuta Gilner, Ph.D., to acetic anhydride in the presence of NaOAc in glacial acetic acid
(Scheme 2). The acetylated substrate 1d was obtained as a colorless powder in quantitative
yield. However, this analog was not cleaved by the enzyme, either due to the need for a charged
cationic species at that position, or due to negative steric interactions or a combination of those
two factors.
Scheme 2. Synthesis of N6-acetyl-L,L/D,D-SDAP substrate 1d.

Reaction Conditions: Ac2O, NaOAc*3H2O, glacial AcOH, 30 oC for 10 min-rt for 1h.
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In contrast, considering the more conservative change of adding a single methyl group
involving minimal steric bulk and still maintaining a positively charged ammonium species at
physiological pH suggested preparation of the monomethyl-L,L-SDAP acid (1b) analog for
study. Cleavage of monomethyl-SDAP substrate 1b would yield succinate (2) and the
monomethyl L,L-diaminopimelic acid, a secondary amine which may be differentiated from
primary amines in reactivity with ninhydrin. The dimethyl-SDAP substrate 1c is more sterically
encumbered at the critical cationic ammonium moiety, but as a tertiary amine it is inert to
reaction with ninhydrin. We selected the more conservative monomethyl derivative, consistent
with modeling that suggests that the tertiary N,N-dimethylamine substrate 1c would be a very
poor substrate.
The N-succinyl-N6-methyl-L,L-diaminopimelic acid substrate 1b was prepared
enantioselectively by Marlon Lutz as summarized in Scheme 3, beginning with commercially
available BOC-L-glutamic acid t-butyl ester 4 to afford the trifluoroacetate salt 1b.TFA in nearly
quantitative yield.
Scheme 3. Synthesis of N6-Methyl-L,L-SDAP substrate 1b.

Summarized synthesis route for preparation of monomethyl substrate analog as the
hydrochloride salt (1b) via the methyl ester, or the trifluoroacetate salt (1b) via the benzyl ester.
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Results and Discussion
Primary Amine Detection with Ninhydrin.
With the monomethyl SDAP substrate 1b in hand, we demonstrated that it functions as a
substrate by observing hydrolysis of the amide bond at 225 nm in the presence of DapE. Since
1b can function as a substrate we set out to design a robust and operationally straightforward
enzymatic assay that would be amenable to inhibition studies for drug discovery. While
ninhydrin reacts with both primary and secondary amines, only primary amines (that bear an
alpha-hydrogen) can form the Schiff base known as Ruhemann's purple, which has a longer
wavelength absorptions with λmax at 570 nm and 450 nm. In contrast, ninhydrin reacts with
secondary amines such as proline to form an iminium salt that is yellow-orange in color, with
λmax at 440 and 405 nm.100
Therefore, control reactions of standard enzyme activity were carried out in triplicate as
follows: to a buffered DapE solution at 30 °C was added the N-methyl SDAP TFA salt 1b. The
reaction was allowed to proceed for 10 min after which a 2 % ninhydrin reagent in 100 % DMSO
was added and subsequently heated to 80 °C for 15 min. The ninhydrin reaction was quenched
by placing the mixture in ice for 2 min after which the absorbance was read at 570 nm. This
control reaction was set as 100 % standard enzymatic activity of DapE.
DapE was incubated with DMSO prior to addition of N-methyl-SDAP substrate under
various times to show the effects of DMSO on the hydrolytic activity of DapE. The DMSO
incubation reactions were carried out with the exchange of buffered solution with DMSO. The
enzyme was allowed to incubate for the desired time between 0 and 10 min. After the allotted
incubation time, N-methyl-SDAP TFA salt 1b was added and the reaction was allowed to
proceed for 10 min. The enzymatic reaction was quenched by addition of 2 % ninhydrin solution
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and was subsequently heated to 80 °C for 15 min. The ninhydrin reaction was quenched by
placing in ice for 2 min and the absorbance was read at 570 nm. Comparison of 100 % standard
enzymatic activity versus rates obtained in the presence of DMSO indicate a ca. 50 % decrease
in enzymatic activity over the 10 min time period in the presence of ninhydrin/DMSO, but
enzymatic activity is not abolished even after 10 min. This demonstrates that the addition of the
ninhydrin/DMSO solution does not fully quench the catalytic activity of DapE.
DapE Ninhydrin-based Enzymatic Assay and IC50 Determination.
It was found that the optimal DapE assay conditions using the trifluoroacetate (TFA) salt
of monomethyl-L,L-SDAP 1b as the substrate and with ninhydrin as the colorimetric probe are
8 nm DapE in 50 mM HEPES buffer at pH 7.5 at 30°C followed by the addition of 2 mM Nmethyl SDAP. After 10 min the reaction is quenched by heating at 100 °C for 1 min. followed
by cooling on ice. A 2 % ninhydrin solution in 100 % DMSO (100 µL) is added and heated at
80 °C for 15 min followed by cooling on ice. Once the sample is cooled to 30 ˚C the absorbance
at 570 nm is determined.
In order to test N-methyl SDAP as a substrate for screening potential inhibitors of DapE,
the potency of several previously-identified inhibitors were examined and found to be
comparable with results from the previous assay. Specifically, captopril was found to have an
IC50 value of 3.3 μM which is identical to that reported using SDAP.93 Likewise, the IC50 values
for 3-mercaptobenzoic acid (IC50 = 25 μM), phenylboronic acid (IC50 =319 μM), and thiophene
boronic acid (IC50 = 166 μM) were found to be in agreement with the literature values of 35 μM,
107 μM, and 92 μM, respectively.93
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Conclusion
In summary, a new spectrophotometric assay for DapE is described, amenable to
identification and optimization of DapE inhibitors as potential antimicrobial agents. Ultimately,
it will be imperative to screen different metalloisozymes of DapE, in particular the Mn2+
enzyme in addition to the Zn2+ form, as captopril was found to be a moderately potent inhibitor
of the Zn2+ enzyme but not of the Mn2+ enzyme. Indeed captopril displayed modest antibiotic
activity against Escherichia coli and Salmonella enterica101 confirming our own observation of
antibiotic activity,93 but Udo found that captopril does not inhibit the Mn2+ enzyme,14 and that,
surprisingly, the antibiotic activity of captopril was independent of DapE inhibition in
bacteria.101 Even within the divalent zinc enzyme, mono- and di-zinc enzymes were determined
to show different activities, and their crystal structures have been determined with structural
insights that impact rational design of inhibitors.63 In summary, utilizing N-methyl SDAP 1b as
the modified substrate enables a ninhydrin-based assay for measuring inhibition of the bacterial
enzyme DapE should support both new lead discovery as well as lead optimization toward the
discovery of new antibiotics with a new mechanism of action to treat bacterial infections.
Experimental Section
Materials.
All solvents were distilled prior to use, and all reagents were used without further
purification unless otherwise noted. Ninhydrin solution was purchased as a 2 % solution in 100
% DMSO with a lithium acetate buffer at pH 4.5. All synthetic reactions were conducted under a
nitrogen atmosphere. Silica gel 60A, 40−75 μm (200 × 400 mesh), was used for column
chromatography. Aluminum-backed silica gel 200 μm plates were used for TLC. All 1H NMR
spectra were obtained using either a 300 MHz spectrometer or a 500 MHz spectrometer with
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trimethylsilane (TMS) as the internal standard. All C NMR spectra were obtained using a 75
MHz spectrometer or a 125 MHz spectrometer. HRMS spectra were measured on a TOF
instrument by electrospray ionization (ESI).
Chemistry.

1d
(±)-(2S,6S/2R,6R)-2-Acetamido-6-(3-carboxylatopropanamido) heptanedioic acid (1d). To a
racemic mixture of D,D/L,L-SDAP (22.8 mg, 0.079 mmol) was added glacial acetic acid (100
uL), acetic anhydride (17.3 uL, 0.236 mmol) and NaOAc*3H2O (24.0 mg, 0.079 mmol). The
reaction was degassed and agitated with mechanical stirring (200 rpm) at 30 oC for 10 min, then
1h at room temperature after which time TLC using 30:1:69 H2O-AcOH-CH3CN on reverse
phase TLC indicated consumption of starting material. The resulting reaction mixture was
quenched with HCl and concentrated to dryness under reduced pressure and the resulting oil was
placed under high vacuum overnight where it became an off-white foam/solid. The racemic
product mixture was collected to afford the N-acetylated SDAP derivative 1d as a colorless
powder (38.5 mg, 99 %). 1H NMR (500 MHz, D2O): δ 4.68 (bs, ammonium ion), 4.07-4.02 (m,
2H), 2.55-2.43 (m, 4H), 1.92 (s, 3H), 1.75-1.65 (m, 2H), 1.63-1.53 (m, 2H), 1.29 (p, J = 8Hz,
2H). 13C NMR (500 MHz, D2O): δ 179.2, 179.1, 178.9, 174.9, 174.0, 55.1, 55.0, 31.4, 31.3, 31.1,
22.2, 22.1, 21.8. HRMS (IT-TOF) m/z calcd. for C13H20N2O8 [M]+:332.1232, found: 332.1220.
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DapE Molecular Modeling.
Ligand models of L,L-SDAP, mono-methyl-L,L-SDAP and di-methyl-L,L-SDAP were
built using the Molecular Operating Environment (MOE) computational suite’s Builder utility
followed by minimization in the gas phase using the force field MMFF94X. The minimized
ligands were the subjected to the Conformational Search protocol to generate structuralconformation-databases populated with as many as 10,000 individual conformations.
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Conformational databases were generated for all three ligands of interest for use in the following
docking experiments.
An X-ray crystal structure of the product-bound DapE crystal structure in the closed
conformation was obtained98 and the molecular system was uploaded into MOE. Following
receptor preparation, molecular docking was performed using the previously-generated ligand
conformation databases. Ligand docking was carried out in the prepared DapE enzyme model
with product structures and solvent atoms inactivated and the docking site specified at the
catalytic metal atoms. Ligand placement employed the Proxy Triangle method with London ΔG
scoring generated 50 data points which were further refined using the induced fit method with
GBVI/WSA ΔG scoring to obtain the top 30 docking results. The docking protocol was repeated
for all three ligand models and analyzed for selection of the best docking pose. Docking poses of
the substrate SDAP (1a) and analogs 1b and 1c were assessed as judged by their similarity to the
product binding interactions seen in the original product-bound crystal structure. A single ligand
docking pose was selected for each of the three ligand models providing initial substrate-bound
ligand/enzyme models.
The three ligand/enzyme models were then solvated in a simple water box at pH of 7.4
which was treated with NaCl counterions to balance the charge. Periodic boundary conditions
were enabled, and the hydrogen bonding network of the model was optimized by automatic
sampling different tautomer/protomer states using Protonate3D102 which calculates optimal
protonation states, including titration, rotamer and “flips” using a large-scale combinatorial
search.103 The system atoms were then optimized with a short, localized molecular minimization
process with atoms further then 8 Å from the ligand fixed and system refinement continued until
a RMS Gradient of 0.1 kcal/mol/Å was attained. Molecular Dynamics parameters were set to
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globally minimize the protein, ligand and solvent atoms in the system using an NPA algorithm
with a Amber12:EHT force field, with a typical heating and cooling protocol. Simulation results
were then minimized once again before the final binding poses were obtained for comparison.
Modified SDAP as Potential Substrates.
The hydrolytic activity of DapE with modified SDAP analogs was monitored by the
decrease in absorbance at 225 nm via Shimadzu UV-2450 UV/Visible Spectrophotometer. All
reaction volumes were 1mL with 8 nM DapE and 5 mM of N-Methyl-SDAP 1b or 5 mM N-AcSDAP 1d in 50 mM HEPES buffer pH 7.5. Spectra were recorded over 35 min with one scan per
minute. Enzyme dilutions were made directly before each trial from the concentrated stock
solution at -80 °C.
Ninhydrin-based Assay for DapE Enzymatic Activity.
The enzymatic activity of DapE is measured in triplicate as follows: To 50 mM HEPES
at pH 7.5 buffered solution with 8 nM DapE at 30 °C was added 2 mM N-methyl SDAP 1b
(final volume 200 μL). The reaction was allowed to proceed for 10 min and quenched by heating
at 100 °C for 1 minute and subsequent cooling on ice for 1 minute. To the cooled reaction was
added the 2 % ninhydrin solution, and the reaction vortexed and subsequently heated at 80 °C for
15 min for the ninhydrin reaction. This reaction was quenched by placing in ice 2 min and the
absorbance of 80 µL was read at 570 nm. These reactions were set as 100 % standard enzymatic
activity of DapE. Glutamic acid concentrations of 0 mM, 0.1 mM, 0.2 mM, 0.3 mM, 0.4 M, and
0.5 mM were used as a standard control of the measurement of primary amine.
IC50 Determinations.
All inhibition assays were conducted with a reaction volume of 200 μL, 2 mM N-methyl
SDAP 1b and 8 nM DapE unless otherwise stated. Glutamic acid standards of 0 to 0.5 mM were
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used in every trial. To a 50 mM HEPES pH 7.5 buffered solution was added desired inhibitor
concentration at 30 oC followed by DapE and allowed to incubate for 10 min. N-methyl SDAP
1b was added and allowed to react for an additional 10 min and quenched by heating at 100 oC
for 1 minute and cooled on ice to 30 oC. The 2 % ninhydrin solution (100 μL) was added, the
reaction vortexed and heated at 80 oC for 15 min. after which the reaction was quenched by
cooling on ice to 30 oC and the absorbance was examined at 570 nm. IC50 values were obtained
through GraphPad Prism software.
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CHAPTER FOUR
DESIGN, MODELING AND SYNTHESIS OF DI-METALLOENZYME INHIBITORS
Inhibiting Di-nuclear Metalloenzymes
Antibiotics rank as some of the most commonly used therapeutic agents prescribed by
doctors today. The study of metalloproteins (MPs) and how to modulate their activity to stem the
rise of the antibiotic resistance in bacteria has become a growing area of research. The
impending dilemma of how to manage antibiotic resistance superbugs and the need to discover
novel mechanisms of action to block bacterial proliferation has sparked our interest in the
bacterial metalloenzymes DapE and NDM-1. The two enzymes possess the unique di-nuclear
metal center motifs, but represent very different enzyme characteristics, with DapE possessing
extraordinarily specific catalytic activity and NDM-1 demonstrating substrate promiscuity. These
two pharmaceutically relevant enzyme targets account for unique challenges to medicinal
chemistry, have still retained many of their secrets. However, our small molecular inhibitory
strategies and in silico analyses efforts towards DapE and NDM-1 are thus presented in the
following in hopes that one day our scientific understanding in the field may grow enough to
develop methods of control over this elusive class of proteins.
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Inhibition of DapE.
The di-Zn metalloenzyme DapE, has been shown to cleave L,L-diaminopimelate (L,LSDAP) into succinate and L,L-diaminopimelic acid (Figure 26).

Figure 26. Enzymatic action for cleavage of L,L-SDAP by DapE.
DapE is ultimately responsible for synthesizing lysine for bacterial peptide synthesis, and
for providing both mDAP and lysine for peptidoglycan cell wall formation in both Gramnegative and most Gram-positive bacteria (Figure 27A).28 Peptidoglycan (PGN) is a major
component of the cell wall of bacteria, and it is covalently linked to other biomolecular
polymers, such as lipoprotein-peptides (LP) and lipoteichoic acids (LTA).104 The PGN structure
of both Gram-positive and Gram-negative bacteria contains repeating disaccharide backbones of
N-acetylglucosamine (NAG) and β-(1-4)-N-acetylmuramic acid (NAM) that are cross-linked by
peptide stem chains attached to the NAM residues. The first two residues of the stem peptide are
generally L-alanine and D-glutamine or isoglutamine, while the last residue is typically Dalanine (Figure 27B) while the third peptide residue is a lysine in Gram-positive bacteria or
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meso-diaminopimelate (mDAP) residue in Gram-negative bacteria as well as in many rod shaped
Gram-positive bacteria such as Listeria and Bacillus species. 105 These two peptide-linking
motifs are commonly referred to as the Lys-type PGN and DAP-type PGN, respectively.105
A

B

Figure 27. A) Cartoon representation of the Gram-positive (left) and Gram-negative (right)
bacteria cell wall. B) Primary structures of Lys-type and DAP-type peptidoglycan.105
Therefore, enzymes involved in the critical mDAP/lysine biosynthetic pathway are all
potential antibiotic targets. The bacterial biosynthesis of lysine utilizes L-aspartate and a series
of four enzymes, aspartokinase, aspartate semialdehyde dehydrogenase, DapA, and DapB, to
produce L-tetrahydropicolinate. The biosynthesis then diverges into three separate pathways: the
acetylase pathway, the dehydrogenase pathway, and the succinylase pathway (see Chapter 2,
Figure 7). The dehydrogenase pathway forms mDAP directly from L-tetrahydrodipicolinate, but
this is a high-energy transformation and is limited to certain Bacillus species.28 The acetylase
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pathway is also a minor biosynthetic pathway for mDAP production and appears to also be
limited to only a few Bacillus species.26 The four-step succinylase biosynthetic branch is
believed to be the major biosynthetic pathway for production of mDAP and ultimately lysine in
most bacterial strains (Figure 28).24

Figure 28. Succinylase Biosynthesis Pathway with DapE Metallohydrolase highlighted in red.24
Furthermore, it has been shown that deletion of the gene encoding DapE is lethal to H.
pylori and M. smegmatis.29, 62 Even in the presence of lysine-supplemented media, the dapE H.
pylori knockout mutant was unable to grow, and only in the presence of supplemented mDAP
could the mutant survive. The succinylase biosynthetic pathway is the predominate source for
lysine in bacteria, making DapE essential for cell growth and proliferation. Inhibitors of
peptidoglycan biosynthesis (vancomycin and β-lactams, to name a few) have proven to be very
potent antibiotics, providing evidence that interfering with cell wall synthesis has deleterious

67
effects on bacterial cell survival. Since there are no similar biosynthetic pathways in mammals,
inhibitors that target an enzyme in the succinylase pathway should exhibit selective toxicity
against bacteria and not the human patient.28 Moreover, the fact that the dapE gene has been
discovered in M. tuberculosis, Escherichia coli (O157:H7), Vibrio cholerae, Puodomonas
aeruginosa, and Staphacocus aureus (strain MRSA252) suggests that inhibitors of DapE may
provide new broad-spectrum antibiotics.24
Inhibition of NDM-1.
Because of their safety and efficacy, β-lactam antibiotics comprise one of the most
popular categories of antibiotics utilized in medicine. Beta-lactam antibiotics, including the
commonly prescribed drug penicillin, function by targeting cell wall development in bacteria
(Figure 29). Altogether, the β-lactam classes including penicillin, cephalosporin and
carbopenems represent more than 50% of antibiotic usage worldwide, and are the cheapest and
among the most effective antibacterial agents available.106

Figure 29. Core structures of the common β-lactam antibiotics. (Side chains omitted for clarity).
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(A) Monobactam core, (B) Penam core, (C) Oxapenam core, (D) Carbapenam core,
(E) Penem core, (F) Carbapenem core, (G) Cephem core, (H) Oxacephem core,
(I) Carbacephem core.107
Fully functional bacterial cell walls are supported by interconnections of neighboring
peptidoglycan monomers, and it is the formation of these interconnections that β-lactam
antibiotics target. The polymerization of bacterial cell wall peptidoglycan (a NAG-NAM
disaccharide bearing a pentapeptide) consists of a transglycosylation reaction and followed by a
transpeptidation reaction, the latter of which is inhibited by β-lactam antibiotics through
formation of irreversibly reacting with the reactive serine residues of these transpeptidases. This
action blocks peptidoglycans from connecting to each other, leading to impeded cell wall
synthesis resulting in bacterial cell death.
Unfortunately, β-lactam antibiotic efficacy has dropped tremendously in recent years
because of the increased spread of antibiotic resistance, and the effects have been devastating. In
the U.S. alone, antibiotic resistant bacteria have caused over 20,000 deaths and two million
infections annually. Resistant bacteria contribute to surgical complications, resulting in the
deaths of countless more individuals. Antibiotic resistance has thus been called one of our most
serious public health threats. To combat the increasingly urgent problem of antibiotic resistance,
we have collaborated with Dr. Walter Fast of UT Austin to assay our series of novel noncovalent metalloenzyme inhibitors against New Delhi Metallo-β-lactamase-1 (NDM-1).
The recently-discovered bacterial enzyme New Delhi Metallo-β-lactamase-1 (NDM-1) is
a di-nuclear metallo-β-lactamase (MBL) belonging to the B1 family. NDM-1 is capable
deactivating commonly administered β-lactam antibiotics by hydrolyzing the amide bond of the
four-membered β-lactam ring (Figure 29).108
The gene responsible for encoding NDM-1 (blaNDM-1) was first isolated in 2009 from
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Klebsiella pneumonia from a UK patient who had attended a hospital in India. The plasmid
encoded NDM-1 is one of a number of metallo-β-lactamase genes that are capable of horizontal
gene transfer which has contributed to the rapid global spread of resistant superbugs.32, 34, 48, 51, 55,
108-148

There are more than 1000 β-lactamases identified and isolated to date that populate four
classes of β-lactamases, A, B, C and D, which can hydrolyze all β-lactam drugs except the
monobactams. 106 Classes C and D represent the serine β-lactamases. Serine-β-lactamases utilize
active site residues including a nucleophilic serine residue to catalyze the hydrolysis of the
lactam. However, while serine-β-lactamases are sensitive to an array of mechanism-based
inhibitors such as clavulanic acid, sulbactams and tazobactams, the B1 class of metallo-βlactamases remains insensitive to known serine-β-lactamases due to the utilization of active-site
metal ions. There are currently no clinical inhibitors in use that are capable of targeting these
enzymes. 106
The search for new antibiotics that target enzymes is essential for humans’ continued
standard of healthcare and lifestyle. Targeting the succinylase biosynthetic pathway is an
advantageous approach for medicinal chemistry as DapE has potential to provide science and the
healthcare system with a much-needed new class of antibacterial inhibitors. In addition,
developing strategies to reinvigorate the potency of existing antibiotics is of great interest to
society. Targeted inhibition of NDM-1 has the potential to reset the clock on β-lactam antibiotic
resistance. Furthermore, these two pharmaceutically relevant di-nuclear metalloenzyme targets
represent very useful model systems to aid in developing novel metalloenzyme inhibition
strategies.
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Original 225nm DapE Assay.
There have been a paucity of medicinal chemistry leads to serve as starting points for the
development of DapE inhibitors, exacerbated by the critical need for a robust assay to monitor
the SAR of inhibition. Mandal recently reported a small molecule docking and fragment-based
in silico screening approach based on the known substrate (L,L-SDAP) that yielded three simple
peptide derivatives (Gly-Gly, N-formyl-Lysine, and a Gly-(nor)Ile derivative)149 that are of
limited utility as starting points to launch a medicinal chemistry effort.
The original assay for DapE activity and inhibition was to monitor the cleavage of the
SDAP substrate at 225 nm.66 The very low wavelength of monitoring amide bond cleavage
precludes using this assay for many drug-like molecules with chromophores that would interfere
with monitoring at 225 nm. Nonetheless, our group employed this assay to screen a targeted
library of potential inhibitors containing zinc-binding groups including thiols and boronic acids,
and identified captopril as a fairly potent lead molecule (IC50 = 3.3 μM, Ki = 1.8 μM,
competitive).93 While captopril might be considered to be a good lead molecule for medicinal
chemistry optimization, given its use as an ACE inhibitor for hypertension, its thiol moiety is
generally considered to be a liability in the ultimate quest for druggability, given concerns about
selectivity, as thiols can bind tightly to zinc in a variety of metalloenzymes. The sensitivity of
thiols toward oxidation also complicates synthesis and analysis. Furthermore, while captopril
both inhibits DapE and exhibits antibiotic activity, its antibiotic activity is independent of DapE
inhibition150, suggesting that inhibition of multiple targets may give rise to its antibacterial
efficacy.
To further understand the catalytic and structural features of DapE enzymes we have
determined the structure of HiDapE in complex with the bound products. The product-bound
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structure of HiDapE reveals conformational changes induced upon substrate binding and
provides significant insight into how this enzyme coordinates hydrolysis, while molecular
dynamics simulation provides insight of the substrate and product release.
High-Throughput Screen & Early Docking Results.
Thus, while captopril serves as a standard DapE inhibitor and ligand for cocrystallization, given the paucity of DapE inhibitor leads, a high-throughput screen (HiTS) was
performed to provide new starting points for medicinal chemistry. This was supported by an
earlier NIH R15 by our collaborator Richard Holz (NIAID 1R15AI085559-01A1), and was
accomplished by screening 33,000 compounds from ChemBridge using the coupled assay shown
in Figure 30 with a cut-off of at least 20 % inhibition at 12 μM concentration of inhibitors.

Figure 30. Coupled assay for HiTS screen.
The successful HiTS screen provided five inhibitors (1-5, Figure 31) belonging to four
distinct chemical classes; two simple indoline sulfonamides, a functionally rich thio-tetrazoylthiazole, a di-fluorinated sulfonamide, and a flexible but hydrophobic β-sulfone. We
hypothesized the leads identified by our previous HiTS screen could ultimately be optimized to
nanomolar potency inhibitors with antibiotic activity. To accomplish this goal, we have focused
synthetic efforts on four different synthetic series possessing 6- and 7-sulfonyl indolines and/or
phenylsulfonamide core structural motifs.
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Figure 31. Five inhibitors identified through the HiTS screen.
Material and Methods
Metalloenzyme Inhibition Assays.
DapE Assay Description. All DapE inhibition and activity assays were conducted in the
Becker lab by Tahirah Heath. The enzymatic activity of DapE was measured in triplicate at 570
nm by the Ruhemann’s purple complex formed through the reaction of the cleaved primary
amine and ninhydrin at 30 °C. To 175 µL of 50 mM HEPES buffer at pH 7.5 with 5 µL of 1µM
DapE stock solution at 30°C was added 20 µL of 10 mM monomethyl SDAP ((2S,6S)-2-(3carboxypropanamido)-6-(methylamino)heptanedioic acid) TFA salt. The reaction was allowed to
proceed for 10 min and quenched by heating at 100 °C for 1 minute and subsequently cooling on
ice for 1 minute. To the cooled reaction was added 2 % ninhydrin reagent in 100 % DMSO (final
volume 300 µL) and subsequently heated to 80 °C for 15 min. This was quenched by placing in
ice water for 2 min, and the absorbance of 80 µL was read at 570 nm via a microplate reader.
These reactions were set as 100 % standard enzyme activity of DapE. Glutamic acid of
concentrations 0 mM, 0.02 mM, 0.04 mM, 0.06 mM, 0.08 mM, 0.1 mM, 0.2 mM, 0.4 mM, 0.6
mM, 0.8 mM, 1.0 mM were used as a standard control of primary amine to compare enzyme
activity.
The IC50 of the inhibitors described herein can be determined using captopril as the
positive control. To a reaction mixture in 50 mM at pH 7.5 HEPES buffer, containing DapE
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(0.25 µM), a solution of the inhibitor is added. Next, the reaction mixture is allowed to incubate
for 10 min. Thereafter, 1 mM of alpha-N-monomethylated SDAP substrate, initially prepared by
reductive amination of the SDAP substrate with aqueous formaldehyde and sodium
cyanoborohydride, was added, and reaction was allowed to incubate for 40 min. Next, 0.33 mL
of the reaction solution was transferred into another 1.7 mL Eppendorf tube, 0.166 mL of 2 %
Ninhydrin reagent was added to the reaction mixture, and the mixture was heated in a boiling
water bath for 15 min. The water bath was cooled. The mixture was vigorously agitated and the
absorbance was measured at 570 nm. The IC50 for the captopril standard is ca. 3.0 μM.
NDM-1 Assay Description. All NDM-1 inhibition and activity assays were conducted
by the Fast Lab at the University of Texas Austin. The ability of the compounds described herein
to inhibit NDM-1 was determined in the following way. A Substrate Working Solution was
prepared from Chromacef (6 µM) and Tween-20 (0.02 % v/v) in water. An Enzyme Working
Solution was prepared with NDM-1 (0.5 µg/mL), HEPES (0.1 M), pH 7 and Tween-20 (0.02 %
v/v). An Inhibitor Working Solution was prepared from 50 mM of the inhibitor in DMSO. The
final assay conditions were 1 mL, HEPES (50 mM), pH 7, Tween-20 (0.02 % v/v), Chromacef (3
μM), Δ35 NDM-1 (0.25 µg/mL). Extra zinc was omitted from these assays because extra ZnSO4
interferes with the metal binding groups in inhibitors.

Figure 32. Structure of Chromacef, a chromogenic cephalosprin used in the detection and assay
of β-lactamases.151
An aliquot of the Inhibitor Working Solution was added to a polystyrene disposable
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cuvette to achieve a final concentration of 0-50 µM (in 1 mL final). Supplemental DMSO was
added to reach a final volume of 4 µL. NDM-1 Working Solution (0.05 mL) was added to the
cuvette and the inhibitor and enzyme were allowed to incubate for about 20 min. The reaction
was initiated by added 0.5 mL Substrate Working Solution. The solution was mixed quickly, but
gently to avoid bubble formation after Chromacef 6 M addition to start the reaction. The
reaction was mixed fast, but gently. The change in absorbance ΔAbs442nm/min was measured for
each inhibitor from the linear slope from each inhibitor concentration.
In Silico Docking Protocols with DapE.
Molecular modeling and docking simulations were performed using the open source web
service SWISSDOCK and the Chemical Computing Group’s Molecular Operating Environment
(MOE) computation suites.76 We have docked three separate ligand library databases into the
open conformation of DapE (PDB ID: 3IC1 or 5UEJ) using the protocol described herein. In
silico screening techniques are instrumental in helping us understand how the native substrate,
standardized compounds from assay development, or compounds found during high throughput
screening experiments can interact with the enzyme at resting state and before the dynamic
enzyme conformational changes leading to mechanistic turnover have occurred.
Early SWISSDOCK In Silico Docking Protocol. Analysis of the hits through docking
suggests a di-Zn binding motif for all four structural types identified. A library of 6- and 7substituted N-acetylindoline sulfonamides with vaious alkyl group substituted to the sulfonamide
nitrogen were prepared based on the two N-acetylindoline sulfonamides hit core structures
(Table 2). Early docking studies using SwissDock were performed with this library using the
open conformational HiDapE crystal structure (PDB ID: 3IC1) as the docking receptor.
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Table 2. Sulfonamide Ligand Library for SWISSDOCK.

Ligand Entry
R
6 Substituted 7 Substituted
5a
5c
-NH-isoPentyl
5b
5d
9a
9b
-NH-cylcohexyl
10a
10b
11a
11b
-N-Pyrrolidinyl
12a
12b
13a
13b
-N-Piperidinyl
14a
14b
15a
15b
-N(2-methoxyethan-yl)2
16a
16b
-N(ethyl)2
17a
17b
18a
18b
-N(propyl)2
19a
19b
20a
20b
-NH-isoPropyl
21a
21b
22a
22b
-PheOMe
23a
23b
-MetOMe
24a
24b
-ProOBz
25a
25b
26a
26b
-GlyOMe
27a
27b
-βAlaOMe
28a
28b
29a
29b
-ValOMe
30a
30b

X
Cl
Br
Cl
Br
Cl
Br
Cl
Br
Cl
Br
Br
Cl
Br
Cl
Br
Cl
Br
Br
Br
Cl
Br
Br
Cl
Br

Later MOE In Silico Docking Protocols with DapE.
HiTS Hit Ligand Library Dock to NmDapE_OC. The five high throughput screen hits
and two simplified 6- and 7-substituted piperidinyl analogs of HiTS hit 4 were built using
ChemDraw and included in an MOE ligand database. Structures containing stereocenters were
separated into individual enantiomers or diasteriomeric analogs and included in the database.
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The nineteen original ligand structures were minimized in the gas phase using the force field
MMFF94X followed by protonation states enumeration at pH = 7.4 using the Wash function in
MOE (Figure 33).

Figure 33. Database Wash utility function in MOE used to quickly prepare large database set for
further analysis in MOE.
The database preparation protocol brought to total number of docking ligands to twentyone and are presented in Table 3 below.
Table 3. High Throughput Screen Ligand Docking Library.a
Seq
1

2

3

4

IUPAC Name
1-(5-bromo-6-(piperidin-1ylsulfonyl)
indolin-1-yl)ethan-1-one
1-(5-bromo-7-(piperidin-1ylsulfonyl)
indolin-1-yl)ethan-1-one
1-(5-bromo-6-(((3R,5S)-3,5dimethylpiperidin-1-yl)sulfonyl)
indolin-1-yl)ethan-1-one
1-(5-bromo-6-(((3S,5S)-3,5dimethylpiperidin-1-yl)sulfonyl)
indolin-1-yl)ethan-1-one

#

MW

cLogP TPSA

HB HB B
acc don rot.

14a
387.30

1.9

57.7

3

0

3

387.30

1.9

57.7

3

0

3

415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

14b

4a

4b
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5

6

7

8

9

10
11
12
13

14

15

16

17

18

19

20

21

1-(5-bromo-6-(((3R,5R)-3,5dimethylpiperidin-1-yl)sulfonyl)
indolin-1-yl)ethan-1-one
1-(5-bromo-6-(((3S,5R)-3,5dimethylpiperidin-1yl)sulfonyl)indolin-1-yl)ethan-1-one
1-(5-bromo-7-(((3S,5R)-3,5dimethylpiperidin-1yl)sulfonyl)indolin-1-yl)ethan-1-one
1-(5-bromo-7-(((3R,5S)-3,5dimethylpiperidin-1yl)sulfonyl)indolin-1-yl)ethan-1-one
1-(5-bromo-7-(((3S,5S)-3,5dimethylpiperidin-1-yl)
sulfonyl)indolin-1-yl)ethan-1-one
1-(5-bromo-7-(((3R,5R)-3,5dimethylpiperidin-1-yl)
sulfonyl)indolin-1-yl)ethan-1-one
1-acetyl-5-bromo-Nisopentylindoline-6-sulfonamide
1-acetyl-5-bromo-Nisopentylindoline-7-sulfonamide
N-(difluoromethyl)-N-(2methoxyphenyl)4-methylbenzenesulfonamide
(R)-2-((1-phenyl-1H-tetrazol-5yl)thio)-N-(thiazol-2-yl)
propanamide
(R)-2-((1-phenyl-1H-tetrazol-5yl)thio)-N-(thiazol-2-yl)
propanamide
(S)-2-((1-phenyl-1H-tetrazol-5yl)thio)-N-(thiazol-2-yl)
propanamide
(S)-2-((1-phenyl-1H-tetrazol-5yl)thio)-N-(thiazol-2-yl)
propanamide
N-((2R,3R)-2,3dimethylcyclohexyl)-3-((4methylbenzyl)sulfonyl)propanamide
N-((2S,3S)-2,3dimethylcyclohexyl)-3-((4methylbenzyl)sulfonyl)propanamide
N-((2R,3S)-2,3dimethylcyclohexyl)-3-((4methylbenzyl)sulfonyl)propanamide
N-((2S,3R)-2,3dimethylcyclohexyl)-3-((4methylbenzyl)sulfonyl)propanamide

4c
415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

415.35

2.6

57.7

3

0

3

389.31

3.0

66.5

3

"1"

6

389.31

3.0

66.5

3

"1"

6

327.35

3.2

46.6

3

"0"

5

332.412

1.7

85.66

5

1

6

333.42

2.2

86.8

4

0

6

332.41

1.7

85.6

5

1

6

333.42

2.2

86.8

4

0

6

351.51

3.4

63.2

3

1

7

351.51

3.4

63.2

3

1

7

351.51

3.4

63.2

3

1

7

351.51

3.4

63.2

3

1

7

4d

4e

4f

4g

4h

5a
5b
6

7a

7b

7c

7d

8a

8b

8c

8d
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a

Table Legend: cLogP = calculated octanol/water partition coefficient. HBacc = number of
hydrogen bond acceptors. TPSA = total polar surface area. HBdon = number of hydrogen bond
donors. B-rot. = number of rotatable single bonds.
The next step in the docking process is to prepare the docking receptor model. The
recent Apo DapE structure from Neisseria meningitidis (PDB ID: 5UEJ, 1.30 Å resolution)
reported by our collaborator Dr. Nocek of Argonne National Laboratory was used due to the high
quality of refinement at the dimerization loops discussed in Chapter 2 to play a role in substrate
binding. The .pdb file was retrieved from the protein databank and loaded into MOE. Then the
structure was prepared in MOE using the Structure Preparation utility to model in any missing
loops and fix format translational errors between different computational platforms (Figure 34).
Structure Preparation was followed by Protonate3D to optimize the protonation network of the
system.

Figure 34. MOE docking receptor preparation of NmDapE_OC model (PDB ID: 5UEJ, 1.30 Å
resolution).
We then determined potential binding pockets which were mapped out using the
'SiteFinder' MOE utility (Figure 35). The SiteFinder calculation can then be used to generate
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dummy atoms that populate empty pocket space which can be used to direct molecular docking
in later steps.

Figure 35. Site Finder operating window in MOE used for calculating the probable ligand
binding sites for NmDapE_OC docking model.
Upon completion of our receptor preparation, the model was reviewed for consistency
and saved as the default DapE_OC docking receptor (Figure 36). The previously generated
ligand database and the prepared receptor model was used to perform the molecular docking
protocol in two separate stages; first, a global induced-fit docking which incorporated the Site
Finder dummy atoms as docking sites, the second, a site-directed induced-fit docking at the diZn metallo center.
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Figure 36. Site-Directed Docking Metal Center Site for NmDapE_OC Receptor Model.
The placement and scoring functions were identical between the two docking stages
enabling our docking results to be merged together. Docking Parameters for both stages are
presented in Table 4.
Table 4. HiTS-hits_NmDapE_OC Docking Parameters.a

a

Global Site Finder Docking Parameters
Receptor: MOE; Receptor Atoms
Site: Dummy Atoms
Pharmacophore: NA
Density: NA
Ligand: MDB File;
DapE_HiTS_hit_docking_database_wash

Site Directed Docking Parameters
Receptor: MOE; Receptor Atoms
Site: Di-Zn Metal Site
Pharmacophore: NA
Density: NA
Ligand: MDB File;
DapE_HiTS_hit_docking_database_wash

Method Placement=
Alpha Triangle; Score: Affinity ΔG
-50 Poses Generated / ligand entry
Method Refinement =
Induced Fit Receptor; Score: GBVI/WSA dG
-15 Poses Kept / ligand entry
Output: HiTS-hits_NmDapE_OC-SFdock.mdb

Method Placement=
Alpha Triangle; Score: Affinity ΔG
-50 Poses Generated / ligand entry
Method Refinement =
Induced Fit Receptor; Score: GBVI/WSA dG
-15 Poses Kept / ligand entry
Output: HiTS-hits_NmDapE_OC-SDdock.mdb

See appendix A for in silico file naming paradigm. Table Legend: MDB = molecular database.
HiTS = high throughput screen. NmDapE_OC = apo DapE from Neisseria meningitidis in the
open conformation possessing 1.30 Å resolution. GBVI/WSA = Generalized Born Volume
Integer Weight Surface Area. SF = Site Finder docking. SD = site directed docking.
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Docking Parameters were carried out into the prepared NmDapE_OC enzyme model with
solvent atoms inactivated. The docking Site was specified at the Site Finder dummy atoms or at
the catalytic metal atoms (Figure 35). Ligand placement employing Alpha Triangle method with
Affinity ΔG scoring generated 50 data points which were further refined using the induced fit
method with GBVI/WSA ΔG scoring to obtain the top 15 docked poses per ligand entry.
Standardized Substrate & Ligand Library Dock to NmDapE_OC. The default
NmDapE_OC docking receptor was used to perform a site-directed induced-fit docking at the diZn metallo center with a database of standardized substrate and inhibitor ligands known for
DapE in enumerated protonation states. The ligand database entries are summarized in Table 5
below.
Table 5. Standardized Substrate & Ligand Library.a
Seq.
1

2

3

4

5

6

7

IUPAC
(2S,6R)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2S,6R)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2R,6S)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2R,6S)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2R,6R)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2R,6R)-2-amino-6(3-carboxypropanamido)
heptanedioic acid
(2S,6S)-2-amino-6(3-carboxypropanamido)
heptanedioic acid

Formal
Charge

MW

cLogP

HB
HB don B-rot
acc

0

290.27

-3.64

8

8

8

-2

288.26

-0.88

1

1

1

0

290.27

-3.64

8

8

8

-2

288.26

-0.88

1

1

1

0

290.27

-3.64

8

8

8

-2

288.26

-0.88

1

1

1

0

290.27

-3.64

8

8

8
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(2S,6S)-2-amino-6(3-carboxypropanamido)
-2
288.26 -0.88
1
1
1
heptanedioic acid
(2S,6S)-2-(3carboxypropanamido)-60
304.30 -0.71
8
8
8
9
(methylamino)
heptanedioic acid
(2S,6S)-2-(3carboxypropanamido)-6-2
302.28 -0.35
1
1
1
10
(methylamino)
heptanedioic acid
(2S,6S)-2-acetamido-60
332.31 -1.07
8
8
8
11 (3-carboxypropanamido)
heptanedioic acid
(2S,6S)-2-acetamido-6-3
329.29 -0.71
2
2
2
12 (3-carboxypropanamido)
heptanedioic acid
(2R,6S)-2-acetamido-60
332.31 -1.07
8
8
8
13 (3-carboxypropanamido)
heptanedioic acid
(2R,6S)-2-acetamido-6-3
329.29 -0.71
2
2
2
14 (3-carboxypropanamido)
heptanedioic acid
0
121.93 0.92
2
2
2
15 phenylboronic acid
-1
120.92 1.40
2
1
2
16 phenylboronic acid
0
154.19 2.11
2
2
2
17 3-mercaptobenzoic acid
-1
153.18 2.23
0
0
0
18 3-mercaptobenzoic acid
-2
152.17 2.23
0
0
0
19 3-mercaptobenzoic acid
0
127.96 0.78
2
2
2
20 thiopheneboronic acid
thiopheneboronic
acid
-1
126.95
1.26
2
1
2
21
0
217.29 0.68
3
2
3
22 L-Captopril
-1
216.28 0.80
1
0
1
23 L-Captopril carboxylate
-2
215.27 0.80
1
0
1
24 L-Captopril di-anion
-1
216.28 0.80
1
0
1
25 L-Captopril thiol anion
a
Table Legend: cLogP = calculated octanol/water partition coefficient. HB acc = number of
hydrogen bond acceptors. HB don = number of hydrogen bond donors. B-rot. = number of
rotatable single bonds.
8

Docking Parameters were carried for the prepared NmDapE_OC enzyme model with
solvent atoms inactivated. The docking site was specified at the catalytic binding pocket.
Ligand placement employing Alpha Triangle method with Affinity ΔG scoring generated 500
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data points which were further refined using the induced-fit method with GBVI/WSA ΔG
scoring to obtain the top 50 docked possesses per ligand entry.
6- & 7-Substituted Sulfonamide Indoline Series.
We have followed up to varying degrees on all five hits from the high-throughput screen
(Figure 31) but the synthetic work discussed herein has focused on the first two indoline
sulfonamide HiTS hits. We have chosen to focus on the indoline scaffold as the top priority, first
because two of the independent hits were indoline sulfonamides, thus providing an internal
confirmation, and also the indoline scaffold is important in natural products as well as in drug
molecules.152 Further, the indoline structure provides a divergent scaffold toward analogs that
may be readily functionalized at different positions including on the indoline nitrogen, the 5position (bromo in the two hits), and the 6- and 7-positions (7-sulfonamide depicted in the hits).
Regarding the actual location of the sulfonamide in hits 4 and 5, Borror has previously shown153
that chlorosulfonylation attacks the 6-position of the indoline, (Figure 37a) correcting a stillpersistent error in the literature that had assumed that electrophilic aromatic substitution would
attack the 7-position, ortho to the o-, p-directly indoline nitrogen. Thus, though encouraged by
initial docking of 7-sulfonamides, we realized that the given structures for the library hits were
probably incorrectly labeled as 7-sulfonamides, since the structures given could not be
synthesized by existing literature methods and should be represented as 6-sulfonamides.
ChemBridge was not able to provide samples for further analysis, nor could they produce a
synthetic protocol for the preparation of those hits, nonetheless, docking of 6- and 7sulfonamides reveals the potential for binding of both isomers. Interestingly there is a preference
for binding of the less-accessible 7-sulfonamides. The only reported synthesis of indoline-7sulfonamides was again by Borror153 who employed a reaction of chlorosulfonyl isocyanate with
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5-bromoindoline to deliver the sulfonyl intramolecularly to the 7-position, then oxidizing the
indoline to the known indole-7-N-methylsulfonamide for structure confirmation. Borror’s
chemistry has been adapted by us to prepare the indoline-7-sulfonamido derivatives via SN2
alkylation of the cyclic sulfonyl urea followed by hydrolysis. (Figure 37b).

Figure 37. a) Synthesis of indoline-6-sulfonamides, b) Borror-adapted synthesis of 7sulfonamides.
Our research team has successfully designed and synthesized 6- and -7 sulfonamide
indolines by the following methods. Batch synthesis of N-acetyl indoline (31) was conducted
per conditions described by Wu et al.154 Indoline in methylene chloride was exposed to acetyl
chloride in the presence of base at low temperatures to afford the N-acetyl indoline product after
recrystallization from DMF.
Halogenation of the N-acetyl indoline at the 5-position was achieved through batch
synthesis conditions described by Borror et al.153, 155, 156 and later through continuous flow
synthesis conditions157, 158 worked out in our lab.
Batch conditions were carried out by exposure of N-acetyl indoline 31 with Nchlorosuccinimide and N-bromosuccinimide, respectively, in the presence of catalytic amounts
of ammonium acetate to afford 32a and 32b analogs in 83 % and 61 % yields, respectively.
Alternatively, continuous flow synthesis using conditions adapted from Pelleter et.al.158 afforded
32a in superior reaction rates and product purity with moderate yields around 50 % after
recrystallization (Figure 34).
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Figure 38. Continuous Flow Chlorination Setup for 5-chloro-N-acetyl indoline. A) Schematic
representation, B) Laboratory apparatus configuration.
The 5-chloro and 5-bromo N-acetyl indoline analogs were each subjected to
chlorosulfonation at the 6-position through heating at 65-70 oC in neat chlorosulfonic acid, at a
7.0 mL/g starting material loading ratio, over a 3 h period. The reaction mixture was then
quenched over ice to afford the desired products as beige colored precipitates that were collected
via vacuum filtration on a water aspirator to allow toxic fumes to be neutralized.153, 156 This
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method produced yields between 75 – 91 %, and NMR analysis shows that the products are pure
enough to be taken to the next step without further purification.
A library of primary and secondary alkyl amines was reacted with chloro and the bromo
analogs of the 6-substituted sulfonyl chloride derivative, respectively, in the presence of
triethylamine base to afford a series of sulfonamide inhibitors according to literature
precedent.153, 159 In the instances where the reacting amine was secondary, a catalytic amount of
DMAP was added to the reaction solution. The sulfonamide products were isolated through a
simple liquid-liquid extraction under acidic condition followed by passing through activated
carbon plug and recrystallization from chloroform-ethyl acetate to afford the final inhibitors in
high purity. Each inhibitor sample was characterized and submitted for enzyme inhibition. A full
description of the synthesis of 6-substituted sulfonamide inhibitors is summarized in Scheme 4
below.
Scheme 4. General Synthesis of 6-substituted Sulfonamide Indoline Inhibitors.

Reaction Conditions: i) AcCl, Et3N, CH2Cl2, 0 oC-RT, 3h. ii) N-halo-succinimide, NH4Cl cat.,
MeCN, RT, 3.5-4h. iii) 1) neat chlorosulfonic acid, 65-70 oC, 3h. 2) quench over ice, filter
product. iv) CH2Cl2, Et3N, RT, 2-3h (cat. DMAP for 2o amines). 2) Acid workup with CH2Cl2. 3)
Pass through activated carbon and recrystallize from chloroform-EA. 153, 154, 156
N-Cbz-indoline-7-(N-acyl-sulfonamide) Series.
Synthesis of N-Cbz-indoline-7-(N-acyl-sulfonamide) derivatives was carried out under
different reaction conditions to the 6-substituted sulfonamide isomers as described by Borror et
al.153 In order to facilitate directed installation of the sulfonyl moiety selectively at the 7-position
of the indoline core structure we employed synthetic conditions (Scheme 5) with modifications
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of literature protocols.

153

Scheme 5. Synthesis of 7-substituted N-Cbz-indoline -7-(N-acyl-sulfonamide).a

a

Reagents and Conditions: (i) chlorosulfonyl isocyanate, nitroethane, -42 oC, (ii) AlCl3, rt-110 oC
2 h; (iii) 50 % H2SO4, 135 oC 2h; (iv) benzyl chloroformate, sodium bicarbonate in 1:1 THFH2O, rt overnight; (v) acyl chloride, Et3N, DMAP, CH2Cl2.
Synthesis of the N-Cbz-indoline-7-(N-acyl-sulfonamide) derivatives was achieved by
first reacting indoline, or the 5-halogenated indoline analog, with chlorosulfonyl isocyanate at
cryogenic temperature to form the corresponding N-urinic sulfonyl chloride intermediate 39 in
situ. The reaction was then subjected to Friedel-Craft acylation-like reaction conditions upon the
addition of aluminum chloride with heating to afford the corresponding tricyclic sulfonyl urea
indoline product 40 in moderate yields.
The tricyclic sulfonyl urea moiety was hydrolyzed open under acidic conditions to afford
the analogous 7-substituted sulfonamide 41. Benzyl carbonylation of the exposed aniline
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nitrogen in the presence of sodium bicarbonate afforded the N-Cbz-indoline-7-sulfonamide 42
derivative in up to 62 % yield and high purity. Acid chloride acylation of the N-Cbz-indoline-7sulfonamide analog at the sulfonamide nitrogen using acetyl chloride (43a), phenylacetyl
chloride (43b) and the 4-methoxybenzoyl chloride (43c) in the presence of base afforded the Nacyl sulfonamide derivatives in high yield and purity.
Simple N-Acetyl Sulfonamide Series.
We have also produced a small series of N-Ac-sulfonamides containing succinyl like
moieties through a non-copper catalyzed synthetic route. In 2014, Morkunaite et al. reported a
class of sulfonyl substituted saccharin compounds and their ability to bind to Zn metal centers of
Carbonic Anhydrase, a mono-Zn metalloenzyme.160 This paper inspired up to pursue the design
and synthesis of a series of N-acetyl aryl sulfonamide derivatives using conditions described by
Liu et al., with modification (Scheme 6).161
Scheme 6. Synthesis of Simple Aryl N-Succinyl and N-Glutamyl Sulfonamides.

Reagents and Conditions: (i) MeOH, DIPEA, catalytic DMAP, rt overnight.161
These compounds were designed with DapE’s native substrate binding mode in mind.
DapE, as previously discussed, can recognize succinyl-like functionality in DapE’s known
metallo-isoforms. It was hypothesized that the succinylate functionality of the compound would
enable binding to DapE’s succinyl binding pocket while the N-Ac sulfonamide moiety, which is
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a carboxylic acid mimetic, could interact with the positive ionic metal center and form a stable
complex. However, there is a possibility that the activated hydroxide could hydrolyze one of the
S-N-C bonds of the N-Ac sulfonamide group leading to deactivation of the inhibitor. If these
bonds are stable enough to survive the hydrolytic conditions of the Zn-(HO-)-Zn active site, the
compounds may chelate one or both metal centers to form a stable complex as was shown in the
molecular docking data of the simple N-succinyl-benzylsulfonamide docked into NDM-1’s
active site (Figure 39). To our knowledge, the N-Ac sulfonamide moiety has never been tested
against a di-nuclear metalloenzyme.
A

B

Figure 39. Docking and minimization of the N-succinyl analog 44a with NDM-1 using MOE. A)
mono-anionic state B) di-anionic state.
Synthesis of the simple aryl N-Ac-sulfonamides was achieved as per literature precedent.
The N-Ac-sulfonamide moiety was installed on primary aryl sulfonamides, benzenesulfonamide
and tosylsulfonamide, through exposure to succinic or glutamic anhydride in the presence of
DIPEA base. The desired products were isolated in moderate yields after quenching over
saturated aqueous H2CO3, washing twice with CH2Cl2, before acidification and extraction with
CH2Cl2. For the two N-succinyl analogs (44a, 44b), upon concentrating to minimal solvent, a
white precipitate was readily formed and found to be pure product after NMR analysis resulting
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in yields of 50 % and 39 % yields, respectively. Both succinyl containing N-Ac sulfonamide
derivatives were submitted to the Walter Fast group for biological testing against NMD-1 and to
Tahirah Heath for testing against DapE.
The N-glutamyl analog purification was slightly more involved, requiring normal phase
column chromatography purification using 40:1:59 Ea-AcOH-Petroleum Ether elution. Desired
glutamyl products 44c & 44d were isolated as clear oils that solidified as off-white semisolids
after a week in moderate yields of 52 % and 44 %, respectively. Samples of each glutaryl
derivative were also included for biological testing with NDM-1 by the Fast group and reprep is
currently underway to assay against DapE.
Sulfonyl Azide-Derivatization Series.
Inspired by evidence that the N-acetyl indoline sulfonamides may be able to interact with
both active site zinc atoms, and encouraged that X-ray confirmation that 8-hydroxyquinolines
interact with both active site zinc atoms in NDM-1162, we proposed the installation of sulfonylcontaining functionality bearing a second ligand atom distal to the sulfonyl group via a variation
on the popular copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction.
N-Acetyl Indoline-6-Sulfonyl Azide Synthesis. We have utilized the product stream
from the sulfonamide series as a source of starting materials for synthesizing sulfonyl azide
possessing the familiar indoline core structure. We have optimized the chemistry for installing
the azide functionality from the sulfonyl chloride. Synthesis of the N-acetyl-5-halooindoline-6sulfonyl azides 45a, 45b, and 45c were achieved after exposure of the corresponding sulfonyl
chloride to sodium azide in dry diglyme with slow addition of water and elevated temperatures
(Scheme 7A). As azide compounds are potentially explosive, all precautions were taken to
ensure safety including mandatory use of a blast shield (Figure 40).
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Figure 40. Reaction Setup for Sulfonyl Chloride Azidation with Sodium Azide.
The freshly prepared sulfonyl chloride was added to a three-neck round bottom flask,
purged with argon, and fitted with a 50 mL glass addition funnel on the right neck, an elongated
glass neck extender on the middle neck and a glass stopper on the left neck. Rubber septa were
fitted at the middle elongated-neck and the right-hand addition funnel as a gas inlet and outlet
respectively. The reaction RBF module is fitted to a IKA thermocouple magnetic stirring/heating
mantle for precise temperature control and the entire apparatus is barricaded with a blast shield
for safety as shown in Figure 40 above. The left neck serves as the addition point for sulfonyl
chloride, sodium azide, and dry diglyme. It was found that use of old diglyme in this reaction
results in failure of the reaction as the dissolved water in the diglyme outcompetes sodium azide
reactivity with the sulfonyl chloride. After addition of the dry starting materials, the sulfonyl
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chloride and sodium azide were added thought the left-hand flask neck, the dry diglyme is
measured in a flame dried glass graduated cylinder and used to rinse the ground glass joint of
static-clung azide solids to prevent friction or impaction of the azide when the glass stopper is
applied. A heavy magnetic stir bar used to suspend the sodium azide in dry diglyme allows us to
control reactivity of the sulfonyl azide until reaction temperature can reach an optimal range. The
previously-used graduated cylinder was used to measure and add DI water, in a 3:2 diglymewater volume ratio, to the 50 mL addition funnel is closed. The RBF reaction mixture was then
heated to 100 oC with stirring, which results in dissolving of the sulfonyl chloride, before a
gradient-temperature increase to 130 oC and slow addition of water over 10-15 min. After the
water addition is complete the reaction was heated for one hour at 130 oC before being left to stir
overnight at rt. The reaction is then quenched by slowly pouring the mixture over cooled
saturated sodium bicarbonate with stirring behind a blast shield. If the reaction is observed to
vigorously effervesce during the pour, it is an indication that sodium azide was unconsumed.
We found this to be the case when wet diglyme was used in the reaction. When successful, the
sodium bicarbonate quench results in a tan solid to precipitate from the solution which is
dissolved during liquid-liquid partitioning with ethyl acetate. The product is isolated with 3-4
extractions of ethyl acetate and the combined organic fractions were washed once with brine
before drying over sodium sulfate and concentration on a rotary evaporator to minimal volume,
still containing some diglyme. The resulting diglyme-ethyl acetate-sulfonyl azide syrup is slowly
triturated with hexane or petroleum ether to crash out desired product which was collected via
vacuum filtration in 70-80 % yield and in high purity according to HPLC. Isolated sulfonyl azide
products were carried into later synthetic steps without further purification.
N-Cbz-Indoline Protected Sulfonyl Azide Synthesis. In addition to synthesis of the N-
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acetyl indoline-6-sulfonyl azide starting materials, we have also synthesized a series of 6- and 7substituted N-Cbz-indoline-protected sulfonyl azides from the corresponding primary
sulfonamides using the azide transfer reagent as described by Wang (Scheme 7).
Scheme 7. Synthesis of N-Cbz-Indoline Protected Sulfonyl Azides.a
A

B

C

D

a

Reaction Conditions: i) NaN3, 3:2 Diglyme-H2O, 130 oC 1h to rt overnight. ii) NH3 sat. MeOH,
CH2Cl2, heat 1 h; iii) 6N HCl, 2 h 110 oC; iv) benzyl chloroformate, NaHCO3, 1:1 H2O-THF, rt
overnight; v) imidazole-1-sulfonyl azide hydrochloride, K2CO3, 1:1 iPrOH-H2O, 2h rt.163
While we could utilize the product stream from the N-Cbz-indoline-7-(NAc-sulfonamide)
synthetic series for the source of the N-Cbz-indoline-7-sulfonamide starting material, synthesis
of the N-Cbz-indoline-6-sulfonamide was more involved. We utilized the 6-sulfonyl chlorides
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33a & 33b from the simple N-acetyl-5-halo indoline-6-sulfonamide series to synthesize the
corresponding 6-sulfonamide products 46a & 46b in high purity and yields in two steps (Scheme
7B). Nucleophilic acyl substitution of the sulfonyl chloride in methanolic ammonium-methylene
chloride solution was followed by acid hydrolysis of the N-acetyl group at 110 °C in 6N HCl for
2.5 h. The cooled hydrolyses reaction was triturated with ether-IPA to isolate the corresponding
47a as the HCl salt.
Benzyl carbonylation selectively at the aniline nitrogen of the indoline core structure for
the 6- and 7-sulfonamides 48a & 42 was achieved by combining the primary sulfonamide
products with benzyl chloroformate in the presence of sodium bicarbonate base and stirring at
room temperatures overnight (Scheme 7C). Crude products were isolated in moderate to good
yields (48a; 52 %, 42; 91 %) and high purity (48a.; 90 %, 42.; 99.7 %) after liquid-liquid
partitioning with ethyl acetate and recrystallization.
Sulfonyl azide transfer onto the primary sulfonamide was facilitated by the azide transfer
reagent, imidazole-1-sulfonyl azide • HBF4 for the two N-Cbz indoline analogs 48a and 42 as
well as the NH indoline derivative 41 as shown in Scheme 7D. Reaction conditions were
identical and a blast shield was used with all precautions taken when handling azide. The
sulfonamide starting material was exposed to the azide transfer reagent in the presence of
potassium carbonate in a 1:1 mix of i-PrOH-H2O at rt. The reaction was then stirred vigorously
with rapid heating until the reaction became homogeneous and allowed to cool to room temp and
stir overnight. The reaction mixture was quenched with saturated NH4Cl(aq.) and products were
extracted with methylene chloride. Pure sulfonyl azide products were isolated from the crude
extracts through flash column chromatography to afford desired sulfonyl azides 49a, 49b, and
49c in good to moderate yields of 79 % and 51 % and 73 %, respectively. HPLC purities of the
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isolated N-Cbz-5-chloroindoline-6-sulfonyl azide and N-Cbz-indoline-7-sulfonyl azide products
were found to be 93 % (product eluting at 15.0 min) and 98 % (product eluting at 11.3 min),
respectively.
Three-component-copper-coupling Reaction Overview.
Once the scaled up syntheses of indoline sulfonyl azide starting materials were
optimizeds we moved onto derivatizing the indoline scaffold under CuI-catalyzed conditions
with a small library of alkyne and oxygen or nitrogen nucleophiles.

Figure 41. Synthesis Versatility of CuAAC-Sulfonyl Azide Chemistry.
A series of sulfonyl azide derived analogs, which include: sulfonyl triazoles, amidines
(1o, 2o, and 3o), imidates, and N-acyl sulfonamides (Figure 41), were prepared directly from the
N-Acetyl-5-halo indoline-6-sulfonyl azides through a three-component-copper-coupling reaction
adapted from the general procedure described by Chang et al.164-167

96
One example of “Click” chemistry refers the ability of the azide-containing functional
group to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) (Scheme 8), which
results in 1,4-disubstituted 1,2,3-triazoles.168-170
Scheme 8. An example of “Click” Chemistry.168-170

“Click” chemistry describes reactions which are modular, highly selective, and proceed
under easily attainable conditions, and therefore provide great potential in medicinal
chemistry.171, 172 Mirroring the remarkable capabilities of “Click” chemistry is the chemistry of
sulfonyl azide catalyzed by transition metals such as copper, which promises new routes to
biologically relevant functionality yet to be accessed.
Sulfonyl Triazoles. We have synthesized a library of sulfonyl triazoles using the general
procedure described by Bock in 2005.168 A solution of sulfonyl azide, copper(I) thiophene-2carboxylate (CuTC), and alkyne in CH2Cl2 was stirred at room temperature over 2 hours before
diluting with a 1:1 mixture of CH2Cl2 and saturated aqueous NH4Cl and isolation of precipitate
via vacuum filtration. The synthetic schemes for these reactions are presented below.
Scheme 9. Synthesis of Sulfonyl Triazole analogs

Reagents and Conditions: (i) CH2Cl2, Alkyne, CuTC, rt 2 h.
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Sulfonyl Imidates and N-Ac Sulfonamides. A small series of sulfonyl imidates and NAc sulfonamides were synthesized from the N-acetyl-5-halo-indoline-6-sulfonyl azide under
identical conditions as the sulfonyl amidines, but with alcohol or water acting as the nucleophile,
respectively, instead of an amine (Scheme 10).
Scheme 10. Synthesis of Sulfonyl Imidate and N-Ac Sulfonamide Analogs.

Reagents and Conditions: (i) CH2Cl2, CuI, Et3N, rt 3h.173-175
Sulfonyl Amidines (1°, 2°, 3°). Sulfonyl amidines are a direct structural bioisostere of
the N-acetyl-sulfonamide derivatives in terms of atom coordinates (Figure 42), with an amine
replacing the oxygen in the carbonyl. However, it is expected that the sulfonyl amidine moiety
may have improved stability over the N-acetyl sulfonamides, and should be able to avoid
hydrolysis by di-Zn metal center of the enzyme. Due to the lower pKa of the sulfonyl amidine,
once the neutral species enters into proximity of the activated catalytic hydroxide group of the
di-Zn metal center, we expect the hydroxide nucleophile to deprotonate the amidine NH moiety
which will result in a negatively charged resonance stabilization throughout the O-S-N-C-NH
atoms. This is in direct contrast to the N-acetyl sulfonamide moiety which is already
deprotonated at physiological pH and would be attacked by the activated hydroxide leading to
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possible cleavage of the N-C=O bond and deactivation of the inhibitor. The pKa for the primary
sulfonyl amidine functional group has not been reported and further pKa exeriments will be
conducted in the future to determine the acidity of the group.

Figure 42. Sulfonyl Amidine Bioisosteric Relationship to N-acetyl-sulfonamides.
Optimization of the synthetic protocol for production of a series of N-acetyl-5-haloindoline-6-sulfonyl amidines and a single N-Cbz-5-chloro-indoline-6-sulfonyl amidine were
established and reported as follows. All reactants and reagents were used at the highest possible
quality. To a solution of N-Cbz-5-halo-indoline-6-sulfonyl azide, NH4Cl(s) (1° sulfonyl amidine)
or an amine nucleophile (2° & 3° sulfonyl amidines), and CuI catalyst in methylene chloride was
added Et3N base followed immediately by alkyne addition under inert atmosphere (Scheme 11).
Scheme 11. Synthesis of 1°, 2°, and 3° Sulfonyl Amidine Derivatives.

Reagents and Conditions: (i) CH2Cl2, CuI, Et3N, rt 3-4 h.165, 166, 176, 177
The reaction proceeds under positive inert gas pressure that was maintained using a gas
bubbler to allow for rapid liberation of nitrogen gas which drives the reaction. The reactions is
agitated over several hours at standard temperatures and pressure until consumption of the
sulfonyl azide by TLC and HPLC. Following literature precedent described for sulfonyl amidine
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reaction workup and purification, we diluted reaction mixtures with a 1:1 mixture of methylene
chloride or chloroform and saturated aqueous NH4Cl for 30 min. If biphasic system became
emulsified, then the layers were allowed to separate and products were isolated with liquid-liquid
extractions with methylene chloride and purified by flash column chromatography. However,
products were collected via vacuum filtration when found to precipitate during biphasic dilution.
The compounds isolated through precipitation and collection via filtration were initially
submitted for enzyme assay with NDM-1 without further purification as NMR analysis showed
good purity in general. Later purification protocols were optimized to take into account copper
contamination carried over in the precipitated products by applying a rigorous purification
process on each compound. The process is summarized in Figure 43 below.

Figure 43. First Iteration of Purification Protocol for Preparing Sulfonyl Azide-derived Inhibitor.
The final iteration of sulfonyl azide-derived analog purification was to completely
replace the saturated ammonium chloride aqueous quench step with a 1:1 saturated sodium
thiosulfate and water mixture followed by dilution with methylene chloride. Products were
isolated via filtration or through liquid-liquid extraction. Copper removal was facilitated by
passing through a plug of activated carbon after dissolving the crude product in a mixture of hot
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acetonitrile-methanol-DMF, followed by recrystallization. Spectral data comparison with
previous product batches show a marked improvement in purity. Enzyme inhibition analysis and
copper content analysis were determined and discussed later in this chapter.
Results
SWISSDOCK Results.
A number of both 6- and 7-substituted sulfonamide indoline derivatives have been
docked into the active site of DapE using Autodock Vina, SwissDOCK, and MOE over the
course of the project. There is agreement between these separate molecular docking algorithms
as to the orientation of the inhibitors, in that the 7-substituted indolines are expected to bind to
the di-metal centers of DapE while the 6-substituted indoline derivatives are expected to be poor
metal binders due to the suboptimal distance between the sulfonyl and amide oxygen atoms.
However, the 7-substituted analogs are expected to possess an optimal distance and
simultaneously bind both Zn metals which orients the N-alkyl groups to fill the hydrophobic
succinate binding pocket, formed by DapE’s flexible loop V. This ring orientation
simultaneously positions the halo functionality into the pocket which would be filled by an
incoming tyrosine residue from the opposite dimer chain in the dimerization domain. The
tyrosine hydroxyl group may then engage in pseudo-hydrogen bonding with the halo group,
increasing the binding. The expected inhibitor binding mode also orients the indoline directly
over the di-metal center with the N-acetyl carbon situated in the cleft, which would accept the
mDAP product during native substrate binding to DapE. This suggests there is room for
functionalization off the N-acetyl group, which could improve structure activity and binding.
Docking suggested that both 6-sulfonamides and 7-sulfonamides can bind to the active
site of DapE, but showed a calculated preference for the 7-sulfonamides as illustrated by the
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docked N-acetyl-5-bromoindoline-7-pyrrolidinyl sulfonamide analog (Figure 44 B-D). The
results suggested that for the 7 sulfonamides, one of the sulfonamide oxygens acts as a ligand for
one active site zinc, while the N-acetyl oxygen acts as a ligand for the second zinc (Figure 44C).
A

C

B
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Figure 44. HiTS Sulfonamide Indoline Derivative Docking to DapE’s open conformation (PDB
ID: 3IC1). A) Lead compound 5d, B) simplified pyrrolidinyl derivative 12b of HiTS hit 4. C)
Surface representation and D) ligand interaction map of 12b.
While there are many single zinc-binding groups (ZBGs) that have been reported and
reviewed,178, 179 the structural motif of ligands bridging two active site metals in metalloenzyme
inhibitors is rare, and was exemplified recently for 8-quinolinol binding to the di-Zn active site
of aminopeptidase (AAP) reported by Hanaya.162 A structural assessment was done using
docking to compare the library of 5-bromo-N-acetyl-indolines-6- & 7-sulfonamides bearing a
variety of substituents on the sulfonamide nitrogen with 7-sulfonamides. While both
regioisomers showed active site binding with ΔG values of -7.7 to -10.2 kcal/mol, 18 of 24
matched pairs examined showed a calculated preference for the 7-sulfonamide (Table 6). These
results also suggest the N-acyl indoline scaffold incorporates a sulfonamide moiety adjacent to
the N-acetyl group can bridge the di-Zn metal center and form a stable bis-metal complex
leading to inhibition.
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Table 6. Sulfonamide Indoline Inhibitor Data Table.

Ligand Entry
ΔG Affinity
R
X
6 Sub. 7 Sub.
6 Sub. 7 Sub.
Cl -7.2 -10.24
5a
5c
-NH-isoPentyl
Br -8.96 -9.46
5b
5d
Cl -8.44 -8.51
9a
9b
-NH-cylcohexyl
Br -7.44 -10.21
10a
10b
Cl -8.35
9.14
11a
11b
-N-Pyrrolidinyl
Br -8.52 -9.58
12a
12b
Cl -8.14 -9.14
13a
13b
-N-Piperidinyl
Br -8.43 -9.08
14a
14b
Cl -8.58 -10.29
15a
15b
-N(2-methoxyethan-yl)2
Br -7.75 -7.53
16a
16b
-N(ethyl)2
Br -8.67 -9.47
17a
17b
Cl -8.58 -9.38
18a
18b
-N(propyl)2
Br -8.66 -7.53
19a
19b
Cl -8.46 -9.29
20a
20b
-NH-isoPropyl
Br -8.33 -10.19
21a
21b
Cl -8.34 -9.75
22a
22b
-PheOMe
Br 7.94
-8.66
23a
23b
-MetOMe
Br -9.41 -8.51
24a
24b
-ProOBz
Br -9.01 -7.44
25a
25b
Cl -8.82
-26a
26b
-GlyOMe
Br -8.45 -9.85
27a
27b
-βAlaOMe
Br -9.54 -10.39
28a
28b
Cl -8.39 -8.99
29a
29b
-ValOMe
Br -9.25 -8.68
30a
30b
a
Generic N-acetyl-5-halo indoline-6- & 7-sulfonamide structural scaffold (Top). Docking results
for N-acetyl-5-halo indoline-6- & 7-sulfonamide with in silico ΔG calculations (Bottom).
HiTS Hit Docking Results.
Docking results for the High Throughput Screen hit database against the open
conformation NmDapE crystal structure were obtained, analyzed in MOE’s database view
window, and sorted into groups of ascending ΔG docking scores with respect to each ligand
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database entry. The ΔG score values were plotted against the overall pose sequence number. The
processed database docking results for the global and site-directed docking experiments were
analyzed and presented as the Line Graph Representation (LGR) plot shown in Figure 45A & B
respectively, as well as a third LGR plot of the combined data sets with identical data plotting
method (Figure 45C). The data points plotted at lower Y-axis values correspond to more stable
docking poses with tighter binding.
A

B
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Figure 45. Line Graph Representation (LGR) of HiTS Hit Ligand Database Docking Results
Against NmDapE Receptor. The Y-axis (bottom) represents ΔG scoring values in kcal/mol. The
X-axis (right-hand) represents ligand pose sequence sorted by two tier organization. Intervals of
15 data points represent docking results of a single ligand entry (1-21) organized in ascending
ΔG scoring values. Horizontal graph lines denote ligand entry transitions. Refer to Table 3 for
ligand entry identities. A) Docking Results for HiTS-hits_NmDapE_OC-SF-dock; B) Docking
Result for HiTS-hits_NmDapE_OC-SD-dock. * Sharp connecting lines at interval transitions
may be ignored.
Analysis of the docking poses in the MOE working window reveals interesting ligandreceptor interactions that might be responsible for inhibition in the original screen. A selection of
HiTS hit docking poses are presented in the following Figure.
A

B
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Figure 46. HiTS hit docking pose selection. A) 6-sulfonamide, B ) 7-sulfonamide, C) HiTS hit 7,
pose 1 D) HiTS hit 7, pose 1, E) HiTS hit 6, pose 1, F) HiTS hit 6, pose 2, G) β-sulfone 8.
A common zone of interaction between docking ligands and receptor seems to be the
pocket made by the junction of R178.A, Gly324.A, Th325.A, Y197.B, and sometimes H194.B,
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where the propensity to coordinate hydrogen bond donors is evident (Figure 46A, B, D, F).
When DapE is in the open conformation we commonly refer to this zone of interaction as the
succinyl-binding patch. It is worth noting that docking of one of the direct HiTS analog hits
(Figure 46A) provided evidence of coordination to this site via hydrogen bond accepting from
the oxygen of the N-acetyl group while the sulfonamide’s oxygen atoms bridge the Zn metals
and NH form hydrogen bond donating interaction with the backbone T325.A. Moreover, this
binding pocket seems to facilitate tetrahedral sulfate-like species more readily as shown in one of
the poses found for the difluoromethyl sulfonamide hit (Figure 46D). The docking pose was
found to incorporates a pseudo-H-bond to R178.A and one of the fluorines of the difluoromethyl,
suggesting that the fluorines may yield enhanced potency toward DapE. Figure 46E and Figure
46F represent the thiazole compound in opposite binding configurations while Figure 46G
represents the sulfone analog hit in a pose reminiscent of what we see in the product bound
substrate hydrogen bonding network as the sulfone oxygen make interaction with the same
arginine residue as the proximal (to the amide) carboxylate of the L,L-SDAP structure. These
docking results lead us to believe we are on the right path with pursuing analogs of the original
HiTS. However, the analogs described herein mostly represent SAR relating to succinic
interaction sites on the enzyme and synthetic efforts should be refocused to pursuing SAR
interaction with the DAP binding sites as well.
Standardized Substrate and Inhibitor Docking Results.
Docking results for the standardized substrate and inhibitor database against the open
conformation NmDapE crystal structure were obtained and analyzed in MOE’s database view
window. The data set was processed in a similar manor to the HiTS docking results, with the
data sets being sorted into groups of ascending ΔG docking scores with respect to each ligand
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database entry. The ΔG score values were plotted against the overall pose sequence number
ending at 1250. The processed database docking results were analyzed and are presented as a
LGR plot in Figure 47 below.

Figure 47. Line Graph Representation (LGR) of Standardized Substrate and Inhibitor Database Docking Results Against
NmDapE Receptor. Y-axis (bottom) represents ΔG scoring values in kcal/mol. X-axis (right-hand) represents ligand pose
sequence sorted by two tier organization. Intervals of 15 data points represent docking results of a single ligand entry (1-21)
organized in ascending ΔG scoring values. Horizontal graph lines denote ligand entry transitions. Refer to Table 4 for ligand
entry identities.
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Analysis of the docking poses in the MOE working window reveals interesting ligandreceptor interactions that may shed light on the transition from the open to the closed
conformations of DapE during substrate binding. A selection of L,L-SDAP docking poses are
presented in Figure 48.
A

B

Figure 48. Selection of substrate docking pose into NmDapE open structure. A) L,L-SDAP, B)
N-methyl-L,L-SDAP assay substrate.
Docking analysis of the native L,L-SDAP and the synthesized assay substrate N-methylL,L-SDAP show common binding interactions. The results seem to suggest that substrates bind
to the dimerization interface through interaction at the succinyl carbonate, proximal carboxylate
and distal DAP carboxylate. The ammonium moiety is observed to form a hydrogen bonding
interaction with the general acid base E134.A while the methylated analog appears to locate the
methyl along the binding groove as described in chapter 3 of this work.
Enzyme Assay Inhibition Results.
Enzyme inhibition was determined under the described method for the library of 6
substituted N-Ac sulfonamide inhibitions that were synthesized. Sample screening
concentrations of 200 μM and 20 μM were used to determent the percent inhibition for DapE and
NDM-1. The results are summarized in Table 7 below.
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a

Table 7. N-Acetyl-5-halo indoline-6-Sulfonamides Inhibition Results.

DapE Inhibition
NDM-1 % Inhibitions
200 uM 20 uM Est. IC50
200uM
20uM
P
P
P
42
8
5b
58.2
21.5
163
uM
-6
9a
40.3
18.9
279 uM
-0
10a
56.7
33.7
145 uM
-0
11a
72.5
29.8
104 uM
20
-12a
97.7
38.6
54 uM
-9
13a
97.5
14.4
97 uM
-3
14a
90.4
31.9
75 uM
-13
15a
P
P
P
3
-16a
80.3
10.2
122 uM
--17a
P
P
P
-5
18a
18.9
-1.78
492 uM
-57
21a
92.9
31.8
74 uM
13
-22a
P
P
P
61
6
23a
87.1
26.2
90 uM
17
-28a
P
P
P
50
20
37
55.9
9
178 uM
-31
38
a
Table Legend: P = Pending Results, -- = no data collected at given concentration.
Compounds

Our early inhibition results for the N-acetyl-5-halo indoline-6-sulfonamides towards
NDM-1 suggests virtually no inhibition, with 21a performing the best. However, this series
performed better towards inhibition of DapE as expected.
Inhibition data of the N-Cbz indoline-7-(N-acyl-sulfonamide) series toward DapE and
NDM-1 are summarized in Table 8.
Table 8. N-Cbz indoline-7-(N-acyl-sulfonamide) Inhibition Results.
DapE % Inhibition
NDM-1 % Activity
200 uM 20 uM Est. IC50
500 uM
95.7
47.5
29 μM
0
43a
98.7
36.8
59 μM
0
43b
P
P
P
0
43c
a
Table Legend: P = pending results.
Compounds

This series of inhibitors performed poorly against NDM-1, but resulted in modest
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inhibition of 47.5 and 36.8 % at 20 μM towards DapE for the two compounds tested. Inhibition
of the simple N-acetyl sulfonamide series towards DapE and NDM-1 are summarized in Table 8.
Table 9. Simple N-Acetyl Sulfonamide Inhibition Results.a
DapE % Inhibition
NDM-1 % Inhibition
500 uM 200 uM 20 uM 500uM
200uM
1
97.4
92.4
36.7
5
-44a
2
97.4
85.7
31.2
4
-44b
3
P
P
P
-3
44c
4
P
P
P
-2
44d
a
Table Legend: P = pending results, -- = no data collected at given concentration.
# Compounds

Inhibition results of the simple sulfonamide series towards NDM-1 indicates virtually no
inhibition. However, inhibition of the N-succinyl sulfonamides, 44a and 44b resulted in nearly
complete inhibition of DapE at 500 μM, modest inhibtion at 200 μM and a respectable inhibition
at 20 μM. Assay results are pending for the two N-glutamyl sulfonamides possessing an extra
CH2, but docking study suggests this extra CH2 may facilitate better interactions between the
positively charged succinyl binding patch and the catalytic metal center in the open form of
DapE, thus hopefully resulting in better inhibition performance.
A series of miscellaneous commercially available analogs, or made in short, simple
syntheses in an attempt to identify new inhibitor scaffolds were included in assays against DapE
and NDM-1. Inhibition results for the compounds are summarized in Table 9.a
Table 10. Miscellaneous Structure Analog Inhibition Results.
#

66a

Miscellaneous
Compounds

DapE % Inhibition
NDM-1 % Inhibition
200 uM
20 uM 200uM
20uM
78.6

21.8

--

(at 500uM)
2

113
42.7

66b

20.2

13

--

(at 100uM) 46
IC50 = 120 ± 10
Hill = 0.4 ± 0.03

66c

27

24.7

62

66d

93.7

15.4

NA

--

66e

--

--

--

(at 500uM)
2

66f

--

--

0

--

66g

--

--

84

48

--

--

81%

59%

66i

--

--

40%

3%

66j

--

--

--

3

66k

--

--

37

0

CTR-a-22 (R,S)

66h
CTR-a-16 (S,S)
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66l

--

--

59

16

aTable Legend: P = pending results, -- = no data collected at given concentration.
We have only assayed a small selection these miscellaneous analogs toward DapE
inhibition, with carboxylic acid 66c showing the most potency. The results from docking
suggests that this compound can interact with the succinyl-sulfonyl interaction patch with one or
both imidine carbonyl oxygens while the benzoic acid moiety can interact with the catalytic
metal center. The inhibitor 66c showed sufficient inhibitory potency to warrant obtaining IC50
and Hill coefficient values which were 120 μM ± 10 and 0.4 ± 0.03, respectively.
The series of thiol containing compounds have only been assayed with NDM-1 to date,
showing modest potency overall, with thiol compound 66h inhibiting NDM-1 59 % suggesting
an IC50 just under 20 μM. However, we decided not to pursue this thiol-containing inhibitor
series due to many possible off-target side effects common to thiol-containing drug classes.
Sulfonyl Azide-Derived Analog Inhibition Results.
A series of potential MBL inhibitors which included sulfonyl triazoles, sulfonyl amidines
(1o, 2o, and 3o), sulfonyl imidates, and N-acyl sulfonamides were submitted to our NDM-1
project collaborator, Dr. Walter Fast, for inhibitor screening against the metallo-β-lactamase
NDM-1. The Fast group started by treating the NDM-1 enzyme with inhibitors at 100 μM to see
if substrate (at near Km concentrations) turnover was inhibited. If any compounds looked
promising, assay conditions (incubation time, fix solubility issues, etc) were optimized. The
initial inhibition results were very promising and we moved to scale up compounds for IC50 and
Hill coefficient determination.
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The first iteration of sulfonyl azide-derived analog purification yielded high-purity
samples of 95% purity or better. Table 11 represents the inhibitory results of those samples that
were re-prepped with side-by-side comparisons of the original batch of inhibitors. However, we
found disturbing discrepancies in NDM-1 inhibitory potency between the old and new inhibitor
batches, with the older, less pure batches possessing greater inhibitory potency. Enzyme
inhibition assays were repeated and performed in unison for all the compounds in Table 11.
Table 11. Side by Side comparison of sulfonyl azide-derived analog batchs.
Structure

53b

55c

57a

57b

Sample Data
% Purity
(6/6/16 batch)
97% pure by HPLC.
Light grey powder.
(4/2/15 batch)
Light green/blue
Powder.
(6/6/16 batch)
95% pure by HPLC
White powder.
(4/2/15 batch)
Off-white/ tan
powder.
(6/6/16 batch)
95.5% pure by HPLC.
A White Powder.
(7/10/15 batch)
Light green powder.
(6/6/16 batch)
94.5% pure by HPLC.
White Powder.
(4/2/15 batch)
Light green powder

IC50 (uM) Hill Coefficient
3.0 ± 0.5

0.65 ± 0.07

1.7 ± 0.5

0.6 ± 0.1

> 100

N/A

2.4 ± 0.4

0.60 ± 0.06

> 100

N/A

0.45 ± .06

0.71 ± 0.06

29.8 ± 3.5

0.9 ± 0.1

3.8 ± 0.8

0.8 ± 0.1

HPLC analysis of the early and later compound batches show identical retention times as
seen in Figure 49A-D. Compounds 57b from both batches were subjected to further LC-MS
analysis and show identical chromatograms and mass spectra (Figure 49E-F).
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B

C

117
D

E

Figure 49. HPLC and LC-MS analytical comparison between NDM-1 inhibitors with identical
structures. A) 53b 6/6/16 batch v. 4/2/15 batch. B) 57b 6/6/16 batch v. 4/2/15 batch C) 57a
6/6/16 batch v. 4/2/15 batch. LC-MS analysis: D) 57b batch 6/6/16, E) 57b batch 4-2-15.
Unfortunately, copper (II) was found to potently inhibit NMD-1 with nanomolar potency
after the discovery of discrepancies in inhibition data between the original, less pure sulfonyl
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azide-derived inhibitors and recent higher purity resubmissions of structurally identical inhibitors
(Results Section). Our sulfonyl azide-derived inhibitors were designed to be strong metal
coordinators and we rationalized the inhibition discrepancy between batches as the presence of
copper in the original samples which were not subjected to re-crystallization protocols to remove
copper ions. This hypothesis was confirmed with follow-up enzyme studies of NDM-1 in the
presence of various Cu(II) salts conducted by the Fast group.
The question of improving the removal of copper ions from our copper-catalyzed reaction
caused us to take a closer look at our quenching workup. The traditional method of removing
copper catalyst from organic reactions is with copper-absorbing resins or quenching with
saturated ammonium chloride solution, which creates a blue aqueous color indicating copper
ions in solution. When we employed saturated NH4Cl in the CuI catalyzed reaction workup we
observe a blue aqueous layer.
However, the question remaining was whether this method was completely removing all
the copper metal from the sulfonyl azide reactions during the workup procedures. A simple
control experiment was set up to probe this question. A 10 mg sample of the reaction-grade CuI
catalyst was added to a dram vial and mixed with a number of different quenching conditions as
depicted in Figure 50.
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Figure 50, A] CuI + Sat. NH4Cl. B] CuI + Sat. NH4Cl + 30% NH4OH buffer solution with pH ~
10. C] CuI + Sat. NH4Cl + TEA. D] CuI + TEA/AcOH buffer solution with pH ~ 7. E] CuI + sat.
EDTA solution. F] CuI + Sat. Sodium thiosulfate. Conditions A, D and E all had CuI remain in
solid phase while B, C and F conditions fully dissolved the CuI.
It was found that CuI(s) does not fully dissolve in the absence of a sufficient amount of
base present. The sulfonyl azide reactions are run with a 1.5 eq excess of TEA which could be
the source of the dissolved copper ions observed, but we do not know if this completely removes
the catalyst. Cuprisorb resin was also assayed for effectiveness of removing copper. However,
the resin was found to require extended periods of time to absorb copper ions and quickly
reaches its upper limit of copper capacity after only a few milligrams of copper per gram of
resin. We also cannot use EDTA reliably to remove CuI from our reaction as it does not
effectively coordinate to Cu+ species. We demonstrated that NH4OH solution was good for fully
dissolving copper, but the basic pH of the quenching media can also lead to unwanted side
products as well as product dissolution into the aqueous washes where acidification would just
lead to copper precipitation with protonated products. It seemed that sodium thiosulfate is a
good candidate for removing copper from the reaction as it can dissolve Cu+2 ions, reducing
them to Cu+ and then forming very soluble Cu+ complexes. The saturated sodium thiosulfate
also has a pH range of 6-8 making it idea for inhibitors with acidic functional groups.
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Purification Procedure to Remove Copper Contamination for DapE Inhibition.
The final iteration of sulfonyl azide-derived analog purification was used to synthesize a
series of highly purified and recrystallized sulfonyl amidine analogs which have been assayed
against DapE (Table 12) to replace the ammonium chloride quenching step with a 1:1 saturated
sodium thiosulfate and water mixture that yielded high-purity sample, 95 % pure or better.
Table 12. Copper-Assayed Sulfonyl Amidine Inhibition Results Against DapE.
Compounds
Entry

% Inhibition of DapE at:
200 uM
20 uM

76.8

24.4

72.1

27.9

79.1

22.7

98.3

36.6

The realization of copper contamination in some of our samples has influenced our group
to adapt a commercially-available copper assay kit for fish tanks to developing a standardized
UV-Vis copper assay using a commercially available aquarium testin kit to quantify the amount
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of copper contamination in each inhibitor sample.
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A screening library of synthesized

compounds produced via of copper catalysis which possessing differing amounts of copper was
used as our pilot experiment. The results of our pilot experiment are summarized in Table 13.
Table 13. Copper Assay Results.a
Copper Purifications Protocols Est. Eq.
Assay Determined
#
Cu (3-0)
Eq. Cu
FS
RC
CA
AC
X
2
7.5
50a
X
2
0.1
51b
X
2
2
52b
X
2
2.5
53b
X
X
X
0
0.03
55a
X
2
1.8
55b
X
X
X
0
1.7
55b
X
X
1
0.065
55c
X
X
X
0
0.025
55c
X
X
X
0
0.2
57a
X
3
2.4
57a
X
2
0.4
57b
X
X
X
0
0.037
57b
X
3
2.2
57b
X
X
1
6
58a
X
X
X
0
0.22
58a
X
X
X
0
0.01
58a
X
X
1
0.01
58b
X
X
X
0
0.125
58b
X
3
1.4
64a
a
Table Legend; FS = quench, precipitate and fitrater products, RC=recrystallized, CA=10% citric
acid wash, AC=passed through activated carbon plug. Est. Eq. Cu= degree of expected copper in
sample on a scale of 3 (Highest) - 0 (Lowest).
Enzyme inhibition assays with NDM-1 and later with DapE looked promising. The
results confirm that the final iteration of copper purification protocol applied to the sulfonyl
azide-derived analogs results in a substantial drop in copper composition of the samples as
compared to the earlier batches. However, our copper assay tests still showed detectable levels
of copper in the samples even after rigorous purification protocols were applied. Since copper is
a nanomolar inhibitior against NDM-1, the inhibition values initially obtained were rendered
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unreliable and discarded. We have made the in-house copper assay standard in our enzyme
inhibition assay workflow to ensure that our future inhibitor samples will be copper free.
Conclusion
We have validated the synthesis of indoline-6-sulfonamides, and have made significant
progress in the development of new chemistry to access the 7-sulfonamide derivatives, which
will provide synthetic accessibility to new derivatives of this medicinally important scaffold to
the scientific community.152 The route to the 7-sulfonamides has utilized Borror’s procedure to
afford the cyclic sulfonyl urea 40 which was hydrolyzed with sulfuric acid and selectively
protected with Cbz on the indoline nitrogen. N-Acylation on the primary sulfonamide of the
Cbz-protected indoline-7-sulfonamides afforded a small library of N-Cbz-indoline-7-(N-acylsulfonamide) which has been assayed against DapE and NDM-1. Synthesis of a small library of
simple N-succinyl and N-glutamyl sulfonamides was also carried out and included with a library
of miscellaneous compounds which were assayed for inhibition against our two model
metalloenzymes. Finally, we have also pursued sulfonyl azide chemistry to access new sulfonyl
triazoles, sulfonyl amidines (1o, 2o, and 3o), sulfonyl imidates, and N-acyl sulfonamides using a
Cu(I)-catalyzed three-component. The information compiled in the work represents a strong
foundation on which to build our understanding of how metalloenzymes function and how to
interact with them using traditional and cutting edge medicinal chemistry techniques.
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31
1-(Indolin-1-yl)ethan-1-one (31). To a RBF was added 0.850 mL (8.42 mmol, 1eq.) indoline
into 9 mL of CH2Cl2 and stirred over an ice bath for 5 min. Then 3.87 mL of TEA was added
and the reaction was left to stir for 5m after which 0.852 mL of acetyl chloride was added to the
stirred reaction mixture over 5 min then left to stir for 2 h. The reaction mixture was quenched
with 15 mL of water and extracted 3x with DCM to yield a brown tar. The crude product was
then purified through flash column using 50:49:1 EA-Petroleum Ether-AcOH solvent system as
eluent to yield the desired product. Product collected (1.10 g, 80 %) as an orange solid: mp
96−99 °C; 1H NMR (500 MHz, CDCl3): δ 2.22 (s, 3H), 3.20 (t, J = 6.8 Hz, 2H), 4.05 (t, J = 6.8
Hz, 2H), 7.00 (d, J= 6.0 Hz, 1H), 7.03−7.18 (m, 2H), 8.20 (d, J= 6.4 Hz, 1H); 13C NMR(125
MHz, CDCl3): δ 24.4, 28.1, 48.9, 117.1, 123.7, 124.6, 127.7, 131.2,143.0, 168.9; MS ESIm/z
184 ([M + Na]+, 100); HRMS EI (DFA) m/z calcd. for C10H11NO [M+] 161.0841, found
161.0840.154, 159
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General Batch Synthesis Procedure for Halogenation of N-Acetylindolines. A mixture of 1acetylindoline (2.01 g, 12.47 mmol) and NCS (1.748 g, 13.09 mmol) or NBS (2.33 g, 13.09
mmol) in 60 mL of acetonitrile was left to stir at room temperature for 3.5 hrs. After the solvent
was removed under vacuum and the residue diluted with water and extracted 3x with CH2Cl2 and
concentrated to dryness. The collected crude product was then purified by flash chromatography
on silica gel eluting with 1:1 EtOAc/hexane.181

32a
1-(5-Chloroindolin-1-yl)ethan-1-one (32a). Product collected (2.02 g, 83%) as an orange solid;
1

H NMR (500 MHz, CDCl3): δ 8.13 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 9.5 Hz, 1H), 7.13 (s, 1H),

4.06 (t, J = 8.0 Hz, 2H), 3.17 (t, J = 8.5 Hz, 2H), 2.21 (s, 3H). 13C NMR (500 MHz, CDCl3): δ
168.9, 141.8, 133.2, 128.6, 127.6, 124.7, 124.8, 1187.0, 49.1, 28.0, 24.3.
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32b
1-(5-Bromoindolin-1-yl)ethan-1-one (32b). Product collected (1.81 g, 61 %) as an orange
crystalline solid: mp 122-124 °C; 1H NMR (500 MHz, CDCl3): δ 8.05 (d, J = 8.5 Hz, 1H), 7.26
(d, J = 9.5 Hz, 1H), 7.24 (s, 1H), 4.01 (t, J = 8.5 Hz, 1H), 3.14 (t, J = 8.5 Hz, 2H), 2.19 (s, 3H).
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Procedure for Continuous Flow Synthesis of N-Acetyl-5-chloroindoline.
Continuous flow synthesis was carried out with a 7 min residence time and reactor
heating at 80 oC. Two 2.0 M DMF solutions of N-Acetylindoline and N-Chlorosuccinimide, line
A and B respectively, were freshly prepared and filtered immediately before loading into
separate 5 mL syringes which were fitted to syringe pumps. A third syringe pump loaded with
an ethyl acetate wash syringe was also prepared (line C) and attached to a three-way solvent
valve spliced into solvent line A. Line C was used to pump ethyl acetate thought the system in
order to remove air from the reactor headspace before reaction initiation. The solvent flow rates
for line A and line B were set to 137.5 μL/min which were combined at a mixing T-joint into the
reactor loop for a final reaction flow rate of 275 μL/min. The reactor loop, possessing a volume
of 1.9 mL, was heated in an 80 oC water bath and fitted with a 100 psi back pressure regulator.
This reactor setup was able to process 5 mL of 2.0M N-Ac-indoline in the initial reaction run and
10 mL in a followup reaction run. The product stream was immediately quenched into H2O by
dripping directly into test tube filled with 4.0 mL H2O at 7.0 min collection intervals whereupon
fluffy white product crystals crash out of solution. Once the syringe volume from line A reached
zero the three-way valve was switched allowing for the EA syringe pump to clear the remaining
1.9 mL reaction volume still left in the reactor headspace. The test tubes were combined into one
filter funnel and rinsed with DI H2O followed by petroleum ether and left to dry under high vac.
Recovered products for the first and second optimized reactions were found to be 1.002 g and
1.920 g of an off-white fluffy crystalline solid in a yield of 51 %. HPLC analysis was performed
on each fraction collected during the second reaction run in order to determine the product
stream composition at each time point (Figure 51). The results of the product stream HPLC
analyss are given below with the first and last fractions omitted due to EA contamination.
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A
B
C
D
E
F
G
H
Figure 51. HPLC analysis, Fractions collected at 7 min intervals: A) tube 2, B) tube 3, C) tube 4,
D) tube 5, E) tube 6, F) tube 7, G) tube 8, H) tube 9. Peaks at 8.8 mins and 10.3 mins correspond
to starting material and products, respectively.
The batch reaction was carried out to simultaneaously with flow protocols to compare the
two different routes to halogenation or the N-acetyl indoline. The procedures were as followed:
N-Ac-indoline (1.0 g) was added to a small RBF and dissolved in DMF (2.0 M, 3.1 mL). Then a
2.4 M solution of freshly prepared NCS in DMF (3.1 mL) was slowly added to the reaction
vessel at rt (batch reaction 1), or 70 oC (batch reaction 2) at a flow rate of 137.5 μL/min with
stirring. Upon completion of the NCS addition the reaction was allowed to stir for 2 hrs and
quenched with water, forming the percipitate. product was collected via filtration while the rt
reaction remained incomplete and allowed to stir overnight. The reactions were then analysed by
HPLC and results summarized in Figure 52.
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Figure 52: Comparing flow vs. batch synthetic protocols. A) NAc-indoline starting material, B)
filtered products from 1st flow reaction 1, C) filtered products from 2nd Flow reaction after
optimization, D) batch reaction 1, run at rt for 2 h), batch reaction 2, ran at 70 oC for 2 h).
The optimized flow reaction only took 30 min for a 1.0 g scale reaction to go to
completion with high purity conversion while the batch reactions either produces multiple
products after heating or does not finish in under two hours on the same scale as flow. These
results illustrate the benefits to using continuous flow synthesis to prepare the 5-chloro-NAcindoline product.

33a
1-Acetyl-5-chloroindoline-6-sulfonyl chloride (33a). To 1-acetyl-5-chloroindoline (300 mg)
was added to chlorosulfonic acid (2.25 M, 7 mL/g of sm) in small portions with intensive stirring
and cooling (ice). The mixture was heated at 60 oC, stirred for 3.5 hrs and TLC was taken using
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60:1:39 EA-petrolium ether-AcOH solvent ratio to confirm reaction completion. The reaction
mixture was quenched over ice in a large earlenmeyer flask by pouring down the sides of the
flask. The precipitate was filtered and re-crystallized from methyl ethyl ketone to yield 341 mg
of an off white solid. Exp mp = 190-195 oC; 1H NMR (500 MHz, CDCl3): δ 8.98 (s, 1H), 7.42 (s,
1H), 4.02 (t, J = 9.0 Hz, 2H), 3.33 (t, J = 8.0 Hz, 2H), 2.09 (s, 3H).

33b
1-Acetyl-5-bromoindoline-6-sulfonyl chloride (33b). To 1-acetyl-5-bromoindoline (1.20 g, 5.0
mmol) was added to chlorosulfonic acid (8.5 mL) in small portions with intensive stirring and
cooling(ice).156 The mixture was heated at 60 oC, stirred for 3 hrs and TLC was taken using
60:1:39 EA-petroleum ether-AcOH to confirm reaction completion. Reaction mixture was
quenched over ice in a large earlenmeyer flask by pouring down the sides of the flask with
stirring. The precipitate was filtered and re-crystallized from methyl ethyl ketone to yield 1.69 g
of a white solid. Exp. mp = 211-212 oC; 1H NMR (300 MHz, CDCl3): δ 9.03 (s, 1H), 7.63 (s,
1H), 4.20 (t, J = 8.5 Hz, 2H), 3.12 (t, J = 8.0 Hz, 2H), 2.28 (s, 3H).

34
1-(5-Fluoroindolin-1-yl)ethan-1-one (34). To neat acetic anhydride (2 mL, 21.2 mmol) was
added 5-fluoroindoline portionwise (427 µL, 3.65 mmol) with stirring. After 15 min stirring at
room temperature under N2, reaction mixture was dripped over ice, stirred for 30 min, and the
precipitate was collected by vacuum filtration, washing with 100 mL H2O, to yield a light pink
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solid (543.3 mg, 83%). H NMR (300 MHz, CDCl3): δ 8.16 (dd, 1H, JF,H = 9.75 Hz, JH,H = 4.95
1

Hz), 6.89-6.84 (m, 2H), 4.07 (t, 2H, J = 8.55 Hz), 3.18 (t, 2H, J = 8.4 Hz), 2.21 (s, 3H).

35
1-Acetyl-5-fluoroindoline-6-sulfonyl chloride (35). The fluoro analog 1-(5-fluoroindolin-1yl)ethan-1-one (500 mg, 2.79 mmol) was dissolved in chlorosulfonic acid (5.0 mL, 75 mmol)
under N2 at 0 oC, and the reaction mixture was gradually heated to 50 oC and stirred for 2 h.
Temperature was then increased to 65 oC and reaction mixture was stirred for an additional 1 h,
then cooled to room temperature. The reaction mixture was slowly dripped over ice, stirred for
10 min, and precipitate was collected by vacuum filtration, washing with 100 mL H2O, to afford
723 mg of a white solid at a 93 % yield. mp = 163.8-175.2 (decomp). 1H NMR (300 MHz,
DMSO-d6): δ 8.35 (d, 1H, J = 6.6 Hz), 6.97 (d, 1H, J = 9.6 Hz), 4.08 (t, 2H, J = 8.55 Hz), 3.10 (t,
2H, J = 8.55 Hz), 2.13 (s, 3H).
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General Procedure for Preparing N-Acetyl-5-haloindolines-6-sulfonamides.159
In a reaction vial was added 100 mg of N-acetyl-5-chlorindoline-6-sulfonyl chloride
(0.340 mmol, 1 eq.) or N-acetyl-5-bromoindoline-6-sulfochloride (0.295 mmol, 1 eq.) along with
a stir bar and a 5 mol% amount of DMAP if the procedure employs a 2o amine. This is followed
by addition of methylene chloride (3 mL), Et3N (1.5 eq.) and the respective amine (1.25 eq.) to
the reaction vial. The reaction is then left to stir at room temperature for 2 to 3 hours or until
TLC indicated complete reaction. Upon completion, the reaction is diluted with dichloromethane
followed by 1N HCl. The aqueous layers then extracted three times with methylene chloride to
remove the product from the aqueous layer, the fractions were then combined and washed once
more with brine, then dried over sodium sulfate and condensed to dryness on the vacuum. The
crude product is the taken up in chloroform and passed through a plug of activated carbon,
concentrating, and recrystallized from 1:2 chloroform-EA.159

5a

132
1-Acetyl-5-chloro-N-isopentylindoline-6-sulfonamide (5a). Product collected (117 mg, 99 %)
as a tan solid: mp = 174-180 °C; 1H NMR (300 MHz, CDCl3): δ 8.89 (s, 1H), 7.28 (s, 1H), 4.90
(t, J = 6.0 Hz, 2H), 4.14 (t, J = 8.7 Hz, 2H), 3.25 (t, J = 8.7 Hz, 2H), 2.93 (dd, J = 13.7, 7.2 Hz,
2H), 2.24 (s, 3H), 1.36 (dd, J = 14.4, 6.9 Hz, 2H), 1.60 (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).

5b
1-Acetyl-5-bromo-N-isopentylindoline-6-sulfonamide (5b). Product collected (0.114g, 99 %)
as a orange tacky solid: mp 190-191 °C; 1H NMR (500 MHz, CDCl3): δ 8.88 (s, 1H), 7.48 (s,
1H), 5.04 (bs, 1H), 4.14 (t, J = 8.5 Hz, 2H), 3.25 (t, J = 9.0 Hz, 2H), 2.92 (t, J = 7.5 Hz, 2H),
2.24 (s, 3H), 1.67 (m, 1H), 1.38 (s, 2H), 0.84 (d, J = 7.0 Hz, 6H),
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9a
1-Acetyl-5-chloro-N-cyclohexylindoline-6-sulfonamide (9a). Product collected (95.3 mg, 79
%) as a white solid: mp 224-232 °C; 1H NMR (300 MHz, CDCl3): δ 8.9 (s, 1H), 7.28 (s, 1H),
4.90 (t, J = 6.0 Hz, 1H), 4.14 (t, J = 8.7 Hz, 2H), 3.25 (t, J = 8.7 Hz, 2H), 2.93 (dd, J = 13.7, 7.2
Hz, 2H), 2.24 (s, 3H), 1.36 (dd, J = 14.4, 6.9 Hz, 2H), 1.6 (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).
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10a
1-Acetyl-5-bromo-N-cyclohexylindoline-6-sulfonamide (10a). Product collected (92.6 mg, 78
%) as a white crystalline solid: mp 226-228 °C; 1H NMR (300 MHz, CDCl3): δ 8.91 (s, 1H),
7.47 (s, 1H), 5.55 (d, J = 7.5 Hz, 1H), 4.14 (t, J = 8.5 Hz, 2H), 3.25 (t, J = 9 Hz, 2H), 3.16 (m,
1H), 2.24 (s, 3H), 1.82-1.14 (m, 10H).

11a
1-(5-Chloro-6-(pyrrolidin-1-ylsulfonyl)indolin-1-yl)ethan-1-one (11a). Product collected (103
mg, 92 %) as a yellowish tan solid: mp 197-201 °C; 1H NMR (500 MHz, CDCl3): δ 8.67 (s, 1H),
7.27 (s, 1H), 4.13 (t, J = 8.6 Hz, 2H), 3.44 (td, J = 6.7, 5.4, 2.9 Hz, 4H), 3.24 (t, J = 8.5 Hz, 2H),
2.23 (s, 3H), 2.04 – 1.89 (m, 4H). 13C NMR (500 MHz, CDCl3): δ 169.3, 142.1, 137.1, 136.4,
128.2, 126.6, 117.4, 49.2, 48.3, 27.9, 26.0, 24.3.
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12a
1-(5-Bromo-6-(pyrrolidin-1-ylsulfonyl)indolin-1-yl)ethan-1-one (12a). Product collected
(98.8 mg, 90 %) as a light brown crystalline solid: mp 238-240 °C; 1H NMR (500 MHz, CDCl3):
δ 8.68 (s, 1H), 7.50 (s, 1H), 4.13 (t, J = 9.0 Hz, 2H), 3.46 (t, J = 6.5 Hz, 4H), 3.24 (t, J = 6.0 Hz,
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2H), 2.23 (s, 3H), 1.98 (t, J = 7.0 Hz, 2H); C NMR (500 MHz, CDCl3): δ 169.3, 142.9, 138.3,
13

137.1, 131.7, 118.0, 114.0, 49.2, 48.4, 27.8, 26.0, 24.3.

13a
1-(5-chloro-6-(piperidin-1-ylsulfonyl)indolin-1-yl)ethan-1-one (13a). Product collected (104
mg, 79 %) as a tan crystalline solid: 1H NMR (500 MHz, CDCl3): δ 8.72 (s, 1H), 7.27 (s, 1H),
4.13 (t, J = 9.0 Hz, 2H), 3.28 (t, J = 66.5 Hz, 4H), 3.24 (t, J = 9.0 Hz, 2H), 2.23 (s, 3H), 1.66-1.61
(m, 4H), 1.54 (dd, J = 11.0, 6.0 Hz, 2H); 13C NMR (500 MHz, CDCl3): δ 169.1, 142.1, 137.2,
135.9, 128.1, 126.6, 118.7, 49.1, 47.0, 27.9, 25.8, 24.2, 24.0.
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14a
1-(5-Bromo-6-(piperidin-1-ylsulfonyl)indolin-1-yl)ethan-1-one (14a). Product collected (114
mg, 70 %) as a off white crystalline solid: mp 212-214°C; 1H NMR (500 MHz, CDCl3): δ 8.73
(s, 1H), 7.47 (s, 1H), 4.12 (t, J = 8.0 Hz, 2H), 3.29 (t, J = 4.5 Hz, 4H), 3.24 (t, J = 8.5 Hz, 2H),
2.23 (s, 3H), 1.63 (m, 4H), 1.552 (m, 2H); 13C NMR (500 MHz, CDCl3): δ 169.3, 142.8, 137.7,
137.4, 131.6, 118.9, 114.0, 49.2, 47.0, 44.8, 27.8, 25.8, 24.3, 24.0.
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16a
1-Acetyl-5-bromo-N,N-bis(2-methoxyethyl)indoline-6-sulfonamide (16a). Product collected
(125 mg, 97 %) as a yellowish tan solid: mp 110-111 °C; 1H NMR (500 MHz, CDCl3): δ 8.78 (s,
1H), 7.49 (s, 1H), 4.23 (t, J = 8.5 Hz, 2H), 3.40 (t, J = 6.0 Hz, 4H), 3.53 (t, J = 5.5 Hz, 4H), 3.30
(s, 6H), 3.24 (t, J = 9.0 Hz, 2H), 2.23 (s, 3H); 13C NMR (500 MHz, CDCl3): δ 169.2, 142.8,
139.0, 137.2, 131.5, 118.7, 114.2, 71.7, 59.0, 48.8, 27.8, 24.3, 8.9.
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17a
1-Acetyl-5-bromo-N,N-diethylindoline-6-sulfonamide (17a). Product collected (110 mg, 99%)
as an off white solid: mp 195-196 °C; 1H NMR (500 MHz, CDCl3): δ 8.72 (s, 1H), 7.47 (s, 1H),
4.13 (t, J = 8.5 Hz, 2H), 3.42 (q, J = 7.0 Hz, 4H), 3.23 (t, J = 8.0 Hz, 2H), 2.23 (s, 3H), 1.19 (t, J
= 7.5 Hz, 6H); 13C NMR (126 MHz, ): δ 169.2, 142.7, 139.6, 136.9, 131.5, 118.1, 114.0, 77.5,
77.2, 77.0, 49.2, 42.3, 27.7, 24.3, 14.4.
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18a
1-Acetyl-5-chloro-N,N-dipropylindoline-6-sulfonamide (18a). Product collected (104 mg, 85
%) as a light brown solid: mp 118-120 °C; 1H NMR (500 MHz, CDCl3): δ 8.78 (s, 1H), 7.49 (s,
1H), 4.23 (t, J = 8.5 Hz, 2H), 3.59 (t, J = 6.0 Hz, 4H), 3.53 (t, J = 5.5 Hz, 4H), 3.29 (s, 6H), 3.24
(t, J = 9.0 Hz, 2H), 2.23 (s, 3H); 13C NMR (500 MHz, CDCl3): δ 169.2, 142.1, 137.9, 136.9,
128.0, 126.6, 118.1, 49.9, 49.6, 49.2, 27.9, 24.3, 22.1, 19.6, 11.5, 11.4.
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21a
1-Acetyl-5-bromo-N-isobutylindoline-6-sulfonamide (21a). Product collected (93 mg, 84 %)
as white crystal: mp 215-220 °C; 1H NMR (500 MHz, CDCl3): δ 8.87 (s, 1H), 7.47 (s, 1H), 5.13
(t, J = 6.5 Hz, 1H), 4.13 (t, J = 8.5 Hz, 2H), 3.25 (t, J = 9.0 Hz, 2H), 2.70 (t, J = 6.5 Hz, 2H), 2.23
(s, 3H), 1.74 (m, 1H), 0.89 (d, J = 8.5 Hz, 6H), 13C NMR (500 MHz, CDCl3): δ 169.2, 143.1,
138.2, 137.7, 130.9, 119.2, 113.1, 50.9, 649.2, 46.1, 28.7, 27.8, 24.3, 8.9.
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36
1-Acetyl-5-bromo-N-(tert-butyl)indoline-6-sulfonamide (36). Product collected (44.2 mg, 40
%) as an off-white solid: mp 225-230 °C; 1H NMR (500 MHz, CDCl3): δ 8.82 (s, 1H), 7.45 (s,
1H), 5.07 (s, 1H), 4.23 (t, J = 9.0 Hz, 2H), 3.24 (t, J = 8.5 Hz, 2H), 2.23 (s, 3H), 1.23 (s, 9H);
C NMR (500 MHz, CDCl3): δ 169.2, 143.1, 141.7, 137.2, 130.8, 118.5, 113.2, 55.2, 49.2, 46.2,

13

30.3, 27.8, 24.4, 8.9.
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23a
Methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)-L-phenylalaninate (23a). Product collected
(127 mg, 90%) as a tan solid: mp 178-183 °C; 1H NMR (500 MHz, CDCl3): δ 8.79 (s, 1H), 7.39
(s, 1H), 7.21–7.08 (m, 5H), 5.66 (d, J = 8.0 Hz, 1H), 4.26 (dt, J = 8.0, 5.8 Hz, 1H), 4.09 (m, 2H),
3.54 (s, 3H), 3. 20 (t, J = 1.0 Hz, 2H), 3.06 (t, J = 4.8 Hz, 2H), 2.21 (m, 3H); 13C NMR (500
MHz, CDCl3): δ 171.0, 169.1, 142.9, 138.4, 137.6, 135.2, 131.0, 129.8, 128.8, 127.4, 118.8,
113.7, 57.2, 52.6, 49.2, 39.7, 27.8, 24.3.

144

26a
Methyl ((1-acetyl-5-chloroindolin-6-yl)sulfonyl)glycinate (26a). Crude product collected (26.4
mg, 22 %) as a tan solid.

27a
Methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)glycinate (27a). Product collected (105 mg,
93 %) as a tan solid: mp 176-182 °C; 1H NMR (500 MHz, CDCl3): δ 8.86 (s, 1H), 7.49 (s, 1H),
5.74 (bs, 1H), 4.13 (t, J = 8.5 Hz, 2H), 3.82 (d, J = 5.5 Hz, 2H), 3.68 (s, 3H), 3.25 (t, J = 8.5 Hz,
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2H), 2.24 (s, 3H); C NMR (500 MHz, CDCl3): δ 169.2, 161.8, 143.0, 137.9, 137.7, 131.1,
13

119.1, 113.7, 49.2, 46.1, 44.6, 24.3, 8.9.

28a
Methyl 3-((1-acetyl-5-bromoindoline)-6-sulfonamido)propanoate (28a). Product collected
(117 mg, 97 %) as an off white solid: mp 190-193 °C; 1H NMR (500 MHz, CDCl3): δ 8.87 (s,
1H), 7.47 (s, 1H), 5.77 (t, J = 6.0 Hz, 1H), 4.11 (t, J = 8.5 Hz, 2H), 3.67 (s, 3H), 3.23 (t, J = 8.5
Hz, 2H), 3.17 (dd, J = 12.0, 6.5 Hz, 2H), 2.50 (t, J = 5.5 Hz, 2H), 2.21 (s, 3H); 13C NMR (500
MHz, CDCl3): δ 172.5, 169.2, 143.1, 138.3, 137.7, 131.0, 119.1, 113.3, 52.2, 49.2, 39.0, 34.1,
27.8, 24.3.
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24a
Methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)-L-methioninate (24a). Product collected
(114 mg, 83%) as a light tan solid: mp 117-119 °C; 1H NMR (500 MHz, CDCl3): δ 8.83 (s, 1H),
7.47 (s, 1H), 5.94 (d, J = 8.1 Hz, 1H),4.13 (t, J = 8.5 Hz, 2H), 3.62 (s, 3H), 3.24 (t, J = 7.2 Hz,
2H), 2.23 (s, 3H), 2.06 (s, 3H); 13C NMR (500 MHz, CDCl3): δ 171.6, 169.2, 143.0, 138.1,
131.1, 118.9, 113.7, 55.3, 52.9, 49.2, 32.8, 29.7, 27.8, 24.3, 15.6, 8.9.
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30a
Methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)-L-valinate (30a. Product collected (111 mg,
87 %) as a tan solid: mp 178-182 °C; 1H NMR (500 MHz, CDCl3): δ 8.50 (s, 1H), 7.46 (s, 1H),
5.70 (d, J = 9.6 Hz, 1H), 4.12 (t, J = 7.8 Hz, 2H), 3.83 (dd, J = 9.3, 5.1 Hz, 1H), 3.54 (s, 3H),
3.23 (t, J = 9.0 Hz, 2H), 2.23 (s, 3H), 2.08 (m, 1H), 0.92 (m, 6H); 13C NMR (500 MHz, CDCl3):
δ 171.5, 169.2, 142.9, 138.4, 137.7, 130.95, 118.8, 113.8, 61.7, 52.4, 49.2, 32.0, 27.8, 24.3, 19.0,
17.8.
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37
1-Acetyl-N-benzyl-5-bromoindoline-6-sulfonamide (37).
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38
1-Acetyl-5-bromo-N-methoxy-N-methylindoline-6-sulfonamide (38).
N-Cbz-Indoline Protected Sulfonyl Azide Synthesis.

40
5,6-Dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (40). To a solution of
chlorosulfonyl isocyanate (1.80 mL, 18.4 mmol) in nitroethane (32 mL) cooled to -42°C was
added indoline slowly drop wise with stirring. The intermediate precipitated and turned cloudy
and white, and the mixture was slowly warmed to room temperature over one hour with
continued stirring. Aluminum chloride (2.45 g, 18.4 mmol) was added in one portion and
allowed to stir for 15 min at room temperature. The solution went from cloudy and white to a
clear, pale yellow solution to a light purple to a dark purple over this time period. The reaction
was then heated to 110 °C for one hour. The mixture was cooled to room temperature and
quenched by pouring into ice water slowly where a black precipitate formed. The solid was
isolated by filtering via vacuum filtration. A dark gray clay-like substance was obtained and
dried overnight via vacuum yielding the cyclic sulfonyl urea indoline 3 (58-83 %) as a dark gray
solid compound. The crude product is recrystallized from a warm 1:3 DMF-H2O mixture. 1H
NMR (300 MHz, DMSO D6): δ 7.55 (t, 2H), 7.22 (t, 1H), 4.18 (2H, t), 3.35 (2H, t).182
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41
Indoline-7-sulfonamide (41). A solution of the cyclic sulfonyl urea indoline 3 in 50 % sulfuric
acid was heated to 135 °C for two hours. The reaction was cooled to room temperature and then
neutralized carefully with a 10 N NaOH solution while over ice. The aqueous layer was extracted
with ethyl acetate three times and the organic fractions were combined and dried over
magnesium sulfate and concentrated in vacuum yielding the hydrolyzed 7-sulfonamide indoline
41 as a light brown needle like solid (50 %).
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Benzyl 7-sulfamoylindoline-1-carboxylate (42). To a round bottom flask was added 7sulfonamide indoline 41 (1.0 g, 5.0 mmol, 1 eq.) in THF (23 mL), followed by NaHCO3 (4.66 g,
55.5 mmol, 11 eq.) and water (2.9 mL). The round bottom flask was sealed and flushed with N2
gas. To this sealed mixture was added benzyl chloroformate (2.7 mL, 19.2 mmol, 3.8 eq.) slowly
over a few minutes by syringe. After complete addition, the reaction was allowed to stir at room
temperature overnight. The reaction was diluted with ethyl acetate and filtered to remove
undissolved excess NaHCO3. The organic portion was acidified with 6M HCl to pH 3. The
aqueous portions were further extracted with ethyl acetate three times, and organic fractions were
combined and washed with brine and dried over NaSO4 and concentrated giving a tacky offwhite solid. The crude product was taken up in a minimal amout of ethyl acetate then Et2O was
added to precipitate a white solid which was collected via vacuum filtration and further washed
with petroleum ether and placed on high vac to fully dry. This reaction afforded 1.52 g of a white
fluffy solid at 91 % yield and found to be 99.7 % pure by HPLC. 1H NMR (500 MHz, d6DMSO): δ 7.69 (d, J=7.5Hz, 1H), 7.49 (d, J=7.5Hz, 1H), 7.45-7.31 (m, 4H), 7.25 (t, J=7.5Hz,
1H), 7.06 (d, 2H), 5.22 (s, 2H), 4.11 (t, J=8Hz, 2H), 3.08 (t, J=7.5Hz, 2H). 13C NMR (500 MHz,
CDCl3): δ 154.9, 138.6, 136.7, 136.1, 132.4, 128.4, 128.4, 128.1, 127.9, 127.2, 124.5, 67.3, 50.8,
28.6.
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General Synthesis Procedure for N-acylation of N-Cbz-indoline-7-sulfonamides.
A solution of acetyl chloride (1.25 eq. acid chloride) dissolved in dichloromethane was
cooled to 0 oC. To a separate solution of dichloromethane and trimethylamine (1.5 eq.) was
added the N-Cbz-indoline-7-sulfonamide 42. The sulfonamide remained suspended in the
solution until 10 % mol of DMAP was added. The mixture was heated until all materials
dissolved and then placed on ice to cool to 0 oC. The first solution of the acid chloride was added
to the sulfonamide solution slowly dropwise with stirring over 10 min making sure to keep the
solution cool. After complete addition, the reaction was allowed to warm to room temperature
and stir until completion as determined by HPLC. The solution was then quenched with water
and extracted with dichloromethane. The organic portions were washed one time with 1M HCl,
once with water and once with brine. The solution was then dried over Na2SO4 and solvent was
removed via rotovap and crude product was recrystallized from MeOH.

43a
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Benzyl 7-(N-acetylsulfamoyl)indoline-1-carboxylate (43a). Recrystallization afforded 106.1
mg of an off white solid at 94 % yield found to be 97 % purit by HPLC. 1H NMR (300 MHz, d6DMSO): δ 11.69 (s, 1H), 7.70 (d, J = 6.6 Hz, 1H), 7.53 (d, J = 7.3 Hz, 1H), 7.41-7.32 (m, 6H),
7.24 (t, J = 15 Hz, 1H), 5.23 (s, 2H), 4.11 (t, J = 8.0 Hz, 2H), 3.08 (t, J = 8.5 Hz, 2H), 1.94
(s,3H).

43b

43c

General Synthesis Procedure for Simple N-Ac-sulfonamides.
In a round bottom flask was suspended a 1.1 eq. of anhydride in methylene chloride or
MeOH and an equal amount of DIPEA. An equivalent of aromatic primary sulfonamide was
added to the anhydride suspension leading to reaction homogeneity. After 3.5 h reaction time at
rt the reaction was worked up by quenching with saturated NaHCO3 and was then washed twice
with methylene chloride. The Aq. layer is acidified to pH 3 followed by extraction three times
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with methylene chloride, dried with sodium sulfate and concentrated to dryness. Reaction is
purified by column chromatography or recrystallization as per lit.

44a
4-Oxo-4-(phenylsulfonamido)butanoic acid. Product collected (413 mg, 50 % yield); white
precipitate. 1H NMR (500 MHz, DMSO-d6): δ 12.16 (s, 2H), 7.93 – 7.87 (m, 2H), 7.74 – 7.67
(m, 1H), 7.62 (dd, J = 8.4, 7.2 Hz, 2H), 2.44 – 2.32 (m, 4H). 13C NMR (500 MHz, DMSO-d6): δ
173.8, 171.4, 134.2, 129.8, 128.0, 31.2, 29.5, 28.5.
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44b
4-((4-Methylphenyl)sulfonamido)-4-oxobutanoic acid. Product collected (312 mg, 39 % yield)
off white solid. mp = 173-175 oC, 1H NMR (500 MHz, DMSO-d6): δ 12.09 (s, 2H), 7.78 (d, J =
8.1 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 2.48 – 2.35 (m, 7H). 13C NMR (500 MHz, DMSO-d6): δ
173.9, 171.2, 144.8, 137.3, 130.2, 128.2, 31.1, 28.5, 21.8.
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44c
5-Oxo-5-(phenylsulfonamido)pentanoic acid (44c). Product collected (446 mg, 52 % yield) off
white solid. 1H NMR (300 MHz, DMSO-d6): δ 12.03 (s, 2H), 7.94 – 7.86 (m, 2H), 7.77 – 7.67
(m, 1H), 7.67 – 7.57 (m, 2H), 2.25 (t, J = 7.4 Hz, 2H), 2.12 (t, J = 7.4 Hz, 2H), 1.60 (p, J = 7.5
Hz, 2H).

44d
5-((4-Methylphenyl)sulfonamido)-5-oxopentanoic acid (44d). Product collected (365.6 mg, 44
% yield) off-white gel. 1H NMR (300 MHz, DMSO-d6): δ 12.03 (s, 2H), 7.84 – 7.71 (m, 2H),
7.47 – 7.36 (m, 2H), 2.39 (d, J = 1.8 Hz, 2H), 2.24 (td, J = 7.4, 2.5 Hz, 2H), 2.12 (td, J = 7.4, 4.2
Hz, 2H).
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General Synthesis Procedure for N-acetyl-5-haloindoline-6-sulfonamides.
The sulfonyl chloride was added to a RBF with a long neck followed by addition of
MeOH and methylene chloride in a 1:3 ratio. The reaction suspension was then heated to reflux
until all the starting material was dissolved. Then anhydrous ammonium gas was bubbled into
the hot solution until ppt formation. The reaction was allowed to stir vigorously for 10 min or
until TLC indicated consumption of sulfonyl chloride starting material. The reaction was
allowed to to cool to rt and the ppt was filtered off. Not allowing to cool will lead to ppt
formation inside filtrate. Alternatively, the reaction can be diluted with EA before filtration to
increase ppt. HPLC indicate ppt collected as a pure compound.

46a
1-Acetyl-5-chloroindoline-6-sulfonamide (46a). Prepared according to general procedure.
Collected product afforded 154.7 mg of a grey powder at 82 % yield found to be 92 % pure by
HPLC with product eluting at 5.762 min (HPLC Method: CTV1, see Appendix B). 1H NMR
(500 MHz, Methanol-d4): δ 8.87 (s, 1H), 7.60 (s, 1H), 4.20 (t, J = 8.6 Hz, 3H), 3.27 (t, J = 8.6
Hz, 2H), 2.24 (s, 3H)
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46b
1-Acetyl-5-bromoindoline-6-sulfonamide (46b). A stirred solution of sulfonyl chloride (500
mg, 1.7 mmol) in methylene chloride (15 mL) and saturated methanolic ammonia (5.0 mL,
approx. 35 mmol) was heated until all solids dissolved, then allowed to return to room
temperature. After 30 min, solids were precipitated out by the addition of EtOAc (5 mL) and
collected by vacuum filtration, washing with methylene chloride, ethyl acetate, and petroleum
ether to yield a white solid (313 mg, 66 %). mp = 231 oC-deflagration at 254 oC. 1H NMR (500
MHz, DMSO-d6): δ 8.74 (s, 1H), 7.64 (s, 1H), 7.44 (s, 2H), 4.15 (t, J = 8.5 Hz, 2H), 3.20 (t, J =
8.8 Hz, 2H), 2.18 (s, 3H). Rf = 0.36 (20:80 EtOAc-CH2Cl2).
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47a
5-Chloroindoline-6-sulfonamide (47a). The sulfonamide starting material N-acetyl-5chloroindoline-6-sulfonamide (397 mg) was combined with 6M HCl (3.5 mL) and heated to
reflux for 2.5 hrs. Reaction was cooled and triturated with Et2O and IPA, and the precipitated
product was vacuum filtered to afford 239 mg of a fluffy white solid at 61 % yield found to be at
95 % pure by HPLC with product peak eluting at 6.590 min (HPLC Method: CTV1). mp =
177.9-180.0 °C. 1H NMR (500 MHz, D2O): δ 8.02 (s, 1H) 7.66 (s, 1H), 3.88, (t, J = 7.5 Hz, 2H),
3.31 (t, J = 7.5 Hz, 2H).
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48a
Benzyl 5-chloro-6-sulfamoylindoline-1-carboxylate (48a). To a three-neck round bottom flask
charged with 5-chloroindoline-6-sulfonamide (51 mg, 0.2 mmol) in THF (1.2 mL) and H2O (0.1
mL) followed by 11 equivalents of sodium bicarbonate. The reaction vessel was degassed using
a septum can after which benzyl chloroformate (89 uL, 0.75 mmol) was added via syringe over 7
min. The reaction was then left to stir overnight and the monitored using HPLC. The reaction
was acidified and water was added to dissolve bicarbonate salt. Reaction was extracted three
times with ethyl acetate, and the organic layer was washed once with brine and dried with
magnesium sulfate. Organic layer was concentrated to dryness on the rotary evaporator and
triturated with ethyl ether to afford 613 mg of a white solid at 45 % yield found to be 99 % pure
by HPLC with product peak eluting at 12.610 min (Method CTV1), mp =161.3-162.0 °C. 1H
NMR (500 MHz, d6-DMSO): δ 8.37 (s, 1H), 7.53-7.33 (m, 8H), 5.25, (s, 2H), 4.07 (t, 2H), 3.17
(t, J= 8.5 Hz, 2H) 13C NMR (500 MHz, CDCl3): δ 152.9, 140.6, 138.2, 137.0, 129.2, 128.8,
128.5, 128.4, 124.4, 114.7, 67.4, 48.5, 27.4.
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General Synthesis Procedure for N-Acetyl-5-Haloindoline-6-Sulfonyl Azide from Sulfonyl
Chloride.
To a stirred solution of sulfonyl chloride in diglyme (0.1 M) at 110 oC was added sodium
azide (5.5 eq.), followed by slow addition of H2O (0.15 M) over 10 min with heating to 130 oC.
The reaction was allowed to stir at temperature for 1 h before leaving to stir at rt overnight. After
overnight stirring under N2, mixture was diluted with saturated aqueous sodium bicarbonate and
extracted with ethyl acetate. The combined organics were washed with brine (200 mL x 1) and
dried over Na2SO4, followed by concentration to a diglyme rich product-syrup. The crude syrup
is triturated with petroleum ether causing the pure product to crash out which is collected via
vacuum filtration.

45a
1-Acetyl-5-fluoroindoline-6-sulfonyl azide (45a). To a stirred solution of sulfonyl chloride
(500 mg, 1.8 mmol) in diglyme (5 mL) at 100 oC was added sodium azide (585 mg, 9.0 mmol)
followed by H2O (2 mL). Reaction mixture was cooled to room temperature and stirred
overnight, then poured over 50 mL H2O at 0 oC and stirred for 30 min. The precipitate was
collected by vacuum filtration, washing with H2O (50 mL), to yield a white solid. Yield: 221.1
mg (43.2 %). 1H NMR (300 MHz, CDCl3): δ 8.725 (d, 1H, J = 6.0 Hz), 7.110 (d, 1H, J = 9.0
Hz), 4.167 (t, 2H, J = 8.7 Hz), 3.307 (t, 2H, J = 8.7 Hz), 2.247 (s, 3H). 13C NMR (75 MHz,
CDCl3): δ 168.953, 155.697 (d, J = 253.35 Hz), 141.0495 (d, J = 8.325 Hz), 139.670, 125.4445
(d, J = 14.625 Hz), 116.914, 113.9555 (d, J = 23.475 Hz), 48.930, 28.404, 24.003. MP: 107.0112.7 oC.
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45b
1-Acetyl-5-chloroindoline-6-sulfonyl azide (45b). To a stirred solution of sulfonyl chloride (1
g, 3.4 mmol) in THF (30 mL) at 50oC was added sodium azide (1.2 g, 18.7 mmol) followed by
H2O (20 mL). After 2 hrs stirring at 55 oC under N2, reaction mixture was poured over saturated
aqueous sodium bicarbonate (200 mL). The reaction flask was washed with additional diglyme
(30 mL heated to dissolve solids) and this was combined with the same aqueous sodium
bicarbonate mixture. Precipitate was collected by vacuum filtration to yield a yellow solid (786
mg, 77% yield). mp = 93.1-95.4 oC 1H NMR (300 MHz, CDCl3): δ 8.89 (s, 1H), 7.37 (s, 1H),
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4.16 (t, 2H, J = 8.7 Hz), 3.29 (t, 2H, J = 8.7 Hz), 2.25 (s, 3H). HRMS (method) m/z calcd. for
C10H10ClN4O3S [M+H]+: 301.0162, found: 301.0159.

45c
1-Acetyl-5-bromoindoline-6-sulfonyl azide (45c). To a stirred solution of sulfonyl chloride (1.0
g, 2.95 mmol) in diglyme (30 mL, 0.1 M) at 110 oC was added sodium azide (1.1 g, 16.2 mmol,
5.5 eq.), followed by slow addition of H2O (20 mL, 0.15 M) over 10 min with heating to 130 oC.
The reaction was allowed to stir at temperature for 1 h befre leaving to stir at rt overnight. After
overnight stirring under N2, mixture was diluted with saturated aqueous sodium bicarbonate (250
mL) and extracted with ethyl acetate (250 mL x3). The combined organics were washed with
brine (100 mL x 1) and dried over Na2SO4, followed by concentration to a diglyme rich productsyrup. The crude syrup is diluted with petroleum ether causing the pure product to crash out
which is collected via vacuum filtration. Product collected (790 mg, 77 %) as a beige solid at
99% purity. Rf = 0.36 (20:80 EtOAc- CH2Cl2), mp = 110-125 0C, 1H NMR (500 MHz, acetoned6): δ 2.22 (s, 3H), 3.38 (t, 2H, J = 8.75 Hz), 4.31 (t, 2H, J = 8.75 Hz), 7.78 (s, 1H), 8.93 (s, 1H).
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13C NMR (500 MHz, CDCl3): δ 169.3, 143.1, 139.6, 137.3, 131.6, 119.3, 114.3, 49.1, 27.9,
24.2. HRMS (ESI-MS) m/z calcd. for C10H10BrN4O3S [M+H]+: 346.9638, found: 346.9634.

General Synthesis Procedure for Sulfonyl Azides Via Azide Transfer.
To a solution of sulfonamide in 1:1 isopropanol-water mixture (0.04M) was added
potassium carbonate (4.0 eq.), and imidazole-1-sulfonyl azide HBF4 salt (1.5 eq.) which was
stirred at room temperature for 18h. The reaction was then diluted with saturated aqueous
sodium bicarbonate and extracted with ethyl acetate and organic fractions were combined was
washed once with brine, dried over Na2SO4, and concentrated. Purified products were isolated by
flash column chromatography or recrystallization.
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49a
Benzyl-6-(azidosulfonyl)-5-chloroindoline-1-carboxylate (49a). Benzyl 5-chloro-6sulfamoylindoline-1-carboxylate and potassium carbonate were added to a 50 mL 2-neck round
bottom flask with a stir bar. Then imidazole-1-sulfonyl azide transfer reagent was added behind a
blast shield, followed by a 1:1 mixture of isopropanol-water. Reaction was stirred vigorously
while rapid heating with the heat gun was applied. After allowing reaction to boil for 5 min, the
reaction mixture becomes dark orange and homogeneous and is allowed to cool overnight while
stirring. The reaction is diluted with sodium bicarbonate solution and extracted with ethyl acetate
three times. Organic layer is washed with brine, and concentrated to dryness on the rotary
evaporator. Solid is transferred to a vial, where it is recrystallized in EA and dried to yield 210
mg of a beige sparkly precipitate yielding 79 % which was found to be 93 % pure by HPLC with
product elution at 15.0 min. mp = 124.8-127.6 oC. 1H NMR (500 MHz, DMSO): δ8.38 (s, 1H),
7.73 (s, 1H), 7.45-7.34 (m, 5H), 5.26 (s, 2H), 4.18 (broadened triplet, 2H), 3.23 (t, J = 8.7 Hz,
2H). 13C NMR (500MHz, d6-DMSO): δ152.3, 141.6, 134.0,126.8, 28.5,128.1, 127.8, 124.6,
114.8, 66.9, 47.8, 40.1, 39.0, 27.1. HPLC purity = 93 % pure at 220 nm.
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49b
Benzyl-7-(azidosulfonyl)indoline-1-carboxylate (49b ). To a solution of benzyl 7sulfamoylindoline-1-carboxylate (350 mg, 1.1 mmol) in 1:1 isopropanol-water mixture (26.3
mL, 0.04 M) was added potassium carbonate (582 mg, 4.2 mmol, 4.0 eq.), and imidazole-1sulfonyl azide HBF4 salt (412 mg, 1.6 mmol, 1.5 eq.) which was stirred at room temperature for
18h. Product was isolated using flash column purification. Two 4 g flash columns were preequilibrated with Pet-E using a Gilson fraction collector. The crude product was loaded onto the
column using an Ether-CHCl3-EA mixture. The product was eluted using a 1:1 Et2O-Petroleum
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Ether and product was collected and concentrated to a white crystalline solid to yield 193.7 mg at
51 % yield, and HPLC purity was found to be 98 % at 220nm. Exp mp = 99.0-102.7 oC, White
crystalline solid. 1H NMR (500 MHz, d6-DMSO): δ 7.73 (d, J = 8 Hz, 1H), 7.68 (d, J = 7.5 Hz,
1H), 7.43-737 (m, 5H), 7.33 (t, J = 7.7 Hz, 1H), 5.22 (s, 2H), 4.16 (t, J = 7.5 Hz, 2H), 3.14 (t, J =
7.5 Hz, 2H). 13C NMR (500 MHz, d6-DMSO): δ 154.6, 140.3, 137.8, 135.9, 131.1, 128.4, 128.1,
127.9, 127.7, 127.3, 125.1, 67.3, 50.7, 28.5.
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49c
Indoline-7-Sulfonyl Azide (49c). To a stirred solution of indoline-7-sulfonamide (170 mg, 0.86
mmol) and K2CO3 (474 mg, 3.43 mmol) in 1:1 iPrOH:H2O (11 mL) was added imidazole-1sulfonyl azide hydrochloride (270 mg, 1.29 mmol). After 1.5 h, reaction mixture was diluted
with saturated aqueous sodium bicarbonate (25 mL) and extracted with ethyl acetate (50 mL x
4). Combined extracts were dried over MgSO4 and concentrated to give a dark red oil. Flash
column chromatography (silica gel, 20:80 ethyl acetate:petroleum ether) yielded a yellow oil
(140.5 mg, 73%). 1H NMR (500 MHz, CDCl3): δ 7.413 (d, 1H, J = 8.5 Hz), 7.288 (d, 2H, J = 6.5
Hz), 6.675 (t, 1H, J = 7.5 Hz), 5.499 (s, 1H), 3.778 (t, 2H, J = 8.5 Hz), 3.151 (t, 2H, J = 8.5 Hz).
RF = .3 (20:80 EtOAc:petroleum ether).

General Synthesis Procedure for Sulfonyl Triazole Via CuAAC.
To a solution of sulfonyl azide and CuTC (10 mol%), in CH2Cl2 (0.3M) was added the
respective alkyne (1.1 eq.) at room temperature under inert atmosphere. The reaction was stirred
at rt for 2-3 hrs before being diluted with CH2Cl2 and saturated NH4Cl(aq), stirred for 30 min, and
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the precipitate was collected by vacuum filtration. The collected solids were washed with H2O,
CH2Cl2 and petroleum ether before drying under reduced pressure. Product isolation was
achieved through flash column chromatography or recrystallization.

50a
1-(5-Bromo-6-((4-phenyl-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan-1-one (50a). A
solution of CuTC (5.5 mg, 0.029 mmol), phenyl acetylene (33 µL, 0.30 mmol), and sulfonyl
azide(100 mg, 0.29 mmol) in CH2Cl2 (2 mL) was stirred at room temperature under N2 for 5 h.
Precipitate was collected by vacuum filtration washing with CH2Cl2, H2O, and petroleum ether
to give an off-white solid (27.4 mg, 21% yield). Rf = 0.4 (10:1:89 EtOAc-AcOH-petroleum
ether). mp = 104-110 0C. 1H NMR (500 MHz, DMSO-d6): δ 2.22 (s, 3H), 3.28 (t, 2H, J = 8.5
Hz), 4.21 (t, 2H, J = 8.75 Hz), 7.42 (t, 1H, J = 7.25 Hz), 7.50 (t, 2H, J = 7.5 Hz), 7.83 (s, 1H),
8.00 (d, 2H, J = 7.5 Hz), 9.02 (s, 1H), 9.54 (s, 1H).

51a
1-(5-Chloro-6-((4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan1-one (51a). Prepared according to general procedure. 1H NMR (500 MHz, d6-DMSO): δ 8.92
(s, 1H), 8.58 (s, 1H), 7.65 (s, 1H), 5.38 (s, 1H), 4.20 (t, J = 9.0 Hz, 2H), 3.26 (t, J = 8.5 Hz, 2H),
2.21 (s, 2H), 1.48 (s, 2H). 13C NMR (500 MHz, d6-DMSO): δ 169.8, 155.6, 143.4, 142.8, 131.0,
128.8, 125.8, 121.6, 117.4, 66.8, 48.6, 30.1, 27.6, 23.8.
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51b
1-(5-Bromo-6-((4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan1-one (51b). Prepared according to general procedure. A solution of CuTC (5.5 mg, 0.029
mmol), 2-methylbut-3-yn-2-ol (37 mg, 0.44 mmol), and sulfonyl azide (100 mg, 0.29 mmol) in
CH2Cl2 (1 mL) was stirred for 5h, then diluted with CH2Cl2 (5 mL) and saturated aqueous NH4Cl
(5 mL) and the aqueous was extracted with CH2Cl2 (10 mL x 2). Combined extracts were dried
over MgSO4 and concentrated. Recrystallization from ethyl acetate afforded 88.8 mg of colorless
needles at a 71 % yield. mp = 120-130 0C with decomposition. 1H NMR (500 MHz, CDCl3): δ
9.02 (s, 1H), 8.21 (s, 1H), 7.5 (s, 1H), 4.11 (t, 2H, J = 7.0), 3.29 (t, 2H, J = 8.5), 2.62 (s, 1H),
2.24 (s, 3H), 1.69 (s, 6H).

52a
1-(5-Bromo-6-((4-(1-hydroxycyclohexyl)-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan-1one (52a). Prepared according to general procedure. A solution of CuTC (5.5 mg, 0.029 mmol),
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1-ethynylcyclohexan-1-ol (65 mg, 0.52 mmol), and sulfonyl azide (100 mg, 0.29 mmol) in
CH2Cl2 (1 mL) was stirred under N2 for 22 h, then diluted with CH2Cl2 (5 mL) and saturated
aqueous NH4Cl (5 mL). Aqueous was extracted with CH2Cl2 (5 mL x 3). The organic layers
were combined, dried over MgSO4, and concentrated to yield a foam, which was redissolved in
minimal CH2Cl2 and diluted with 8:2 Et2O-petroleum ether. Precipitate was collected by vacuum
filtration and washed with H2O and Et2O to afford 72.4 mg of a white powder at an 53 % yield.
mp = 112.4-130 oC (decomposes at 130 oC). 1H NMR (500 MHz, CDCl3): δ 9.02 (s, 1H), 8.21
(s, 1H), 7.48 (s, 1H), 4.16 (t, 2H, J = 8.25 Hz), 3.28 (t, 2H, J = 8.5 Hz), 2.47 (s, 1H), 2.24 (s,
3H), 2.0-1.2 (m, 10H).

53a
1-(5-Chloro-6-((4-(2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan-1-one
(53a). Prepared according to general procedure. 1H NMR (500 MHz, d6-DMSO): δ 8.92 (s, 1H),
8.65 (s, 1H), 7.63 (s, 1H), 4.75 (d, J = 3.5 Hz, 1H), 4.19 (t, J = 9 Hz, 2H), 3.92 (m, 1H), 3.26 (t, J
= 8 Hz, 2H), 2.75 (d, J = 6 Hz, 2H), 2.51 (s, 3H), 1.06 (d, J = 5 Hz, 3H).
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53b
1-(5-Bromo-6-((4-(2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)sulfonyl)indolin-1-yl)ethan-1-one
(53b). Prepared according to general procedure. A solution of CuTC (5.5 mg, .029 mmol), 4pentyn-2-ol (33 µL, .36 mmol), and sulfonyl azide (100 mg, .29 mmol) in CH2Cl2 (1 mL) was
stirred at room temperature under N2 for 2 h, then diluted with 3 mL CH2Cl2 and 3 mL saturated
aqeous NH4Cl, stirred for 30 seconds, and the precipitate was collected by vacuum filtration
washing with CH2Cl2, saturated aqueous NH4Cl, and H2O to afford 32.5 mg of a white solid at
an 26 % yield. mp = Decomposes at 142.2 oC.1H NMR (300 MHz, DMSO-d6): δ 8.95 (s, 1H),
8.63 (s, 1H), 7.80 (s, 1H), 4.77 (d, J = 4.2 Hz, 1H), 4.161 (t, 2H, J = 8.7 Hz), 3.91 (m, 1H), 3.26
(t, J = 8.6 Hz, 2H), 2.75 (d, J = 6.0 Hz, 2H), 2.20 (s, 3H), 1.05 (d, J = 6.0 Hz, 3H).
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General Synthesis Procedure [A] for Sulfoyl Imidates Via CuAAC.
To a stirred solution of sulfonyl azide, copper iodide (15 mol%), and Et3N (1.5 eq.) in
methanol (1.2 M, 20 eq.) was slowly added the respective alkyne (1.5 eq.) at room temperature
under positive pressure inert gas. After 1-3 h of stirring the reaction mixture is diluted with
CH2Cl2 and a solution of 1:1 saturated aqueous Na2S2O3-H2O and stirred for 30 min. The layers
were allowed to separate and product was extraction from aqueous with CH2Cl2, and the
combined extracts were dried over MgSO4, filtered through activated carbon, concentrated in
vacuo followed by recrystallization from ethyl acetate.

54
Methyl (Z)-N-((1-acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxy-3-methylbutanimidate
(54). Prepared according to general procedure. To a stirred solution of sulfonyl azide (100 mg,
0.29 mmol), copper iodide (5.5 mg, 0.029 mmol), and Et3N (150 µL, 0.36 mmol) in methanol
(235 µL, 5.8 mmol) was slowly added the 2-methylbut-3-yn-2-ol (35 μL, 0.36 mmol) at room
temperature under positive pressure inert gas. After 30 min of stirring under N2 at room
temperature, reaction mixture was diluted with CH2Cl2 (2 mL) and saturated aqueous NH4Cl (3
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mL) and stirred for 15 min, and the layers were allowed to separate and product was extraction
from aqueous with CH2Cl2, and the combined extracts were dried over MgSO4, and
recrystallized from ethyl acetate to afford 41.2 mg of clear crystals at 33 % yield. Rf = 0.47 (5:95
MeOH-CH2Cl2). mp = 151.6-171.2 0C. 1H NMR (500 MHz, CDCl3): δ 9.00 (s, 1H), 7.49 (s, 1H),
4.12 (t, J = 8.5 Hz, 2H), 3.88 (s, 3H), 3.25 (t, J = 8.5 Hz, 2H), 3.16 (s, 2H), 2.23 (s, 3H), 2.05 (s,
1H), 1.38 (s, 6H).

General Synthesis Procedure [A] for N-Acyl-Sulfonamides Via CuAAC.
To a mixture of sulfonyl azide (100 mg, 0.29 mmol), copper iodide (15 mol%), and Et3N
(1.5 eq.) in 2:1 t-BuOH-H2O (0.1 M) was added the respective alkyne (1.5 eq.) slowly at room
temperature under positive pressure inert gas. Reaction mixture was stirred under N2 for 3-4 h,
then diluted with CH2Cl2 and saturated aqueous NH4Cl, stirred for 30 min and extracted with
CH2Cl2. Combined organics were dried over Na2SO4, concentrated on rotavap, and purified with
flash column chromatography. Alternatively, if precipitate forms during quenching stage then the
biphasic system was diluted with Et2O and solids collected via vacuum filtration. Solids were
washed with cold 10 % citric acid, H2O, and petroleum ether. Product isolation achieved by
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taking up in a warm solution of 2:1:1 MeOH-AN-H2O, passed through activated carbon/cotton
plug into 40 mL cold ether and collected by vacuum filtration.
General Synthesis Procedure [B] for N-Acyl-Sulfonamides Via CuAAC.
To a stirred solution of sulfonyl azide, copper iodide (15 mol%), and Et3N (1.5 eq.) in
CH2Cl2 (0.3M) was added H2O (1.5 eq.) followed by the respective alkyne (1.5 eq.) slowly at
room temperature under positive pressure inert gas. After 1-3 h of stirring the reaction mixture is
diluted with CH2Cl2 (2 mL) and a 1:1 solution of saturated aqueous Na2S2O3-H2O and stirred for
30 minutes. The layers were allowed to separate and product was extraction from aqueous with
CH2Cl2, and the combined extracts were dried over MgSO4, filtered through activated carbon,
concentrated in vacuo followed by recrystallization.

55a
N-((1-Acetyl-5-chloroindolin-6-yl)sulfonyl)-3-hydroxypropanamide (55a). Prepared
according to general procedure [A]. Product collected as a white powder and found to be 95 %
pure by HPLC. *nmr broadened by paramagnetic interference [Cu]. 1H NMR (500 MHz, d6DMSO): δ 8.58 (s, 1H), 7.23 (s, 1H), (7.43 bs = NH4Cl contaminant), 4.10 (t, J = 8.5 Hz, 2H),
3.48 (t, J = 6.8 Hz, 2H), 3.12 (t, J = 8.4 Hz, 2H), 2.15 (s, 3H), 2.12 (t, J = 6.7 Hz, 2H).13C NMR
(500 MHz, d6-DMSO): δ 175.6, 168.6, 141.7, 141.1, 135.7, 126.5, 124.1, 117.6, 58.3, 48.5, 41.8,
27.0, 23.9.
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55b
N-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxypropanamide (55b). Prepared
according to general procedure [A]. Product collected as a while fluffy powder found to be 95%
pure by HPLC. *nmr broadened by paramagnetic interference [Cu]. 1H NMR (500 MHz, d6DMSO): δ 8.68 (s, 1H), 7.50 (s, 1H), (7.43 bs = NH4Cl contamination), 4.11 (t, J = 9.0Hz, 2H),
4.50 (t, J = 4.5Hz, 2H), 3.15 (t, J = 8.0Hz, 2H), 2.21(t, J = 1.5Hz, 1H), 2.15 (s, 3H).

55c
N-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxy-3-methylbutanamide (55c). Prepared
according to general procedure [A]. Product collected to afford 213.4 mg of an off-while powder
at an 88 % yield that was found to be 96 % pure by HPLC. 1H NMR (300 MHz, DMSO-d6): δ
8.67 (s, 1H), 7.43 (s, 1H), 7.07 (br s, 1H), 4.11 (t, J = 8.4 Hz, 2H), 3.14 (t, J = 8.25 Hz, 2H), 2.16
(s, 3H), 2.04 (s, 2H), 1.05 (s, 6H). 13C NMR (126 MHz, d6-DMSO): δ 176.34, 176.31, 168.47,
143.90, 141.66, 135.54, 135.52, 129.62, 118.03, 112.10, 68.19, 50.58, 48.47, 40.11, 40.01, 39.93,
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39.84, 39.76, 39.67, 39.59, 39.53, 39.50, 39.34, 39.17, 39.03, 39.00, 29.64, 26.81. HRMS (ESIMS) m/z calcd. for C15H20BrN2O5S [M+H]+: 421.0257, found: 421.0255. MP: 219-234oC
(decomp.)

General Synthesis Procedure [A] for Sulfonyl Amidines.
To a stirred solution of sulfonyl azide, copper iodide (15 mol%), Et3N (1.5 eq.) and 28 %
NH4OH(aq) (1.5 eq.) or alkyl amine (1.5 eq.), in CH2Cl2 or THF (0.3 M) was added the respective
alkyne (1.5 eq.) slowly at room temperature under positive pressure inert gas. After 3-4 h of
stirring the reaction mixture diluted with CH2Cl2 and saturated NH4Cl(aq), stirred for 30 min and
extracted with CH2Cl2. Combined organics were dried over Na2SO4, concentrated on rotavap,
and purified with flash column chromatography. Alternatively, if precipitate forms during
quenching stage, the biphasic slurry was diluted with Et2O and solids collected via vacuum
filtration. Crude solids were washed with cold 10 % citric acid, H2O, CH2Cl2, ether and
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petroleum ether before drying under reduced pressure. Product isolation achieved by taking up in
a warm solution of 5:5:1 MeOH-AN-DMF, passed through activated carbon/cotton plug and
dripping into large amount of stirred cold ether, forming white percipitate which was collected
by vacuum filtration.
General Synthesis Procedure [B], Optimized for Sulfonyl Amidines.
To a stirred solution of sulfonyl azide, copper iodide (15 mol%), Et3N (1.5 eq.), and
NH4Cl(s) (1.5 eq.) in CH2Cl2 or THF (0.3M) was added the respective alkyne (1.5 eq.) slowly at
room temperature under positive pressure inert gas. After 1-3 h of stirring the reaction mixture is
diluted with CH2Cl2 (2 mL) and a 1:1 solution of saturated aqueous Na2S2O3-H2O and stirred for
30 min. The layers were allowed to separate and product was extraction from aqueous with
CH2Cl2, and the combined extracts were dried over NaSO4, filtered through activated carbon,
concentrated in vacuo. Alternatively, if precipitate formed during quenching stage then the
biphasic slurry was diluted with Et2O and solids collected via vacuum filtration. Solids were
washed with cold 10% citric acid, H2O, CH2Cl2, ether and petroleum ether before drying under
reduced pressure. Product isolation was achieved by taking up in a warm solution of 5:5:1
MeOH-AN-DMF, passed through activated carbon/cotton plug, and re-crystallized upon cooling.

56
(Z)-3-Hydroxy-3-methyl-N'-tosylbutanimidamide (56). Prepared according to general
procedure [A]. Flash column chromatography (silica gel, 4g, 1:1 EA-Pet. E.) afforded 52 mg of a
yellow oil at 38 % yield. 1H NMR (300 MHz, CDCl3): δ 8.01 (br s, 1H), 7.81 (d, J = 8.1 Hz,
2H), 7.28 (d, J = 8.1 Hz, 2H), 7.00 (br s, 1H), 2.69 (s, 1H), 2.44-2.41 (m, 5H), 1.25 (s, 6H). 13C
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NMR (75 MHz, CDCl3): δ 167.2, 143.3, 139.2, 129.6, 126.6, 70.7, 48.9, 29.5, 21.7. HRMS (ESIMS) m/z calcd. for C12H19N2O3S [M+H]+: 271.1116, found: 271.1106.

57a
N'-((1-Acetyl-5-chloroindolin-6-yl)sulfonyl)-3-hydroxypropanimidamide (57a). Prepared
according to general procedure [B]. Recrsytallization from 5:5:1 MeOH-AN-DMF afforded
152.3 mg of a colorless crystals at 66 % yield found to be 97 % pure by HPLC. mp = 230-232
C. 1H NMR (500 MHz, d6-DMSO): δ 8.67 (s, 1H), 8.60 (s, 1H), 8.01 (s, 1H), 7.43 (s, 1H), 4.74

o

(t, J = 5.5 Hz, 1H), 4.14 (t, J = 8.0 Hz, 2H), 3.62 (q, J = 11.0, 6.0 Hz, 2H), 3.18 (t, J = 9.0 Hz,
2H), 2.44 (t, J = 7.0 Hz, 2H), 2.17 (s, 3H). 13C NMR (500 MHz, d6-DMSO): δ 169.0, 168.4,
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141.7, 138.7, 137.7, 127.5, 124.8, 115.4, 58.2, 48.5, 39.4, 27.1, 23.8. HRMS (IT-TOF) m/z
calcd. for C13H16ClN3O4S [M-]+: 345.0533, found: 345.0550

57b
N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxypropanimidamide (57b). Prepared
according to general procedure [B]. Recrsytallization from 5:5:1 MeOH-AN-DMF afforded 38.8
mg of a colorless needle crystal at 18 % yield (loss to spill) found to be 97 % pure by HPLC. mp
= 230-235 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.71 (s, 1H), 8.40 (br s, 1H), 7.97 (br s, 1H),
7.60 (s, 1H), 4.74 (t, 1H, J = 4.8 Hz), 4.14 (t, 2H, J = 8.4 Hz), 3.63 (td, JH,H = 6.6 Hz, JO,H = 5.1
Hz), 3.18 (t, J = 7.95 Hz, 2H), 2.446 (t, 2H, J = 6.6 Hz), 2.164 (s, 1H). 13C NMR (500 MHz, d6-
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DMSO): δ 169.1, 168.4, 142.3, 140.3, 137.8, 130.8, 115.8, 112.7, 58.2, 48.6, 39.5, 27.0, 23.8.
HRMS (ESI-MS) m/z calcd. for C13H17BrN3O4S [M+H]+: 392.0104, found: 392.0094.
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58a
((Z)-N'-((1-Acetyl-5-chloroindolin-6-yl)sulfonyl)-3-hydroxy-3-methylbutanimidamide (58a).
Prepared according to representative procedure [B]. Recrystallization from 5:5:1 AN-MeOHDMF afforded 77.3 mg of colorless needle crystals at 30 % yield found to be 97 % pure by
HPLC. mp = 210-222 oC. 1H NMR (300 MHz, d6-DMSO): δ 8.69 (s, 1H), 8.57 (br s, 1H), 8.03
(br s, 1H), 7.46 (s, 1H), 4.89 (br s, 1H), 4.15 (t, J = 8.4 Hz, 2H), 3.20 (t, J = 8.55 Hz, 2H), 2.38
(s, 2H), 2.18 (s, 3H), 1.13 (s, 6H). 13C NMR (500 MHz, d6-DMSO): δ 169.0, 167.5, 141.7, 138.4,
137.9, 127.5, 124.8, 115.5, 69.0, 48.6, 48.5, 29.1, 27.1, 23.8. HRMS (ESI-MS) m/z calcd. for
C15H21ClN3O4S [M+H]+: 374.0941, found: 374.0930.
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58b
((Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxy-3-methylbutanimidamide
(58b). Prepared according to representative procedure [B]. Recrystallization from 5:5:1 ANMeOH-DMF afforded 84.5 mg of colorless needle crystals at 34 % yield found to be 98 % pure
by HPLC. mp = 240-245 °C 1H NMR (500 MHz, d6-DMSO): δ 1.03 (s, 6H), 2.07 (s, 3H), 2.26
(s, 2H), 3.09 (t, J = 8.0 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 4.75 (s, 1H), 7.52 (s, 1H), 7.92 (s, 1H),
8.34 (s, 1H), 8.63 (s, 1H). 13C NMR (500 MHz, d6-DMSO): δ 169.1, 167.6, 142.3, 140.0, 138.0,
130.9, 115.9, 112.7, 69.0, 48.6, 48.5, 29.2, 27.0, 23.8. HRMS (ESI-MS) m/z calcd. for
C15H21BrN3O4S [M+H]+: 420.0417, found: 420.0403. Rf = 0.18 (1:9 EtOAc-CH2Cl2).
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59a
(Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-2-(1-hydroxycyclopentyl)acetimidamide
(59a). Prepared according to general procedure [A]. Flash column chromatography afforded 61.8
mg of a white solid at a 48 % yield. mp = 194.6-199.5 oC. 1H NMR (300 MHz, d6-DMSO): δ
8.723 (s, 1H), 8.45 (br s, 1H), 8.03 (br s, 1H), 7.62 (s, 1H), 4.73 (s, 1H), 4.14 (t, J = 8.7 Hz, 2H),
3.19 (t, J = 8.6 Hz, 2H), 2.48 (s, 2H), 2.17 (s, 3H), 1.67-1.49 (m, 8H). 13C NMR (300 MHz, d6DMSO): δ 169.9, 168.7, 143.0, 140.7, 138.8, 131.6, 116.6, 113.5, 80.2, 49.3, 46.8, 27.7, 24.6,
23.8. HRMS (ESI-MS) m/z calcd. for C17H23BrN3O4S: 446.0573, found: 446.0558.
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60a
(Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-2-(1-hydroxycyclohexyl)acetimidamide
(60a). Prepared according to general procedure [A]. Yield: 49.3 mg white solid (37.1%). mp =
196.8-201oC (decomp). 1H NMR (300 MHz, DMSO-d6): δ 8.72 (s, 1H), 8.43 (br s, 1H), 8.02 (br
s, 1H), 7.62 (s, 1H), 4.62 (s, 1H), 4.14 (t, J = 8.55 Hz, 2H), 3.19 (t, J = 8.7 Hz, 2H), 2.35 (s, 2H),
2.16 (s, 3H), 1.50-1.15 (m, 10H). 13C NMR NMR (300 MHz, d6-DMSO): δ 169.2, 167.6, 142.4,
140.0, 138.1, 131.0, 116.0, 112.8, 70.1, 48.6, 47.3, 36.9, 27.0, 25.2, 23.9, 21.6. HRMS (ESI-MS)
m/z calcd. for C18H25BrN3O4S [M+H]: 460.0730, found: 460.0701.
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61a
(Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-2-phenylacetimidamide (61a).
Prepared according to general procedure [A]. Flash column chromatography (silica gel, with
1:99 MeOH (sat. NH3)-CH2Cl2 as eluent) for afford 54.1 mg of a yellow solid at 43 % yield.
Rf=0.4 (5:95 MeOH sat. NH3-CH2Cl2). 1H NMR (500 MHz, DMSO-d6): δ 2.16 (s, 3H), 3.17 (t, J
= 8.25 Hz, 2H), 3.59 (s, 2H), 4.13 (t, J = 8.75 Hz, 2H), 7.24 (m, 5H), 7.57 (s, 1H), 8.70 (s, 1H),
8.81 (s, 1H). HRMS (ESI-MS) m/z calcd. for C18H19BrN3O3S: 438.0311, found: 438.0296.

62a
(Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxy-3-phenylpropanimidamide
(62a). Prepared according to general procedure [A]. Flash column chromatography afforded 90.3
mg of a green solid at 67 % yield. mp = 198.3 - 201 oC (decomposition at 201). 1H NMR (300
MHz, DMSO-d6): δ 8.74 (s, 1H), 8.58 (br s, 1H), 8.02 (br s, 1H), 7.62 (s, 1H), 7.34-7.20 (m, 5H),
5.52 (d, J = 4.5 Hz, 1H), 4.99 (dd, JH,H = 6.9 Hz, JO,H = 4.5 Hz, 1H), 4.15 (t, J = 8.7 Hz, 2H),
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3.20 (t, J = 8.25 Hz, 2H), 2.61 (d, J = 6.6 Hz, 2H), 2.17 (s, 3H). HRMS (ESI-MS) m/z calcd. for
C19H21BrN3O4S [M+H]+: 468.0417, found: 468.0406.

63a
Methyl (Z)-3-(((1-acetyl-5-bromoindolin-6-yl)sulfonyl)imino)-3-aminopropanoate (63a).
Prepared according to representative procedure [A]. Flash chromatography afforded 39.7 mg of
an off-white solid at 32 % yield. mp = 183.4 - 191.4 oC. 1H NMR (300 MHz, DMSO-d6): δ 8.742
(br s, 1H), 8.703 (s, 1H), 8.248 (br s, 1H), 7.608 (s, 1H), 4.140 (t, 2H, J = 8.55 Hz), 3.596 (s,
3H), 3.485 (s, 2H), 3.187 (t, 2H, J = 8.4 Hz), 2.169 (s, 3H). HRMS (ESI-MS) m/z calcd. for
C14H17BrN3O5S [M+H]+: 420.0053, found: 420.0040.

190

64a
(Z)-N'-((1-Acetyl-5-bromoindolin-6-yl)sulfonyl)-3-hydroxy-N,3-dimethylbutanimidamide
(64a). Prepared according to general procedure [A]. Flash column chromatography (silica gel,
with 1:99 MeOH (sat. NH3)-CH2Cl2 as eluent) for afford 52.6 mg of a white solid at 42 % yield.
mp = decomposes at 218 oC. 1H NMR (500 MHz, DMSO-d6): δ 8.74 (s, 1H), 8.28 (br s, 1H),
7.59 (s, 1H), 5.11 (s, 1H), 4.14 (t, J = 8.75 Hz, 2H), 3.18 (t, J = 8.5 Hz, 2H), 2.87 (s, 2H), 2.74
(d, J = 4.5 Hz, 3H), 2.17 (s, 3H), 1.15 (s, 6H). 13C NMR (500 MHz, DMSO-d6): δ 170.0, 167.,
142.9, 142.3, 138.1, 131.5, 116.4, 113.3, 69.7, 49.2, 45.2, 30.2, 29.1, 27.7, 24.6.
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65a
Benzyl (Z)-6-(N-(1-amino-3-hydroxy-3-methylbutylidene)sulfamoyl)-5-chloroindoline-1carboxylate (65a). To NH4Cl(s), CH2Cl2, and triethylamine were added to 1-Cbz-5-chloroindoline-6-sulfonyl azide starting material at room temperature, followed by addition of copper
iodide and the alkyne. Reaction was left to react at room temperature for 3.5 hours and
monitored by TLC and HPLC. At 3.5 hours, a TLC was taken in 80-20 EA-PE, which indicated
consumption of starting material. Then the reaction was diluted with CH2Cl2 (804 μL) followed
by 500 μL NH4Cl. Reaction was allowed to stir at room temperature for 30 min. Reaction was
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then concentrated to dryness on the rotary evaporator (not heated more than 40 C) and left to
dry overnight under vacuum. The crude product was dissolved in EA and pipetted from NH4Cl(s).
Gravity column chromatography (334 mg silica gel, 80-20 EA-Pet. E.) afforded 28 mg of a dark
yellow solid at 47 % yield found to be 96 % pure by HPLC. mp = 165.4 -168.8 oC. 1H NMR
(500MHz, d6-DMSO): δ 8.40 (d, J = 28.5 Hz, 2H), 8.04(s, 1H). 7.45-7.33 (m, 6H), 5.25 (s, 2H),
5.25 (s, 2H), 4.87 (s, 1H), 4.06-4.02 (m, 2H), 3.16 (t, J = 8.5 Hz, 2H), 2.35 (s, 2H), 1.23-1.10 (m,
6H). 13C NMR (500MHz, d6-DMSO): δ168.3, 152.9, 139.4, 129.2, 128.8, 128.5, 125.2, 69.7,
49.4, 40.7, 40.6, 40.4, 29.9. HRMS (ESI/APCI on IT-TOF) m/z calcd. for C21H24N3O5SCl [M]+:
465.1102, found: 465.1125.
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CHAPTER FIVE
CYCLOBUTANONE BINDING IN COBALT FUNCTIONALIZED
HOMOSERINE METALLO-γ-LACTONASE AiiA
Abstract
We have synthesized and tested several α-amido cyclobutanones possessing a C6 or C10
hydrocarbon tail which exhibit binding to AiiA related di-Zn-dependent lactonase metallo
centers, enabling determination of two separate three-dimensional structures of N-(2oxocyclobutyl)hexanamide (1) and N-(2-oxocyclobutyl)decanamide (2), bound to AiiA-Cobalt
active site, respectively. The electron density of the C6 analog (1) co-crystal was not resolved
enough to make an accurate ligand atom placement. However, the extra length of the C10 alkyl
chain of compound 2 enabling interaction with the hydrophobic phenylalanine clamp region of
AiiA, adjacent to the active site,60 resulted in higher resolution structure enabling atomic
placement of the ligand atoms including the C10 alkyl chain. The determination of the cocrystalized cyclobutanone did not show the presence of the trapped tetrahedral transition-state
mimetic of cyclobutanone, as expected, but rather the ring-opened byproduct 4decanamideobutanoic acid (3). Follow-up experiments were performed to determine whether the
presence of the observed ring-opened product originated from
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enzymatic catalysis or radiation damage during crystallographic data collect. A discontinuous
assay experiment was performed in conjunction with radical-catalyzed organic reaction
screening with AIBN, H2O2, and H2O2 in the presence of various metal salts. A series of radicalmediated synthetic experiments were also carried out to assess the ability the cyclobutanone to
be opened under chemical means.
Introduction
Bacterial infections are a growing global medical problem, and there is an urgent need for
antibacterial agents with new cellular mechanisms of action. There has been increasing attention
surrounding cyclobutanones and their specific inhibitory properties towards serine hydrolases,
serine-β-lactamases and metallo-β-lactamases. The restricted nature of a four-membered
cyclobutanone ring causes the carbonyl carbon to become much more electrophilic.183, 184 Thus,
this increased strain associated with the four-membered cyclic ketone is partially released upon
hydration, with the hydrated form of cyclobutanone closely resembling transition state of a widerange of metalloenzyme classes.
OXA-10, KPC-2, and CG1 are broad spectrum serine-β-lactamases that have been shown
to be susceptible to inhibition by cyclobutanones. Recent studies have reported crystal structure
showing a cyclobutanone analog of penicillin covalently bound to the catalytic serine in OXA10’s active site (Figure 53A).185
A recent crystal structures of FTT258, a serine hydrolase with broad substrate specificity
that binds to bacterial membranes in the Gram-negative bacterium F. tularensis, shows a
cyclobutanone inhibitor covalently bound to Ser116 was also reported by our research group
(Figure 53B). Large conformational changes were observed in the protein structure when in the
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presence of this cyclobutanone ligand, presumably interfering with regulating membrane binding
and catalytic activity of acyl protein thioesterases.186
A

B

Figure 53. A) Structure of Oxa-10 complexed with Cyclobutanone derivative of penicillin as
serine-bound hemiketal (PDB ID: 3LCE), B) Structure of a serine hydrolase from Francisella
tularensis complexed as a serine-bound hemiketal with N-Cyclobutanone sulfonamide inhibitor
(PDB ID: 4F21). The tosylamide was not observed in the crystal structure, but has been modeled
in for this Figure.
Continuing our investigation toward developing new methods of interacting with
pharmaceutically relevant metalloenzymes, we explored the ability for cyclobutanone
functionalities to interact at the di-metallo site of metalloenzyme. We chose to investigate cocrystallization experiments with the wildtype di-cobalt functionalized metalloenzyme
Autoinducer inactivator A (AiiA) provided by our collaborators in the Walter Fast group at UTAustin. AiiA is a metal-dependent N-acyl homoserine lactone (AHL) hydrolase that displays
broad substrate speciﬁcity, but shows a preference for substrates with long, hydrophobic N-acyl
substituents (Figure 54).60, 187

Figure 54. N-acyl-L-homoserine metallo-γ-lactonase (AiiA, AHL lactonase) catalyzes the
hydrolysis of N-acyl-L-homoserine lactones to the corresponding ring-opened products, the
corresponding N-acyl-L-homoserines.187
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AiiA and related metallo-lactonase AidC utilize a di-Zn metallo center to catalyze the
hydrolysis of important N-acyl homoserine lactones that are important for cell to cell
communication between bacteria.56, 58, 59, 188 Development of drug-like molecules that are capable
of targeting metal centers in AiiA and related enzymes is predicted to disrupt the quorum
sensing/quenching mechanism between bacterial communities and provide another chemical tool
for studying these systems. Since each species of bacteria has specific and unique molecules for
quorum sensing, tailor-made inhibitors may modulate the risk of specific bacterial proliferation59
Recently, we have made efforts to target AiiA related di-Zn-dependent lactonase with a small
series of α-amido cyclobutanones possessing a C6 and C10 hydrocarbon tail, synthesized using
chemistry pioneered in our laboratory,189 and our collaborators in Dr. Liu’s lab here at Loyola
were able to obtain and solve the crystal structures of AiiA complexed to a cyclobutanone analog
bearing a 10-carbon hydrophobic tail.
The electron density of the C6 cyclobutanone co-crystal was not resolved enough to
make an accurate atom placement. However, because the extra length, the C10 alkyl chain
derivative was able to interact with the hydrophobic phenylalanine clamp region of AiiA
adjacent to the active site60 enabling atomic placement of the C10 alkyl chain and
cyclobutanone-derived functionality of N-(2-oxocyclobutyl)decanamide (2). However, the
determination of the co-crystalized cyclobutanone did not show the presence of the hypthesized
tetrahedral transition-state mimetic of cyclobutanone as depicted in Figure 55A, but rather a ringopened byproduct 4-decanamideobutanoic acid (3) shown in Figure 55B. The ring-opened
byproduct 3 was synthesized, and the structure was confirmed with NMR.
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Figure 55. Depiction of AiiA_Co AHL metallo-lactonase structure bound to: A) Hypothesized
N-(2-oxocyclobutyl)decanamide as the tetrahedral transition state mimetic (PBTSM Generated
Model), B) Observed ring-opened byproduct 4-decanamideobutanoic acid (PDB ID: TBD). We
hypothesize that the opening is mediated by hydroxyl radicals generated during X-ray
irradiation.
Our working hypothesis is that the C-C bond breakage was catalyzed by either bulk
solvent radical hydroxides or by a radical induced tyrosine in close proximity to the metal active
site. Follow-up experiments were performed to determine whether the presence of the observed
ring-opened GABA product originated from enzymatic catalysis, radicals in the presence of
enzymes, or purely through radiation damage during crystallographic data collect. We
performed a series of cyclobutanone digestion experiments to test our hypothesis. A
discontinuous HPLC assay experiment was performed with cyclobutanone 2 with varied
incubation times and concentrations of AiiA_Co enzyme. We also attempted a series of radicalmediated synthetic cyclobutanone digestions experiments to assay the ability the cyclobutanone
to be opened under chemical means. Reaction screenings with our 2 in the presence AIBN,
H2O2, or H2O2 in the presence of various metal salts to chemically generate radicals in situ.
Recently we have conducted experiments at Argonne National Lab using the X-ray beamline to
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perform X-ray induced cyclobutanone digestion experiments in the presence or absence of
AiiA_Co. The cyclobutanone in buffer was exposed to X-rays under varying concentrations of
enzyme and exposure times followed by analysis using LC-MS.
Supplemental in silico modeling was performed in order to gain further understanding of
the pre-ring opened binding mode of the bounding dynamics of cyclobutanone analog. We
employed the in silico Product-Based Transition-State Modeling (PBTSM) technique using the
Molecular Operating Environment (MOE) computation suite provided through Loyola’s
Department of Chemistry and Biochemistry, to reconstruct the hypothetical intact cyclobutanone
ring inside the active site of AiiA_Co.
Materials and Methods
Materials.
All solvents were distilled prior to use, and all reagents were used without further
purification unless otherwise noted. All synthetic reactions were conducted under a nitrogen or
argon atmosphere. Silica gel 60A, 40−75 μm (200 × 400 mesh), was used for column
chromatography. Aluminum-backed silica gel 200 μm plates were used for TLC. 1H NMR
spectra were obtained using either a 300 MHz spectrometer or a 500 MHz spectrometer with
trimethylsilane (TMS) as the internal standard. 13C NMR spectra were obtained using a 500 MHz
spectrometer. HRMS spectra were measured on a TOF instrument by electrospray ionization
(ESI). All other reagents for biochemical assays were purchased at the highest quality available.
Synthesis.
Installation of the alpha-amidocyclobutanones were carried out per protocol described by
Becker et al.189 1,2-Bis(trimethylsilyoxy)cyclobutene was reacted with hexanamide, and also
with decanamide, affording the α-amido cyclobutanone derivatives 1 and 2, respectively. As
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detailed below, 1 and 2 were included in co-crystallization efforts with AiiA-Cobalt
metallolactonase. Compounds 1 and 2 yielded electron density with only the latter possessing
sufficient resolution for structural determination. As per literature precedent, 190 γ-aminobutyric
was reacted with decanoic acid in the presents of triethylamine to afford the ring-opened GABA
derivative 3, as observed in the aforementioned crystal structure. The desired products were
isolated in high purity and synthetic routes summarized in Scheme 12 below.
Scheme 12: Synthesis of α-amido cyclobutanones 1; n=4 & 2; n=7, under anhydrous acidic
conditions with primary amides.191, 192 B) Synthesis of ring-opened analog 4decanamideobutanoic acid 3. 190
A

B

Discontinuous HPLC analysis.
High-performance liquid chromatography (HPLC) analysis was performed according to
previously described method, with modifications.193 To analyze the possible carbon-carbon bond
cleavage catalyzed by AiiA-Cobalt, Romilla Mascarenhas and I set up a several enzyme
incubation experiments with the C10 cyclobutanone in the presence of AiiA_Co (in 50 mM
HEPES pH7.5) at 37 °C. Reaction trials were quenched with acetonitrile at 10 sec, 30 sec, 1 min,
5 min, 2 hours, and 2.5 days. Final concentrations were set for C10 cyclobutanone = 0.5mM and
AiiA_Co = 0.04 mg/mL with blanks having all of the above except for the AiiA_Co. Samples
were chromatographed on an HPLC system Hewlett Packard 1050 series with a diode array
detector (DAD) set to monitor at 205 nm by use of a Regis Little Champ II ODS guard column
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coupled to a SymmetryShield RP18, 3.3 μm, 100A. Pre-incubated and filtered samples were
loaded into standard sized VWR autosampler HPLC vials fitted with 300 μL conical glass insert.
Samples were eluted on a 5 % AN (0.1v/v TFA)-H2O [A]/ 5 % AN (0.1v/v TFA) [B] at 1
mL/min flow rate. The analysis method employed a solvent gradient from 90 % A / 10 % B at
time 0 to 10 % A / 90 % B at time 15 mins. At time 15.1 mins the gradient switch to 90 % A / 10
% B for a re-equilibration period until the end of the method at time = 25 mins.
Chemically-Induced Radical-Mediated Cyclobutanone Ring-opening.
Along with the discontinuous HPLC enzyme assay analysis we also set up a series of
experiments where cyclobutanone 2 was incubated in the presence of various radical forming
reagents which include, AIBN in MeOH at 60 oC for 2-8 h, low concentrations of H2O2 in H2O at
60 oC for 2 hours, high concentration of H2O2 in acetone at room temperature over 3 hours, low
concentrations of H2O2 and catalytic amounts of FeCl2 at room temperature of 2 hours. HPLC
samples were collected from the incubated reactions and analyzed against standards of 2 and 3.
X-ray Exposure Cyclobutanone Digestion.
We have synthesized a C10 cyclobutanone for AiiA for our collaboration with the Liu
crystallography lab and have obtained a structure. However, the we observe the ring-opened
C10-GABA derivative in the active site which begs the interesting question of how this C-C
bond in the cyclobutanone structure was broken. Whether the enzyme caused or somehow
participates in the opening, or whether a hydroxyl radical from X-ray irradiated H2O molecules
in the crystal sample are generated around the active site and subsequently abstracts a hydrogen
atom from the cyclobutanone bound tetrahedral structure is still under debate. To test the
contribution of high energy X-ray irradiation in the mechanism that led to the opening of the
cyclobutanone ring in the active site of AiiA_Co, we have conducted series of X-ray exposure
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experiments at Argonne National laboratory’s X-ray beamline. The experiment was conducted
by preparing a series of buffered solutions charged with the C10-cyclobutanone derivative 2 in
the presence of varying concentrations of AiiA_Co. The samples were loaded into 150 μL glass
HPLC insert with 50 μL reaction solution and mounted to the crystal holding apparatus of station
19BM using green hobby clay (Figure 56A). The mounted samples were capped with a plug
with clay and then rotated along the glass tubes axis and irradiated with a continuous X-ray flux
= 1.7x1011 eV, rotating every 2o for 360o with 1 or 10 second X-ray exposures per intervals per
degree. The X-ray exposures were observed to create visible glass etching rings on the sample
vial inserts for every complete revolution around the radial axis (Figure 56B).
A

B

Figure 56. X-ray exposure cyclobutanone digestion setup. A) sample mounting setup, B) X-ray
etched glass inserts.
A total of 11 samples were collected over two visits to Argonne. Conditions for the 11
samples are summarized in Table 14 below. The processed samples were further analyzed for
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ring-opened GABA derivative peak development through LC-MS by Marlon Lutz of Regis LLC.
Results are still pending.
Table 14. X-ray Exposure Cyclobutanone Digestion Sample Conditions.a

# Exposure Revolution
2rev
C1 10.0 s / o
2rev
C2 10.0 s / o

AiiA_Co
Conc.
NA
NA

C10-CB
Conc.
NA
50.0 mM

HEPES
Conc.
100.0 mM
NA
(CH3CN Blank)

1.0 s / o
10.0 s / o
1.0 s / o

NA
1.0 mM
50.0 mM
NA
1.0 mM
50.0 mM
1.0 μL 1.2 mg/mL
1.0 mM
50.0 mM
of AiiA_Co
o
10.0
s
/
3rev
1.0
μL 1.2 mg/mL
1.0 mM
50.0 mM
4
of AiiA_Co
o
1.0
s
/
4rev
5.0
μL 1.2 mg/mL
2.5 mM
50.0 mM
5
of AiiA_Co
o
10.0 s /
2rev
5.0 μL 1.2 mg/mL
2.5 mM
50.0 mM
6
of AiiA_Co
10.0 s / o
2rev
10.0 μL 1.0 mg/mL 2.5 mM
10.0 mM
7
of AiiA_Co
10.0 s / o
2rev
10.0 μL 1.0 mg/mL 1.0 mM
10.0 mM
8
of AiiA_Co
10.0 s / o
2rev
10.0 μL 1.0 mg/mL 5.0 mM
10.0 mM
9
of AiiA_Co
a
Table Legend: C1 & C2 = control sample 1 & 2. rev = revolutions around sample vial radial
axis.
1
2
3

4rev
3rev
4rev

Product-Based Transition-State Modeling (PBTSM) of AiiA_Co.
We employed the ring-opening C10-GABA derivative bound co-crystal structure as a
starting point to model in reverse chronology the hypothesized cyclobutanone tetrahedral
transition state intermediate structure, as well as the cyclobutanone inhibitor-bound AiiA models
containing metal bound catalytic hydroxyl or catalytic water respectively. This method, which
we refer to as “Product-Based Transition State Modeling” (PBTSM or PBTS modeling), is
intended to provide a hypothetical model of the cyclobutanone’s tetrahedral transition state
mimetic binding geometry in AiiA’s active site before the presumed X-ray induced ring opening
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event. This modeling technique was performed using the Chemical Computing Group’s
Molecular Operating Environment (MOE).76 A step by step description of the PBTSM protocol
is outline in Figure 57 below, which for hereafter will be referred to as Figure 57-Step# in the
following text to reference steps 1 through 7.

Figure 57. PBTSM Protocol for AiiA_Co.
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After upload of the crystallographic data, the system was prepared using MOE’s utility
Structure-Prep to correct problems encountered in crystallographic data such as missing loops,
empty residues, chain termini or breaks, missing disulfide bonds or atom names, picking
alternate conformations, and other potential artifacts.76 The model was then solvated in a simple
water box at pH of 7.4 which was treated with NaCl counter ions to balance the charge. Periodic
boundary conditions were enabled, and the hydrogen bonding network of the model was
optimized by automatic sampling different tautomer/protomer states using Protonate3D.77
Protonate3D is employed to calculate optimal protonation states, including titration, rotamer and
“flips” using a large-scale combinatorial search.78 A localized energy minimization was run on
the solvated system using the MOE function QuickPrep followed by a short global minimization
to equilibrate the system for further modeling. After structural preparation, solvation and energy
optimization using MOE, the ring-opening C10-GABA bound AiiA_Co molecular model is
referred to as the C10-GABA-prod_AiiA_Co model (Figure 57-Step1).
Upon completion of system equilibration, product atom coordinates were used to model
the tetrahedral transition state mimetic expected with the cyclobutanone-catalytic hydroxyl
bound structure. This model was referred to as the C10-CB-TS_AiiA_Co model and reflects the
moment just after nucleophilic attack by the activated hydroxyl group at the ring strained
cyclobutanone which forms the tetrahedral transition state memetic structure. The double bond
of the C10-GABA carbonyl, proximal to the metal center, were converted to a single bond the
bond between the γ carbon and carbonyl carbon of the C10-GABA derivative was reformed
using the Builder utility in MOE. The results of these modeling transformations are the creation
of a distorted four membered cyclobutanone ring in the hypothesized tetrahedral transition state
mimetic inhibitor state. (Figure 57-Step2).
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The hydrogen bonding network of the model was then systematically optimized. Charge
adjustment of the tetrahedral atoms were applied to the formal catalytic hydroxyl/water atoms
and the oxygen associated with the ketone carbonyl resulting in a neutral and negative charge
respectively. This was followed by hydrogen bond network optimization of the important active
site residues critical for catalysis and transition state mimetic stabilization. These residues were
manually adjusted so that active site formal charges kept the overall net charge of the system
balanced throughout the process and conservation of matter was strictly adhered too. In total,
these minor, but critical system adjustments most heavily effected the ionization states and
hydrogen bonding motifs of the Asp108 side chain, considered to be the general acid-base during
catalysis, and the atoms associated with the ketone oxygen atoms and catalytic water/hydroxyl
group atoms.

Figure 58. Distorted cyclobutanone transition state mimetic before minimization.
At this stage in the protocol, a localized minimization was conducted to normalize the
bond distances/angles of the cyclobutanone ring and tetrahedral atom center to reasonable values
as well as balance the net charges of ligand/receptor system (Figure 57-Step3). Following
preparation of the in silico generated substrate transition state intermediate model, a relatively

207
short 1.0 ns molecular dynamics equilibration was performed using an NPA algorithm with a
Amber12:EHT force field. The MD experiment was initiated with parameters as followed:
initial heating from 0K to 300 K over 100 ps followed by equilibration for 100 ps at 300 K,
followed by a 700 ps production run, and finally a 100 ps cooling from 300K to 0 K (Figure 57Step4).
After completion of the dynamics equilibration run, three major changes were observed
in the transition state mimetic bound model. The hydrogen bond network strengthened, as
indicated by swelling hydrogen bond and VDW contact-cylinder representations, an increase in
atom distance of the two catalytic Cobalt atoms from 3.67 Å to 4.09 Å was observed, and the
C10 alkyl chain relaxed slightly (Figure 59). This relaxation can be explained by an overall
relaxation of crystal packing effects in the model system.
A

B

Figure 59. Molecular geometry differences of the active site resulting from transformations in
steps 4 to 5 of the PBTSM protocol.
Step 5 in the PBTSM protocol used the final transition state mimetic model from the
previous steps to estimate the atomic coordinates of the catalytic hydroxyl group and C10
cyclobutanone ligand bound to the metal center of AiiA. This following model was referred to
as the C10-CB_OH_AiiA_Co model and reflected the moment just after deprotonation of the
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catalytic water by general acid-base Asp108 but just before nucleophilic attack by the activated
hydroxyl group at the cyclobutanone carbonyl to relieve ring strain. MOE’s Builder utility was
again utilized to first remove the bond between the tetrahedral carbon center and the oxygen
closest to Asp108 followed by a ionization state adjustment of the newly formed catalytic
water/hydroxide oxygen to a negative ( O--C---X---OH to O--C -OH). Thus, the catalytic
hydroxyl group, coordinated to the metallo-center, was modeled into the system in the
approximate area observed in other known dinuclear metalloenzymes. Next, a double bond was
reestablished between the tetrahedral carbon center and the anionic oxygen of the tetrahedral ( O-C to O=C ) to reform the cyclobutanone carbonyl. Finally, a local minimization with constraints
was initiated to correct for distorted molecular bond angles and distances resulting from the
Builder manipulations (Figure 57-Step5).
After the in silico generated cyclobutanone and catalytic hydroxide model was prepared,
a second 1.0 ns molecular dynamics equilibration was performed using an NPA algorithm with a
Amber12:EHT force field. The MD experiment was initiated with parameters as followed:
initial system heating from 0K to 300 K over 100 ps followed by an equilibration stage at 300 K
over 100 ps before an 800 ps production run at constant temperature. The dynamics experiment
was concluded with a final 100 ps cooling stage from 300 K to 0 K (Figure 57-Step6).
After completion of the dynamics equilibration run, changes at the metal center were
observed in the model. The negatively charged catalytic hydroxyl group forms a strong
interaction with both cobalt ions leading to a decrease in distance between the cobalt atoms from
to 4.09 Å to 3.63 Å. The C10 alkyl chain again was seen to further relax as seen in Figure 60.
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A

B

Figure 60. Molecular geometry differences of the active site resulting from transformations in
steps 4 to 5 of the PBTSM protocol.
The last step in the PBTSM protocol was a continuation of the previously generated
model which was used to estimate the atomic coordinates of the C10 cyclobutanone and catalytic
water group bound to the metal center of AiiA. This last model was referred to as the the
C10CB-TS_AiiA_Co-refined model and reflected the moment just after ligand complexation to
the Cobalt metal site but just before activation of the catalytic water by Asp108 deprotonation.
The final model was generated using Protonate3D followed by QuickPrep to reoptimize the
hydrogen bonding network and perform a localized energy minimization before a final global
energy minimization was applied to the model (Figure 57-Step7). The final steps in the PBTSM
protocol results in deprotonation of the neutralized carboxylic acid side chain of Asp108 along
with a simultaneous protonation of the catalytic hydroxyl group to form the catalytic water as
depicted in Figure 61.
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Figure 61. Final ligand binding geometry generated through PBTSM protocol.
Results and Discussion
Design of substrate analogs.
We previously found that the reactive α-amido cyclobutanone moiety could form a
tetrahedral intermediate species through covalent bond formation at the reactive serine residue as
seen in the crystal structure of a serine hydrolase from Francisella tularensis complexed as a
serine-bound hemiketal with N-Cyclobutanone sulfonamide inhibitor (PDB ID: 4F21).186 We
hypothesized that the extreme bond angles of the labile cyclobutanone moiety would translate
into increase reactivity with the metal center of Quorum Quenching AiiA Metallo-γ-lactonase
through a similar tetrahedral species after reacting with the metal bound catalytic water/hydroxyl
group. The reactive cyclobutanone warhead properties would be paired with modulation of the
hydrocarbon tail to achieve interaction with the phenylalanine hydrophobic clamp to lock the
ligand in place in the binding pocket.60 Preliminary co-crystallization results with the C6 αamido cyclobutanone derivative yielded X-ray structures that possessed limited electron density
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at the metal center but undefined density where the hydrocarbon tail would be expected. Cocrystallization results with the C10 α-amido cyclobutanone show well-defined electron density of
the hydrocarbon tail sandwiched in a hydrophobic pocket region formed by the side chains of
Thr67, Phe64, Phe68, Phe107 and Met136 as well as a disordered backbone loop made with the
residues Glu136, Try137 and Met138. However, the existence of the ring-opened product bound
in the active site of AiiA-Co begged the question of whether 4-decanamideobutanoic acid (3)
was produced enzymatically, through radical induced side reactions initiated during
crystallographic data collection, or a combination of both.
Ring-opened Analog Formation Via Enzyme-mediated Mechanism.
Analysis of the discontinuous enzyme assay with our cyclobutanone analog after
exposure to AiiA-Cobalt did not give rise to any detectable ring-opened by-product as indicated
by the HPLC results in Table 15 below.
Table 15. HPLC Results of discontinuous enzyme assay with cyclobutanone 2 exposure to
AiiA_Co. A) Standard HPLC of GABA analog 3. B) Control HPLC of cyclobutanone 2 in
Buffer only. C) HPLC Assay with 2.0 mM cyclobutanone 2 + 0.05 mM AiiA_Co in Buffer
incubated over 2 hours, D) HPLC Assay with 2.0 mM cyclobutanone 2 + 0.01 mM AiiA_Co in
Buffer incubated over 2 hours, E) HPLC Assay with 2.0 mM cyclobutanone 2 + 0.05 mM
AiiA_Co in Buffer incubated over 2.5 d.
[A] HPLC Assay; Compound 3 Standard
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[B] HPLC Assay; Control

[C] HPLC Assay; Trial 1

[D] HPLC Assay; Trial 2
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[E] HPLC Assay; Trial 3

Ring-opened Analog Formation Via Radical-mediated Mechanism.
The results of the chemically induced ring-opening experiments were inconclusive.
Incubation of the cyclobutanone with AIBN showed no production of the ring opened C10GABA product at 2 hrs and 8 hrs sampling by HPLC analysis (Table 16C). Fenton-like reaction
conditions by the addition of FeCl2 to the H2O2 were shown to lead to decomposition of 2 with
no observable formation of 3 by HPLC (Table 16D). Incubation with H2O2 only showed
evidence of 3 in small amounts, observable by HPLC, when the cyclobutanone 2 was subjected
to high concentration of 30 % H2O2 (Table 16E). However, we were unable to reproduce this
result and without LC-MS capabilities we could not confirm if this very minor byproduct
corresponds to the C10-GABA.
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Table 16. HPLC Analysis of radical-mediated cyclobutanone ring opening under various
conditions.a
*VW D1 A, W avelength=205 nm (161008A\031-0101.D - 161008A\001-0601.D)

[A]

m AU
800
700
600
500
400
300
200
100
0
0
2
4
6
8
*VW D1 A, W avelength=205 nm (161008A\041-0301.D - 161008A\001-0601.D)

10

12

14

16

18

m in

10

12

14

16

18

m in

10

12

14

16

18

m in

10

12

14

16

18

m in

m AU

[B]

300
200
100
0
0
2
4
6
8
*VW D1 A, W avelength=205 nm (161008A\011-0401.D - 161008A\001-0601.D)
m AU

[C]

150
125
100
75
50
25
0
-25
0
2
4
6
8
*VW D1 A, W avelength=205 nm (161008A\022-0501.D - 161008A\001-0601.D)
m AU
250

[D]

200
150
100
50
0
-50
0

2

4

6

8

*VW D1 A, W avelength=205 nm (160915A\071-0301.D - 160915A\001-0801.D)

[E]

m AU

700

600

500

400

300

200

100

0
10.2
10.4
10.6
10.8
*VW D1 A, W avelength=205 nm (160915A\072-0401.D - 160915A\001-0801.D)

11

11.2

11.4

11.6

11.8

12

m in

11

11.2

11.4

11.6

11.8

12

m in

m AU

6

5

4

3

2

1

0

10.2

10.4

10.6

10.8

a

A) Standard of N-(2-oxocyclobutyl)decanamide (2), B) Standard of 4-decanamideobutanoic
acid (3), C) AIBN mediated reaction at 2 hours, D) H2O2-mediated reaction at 2 hours with low
concentration H2O2. E) Zoom in comparison view of Control spectrum 3 (Top) and H2O2mediated reaction at 30 % H2O2 concentration (bottom).
Product-Based Transition-State Modeling Analysis.
The X-ray co-crystal structure containing the ring-opened C10-GABA analog was used
to model the intact C10 cyclobutanone and tetrahedral transition state mimetic bound to the
metal center in an effort to understand substrate recognition and critical enzyme mechanistic
machinery. We have employed the in silico modeling technique that we refer to as “ProductBased Transition State Modeling” (PBTSM) to model the hypothetical cyclobutanone and the
catalytic water/hydroxide bound to AiiA_Co models respectively as well as the cyclobutanone
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tetrahedral transition state mimetic bound AiiA_Co model. This technique, described in Figure
57 above, employed the ring-opened C10-GABA analog-bound co-crystal structure as a starting
point to generate these models in reverse chronology back through the substrate tetrahedral
intermediate and further back through two distinct cyclobutanone / catalytic water-hydroxide
binding modes.
The atomic coordinates of the structurally prepared model of the C10-GABA bound
AiiA_Co crystal structure, C10-GABA-prod_AiiA_Co were used to generate three additional
AiiA molecular models of cyclobutanone inhibitor species at key stages along the enzyme’s
hypothetical catalytic trajectory, which inclue the C10-CB_HOH_AiiA_Co cyclobutanone
inhibitor bound with inactivated catalytic water model, C10-CB_OH_AiiA_Co cyclobutanone
inhibitor bound with activated catalytic hydroxide model, and the C10-CB-TS_AiiA_Co
transition state mimetic bound model after nucleophilic attack at the cyclobutanone carbonyl by
the catalytic hydroxide.
Analysis of the binding interaction reveals how the TS mimetic may be stabilized in the
active site before X-ray radiation opening of the cyclobutanone ring. Figure 62 shows the
tetrahedral transition state mimetic carbonyl oxygen (-O) makes H-bond interaction between the
side chain of Try194 and Co2.2 while the catalytic hydroxyl oxygen forms interactions with both
cobalt ions as well as the protonated general acid base Asp108. As discussed in Chapter 2, the
propensity for a dinuclear metalloenzyme to utilize both an organic H-bond donor and inorganic
species to form a pseudo-oxianion hole to achieve polarization of the carbonyl suggested a
common mechanistic feature among dinuclear metalloenzymes.
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Figure 62. Transition state mimetic stabilization by cobalt, Tyr194 and Asp108.
Additionally, this modeling analysis suggests that the C10 compound 2 forms a water
bridge between its amide NH and Tyr194 as well as the amide O between Phe107 backbone NH
& Glu136 backbone CO. These crystallographic waters were well defined in the X-ray
structures.
The free energy of binding was calculated for the four models using the Generalized Born
Volume Integral Weighed Surface Area (GBVI/WSA) ΔG method using MOE as previously
described in Chapter 2. Binding Affinity found for all four molecular models in the PBTSM
series were calculated and reported in Table 17.
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Table 17. GBVI/WSA ΔG Binding Affinity Calculations for PBTSM-Generated AiiA Structures.
Model ID

GBVI/WSA ΔG

C10-CB_HOH_AiiA_Co

-7.29 kcal/mol

C10-CB_OH_AiiA_Co

-6.67 kcal/mol

C10-CB-TS_AiiA_Co

-11.05 kcal/mol

C10-GABA-prod_AiiA_Co

-11.60 kcal/mol

The binding affinity calculations shows an exothermic reaction profile with a clear
downhill trend from bound cyclobutanone to the observed crystallographic product.
Conclusion
The employment of small molecule peptidomimetic derivatives to mimic peptide
conformational ensembles is critical in drug discovery toward the development of new
pharmaceuticals. The results disclosed above suggest formation of the hypothesized transitionstate memetic occurs but is destroyed upon exposure to high intensity X-ray irradiation during
data collection. This would suggest that the cyclobutanone moiety can be utilized as a warhead
in targeting alternative di-metalloproteins metal centers for future studies. Ligand hydrocarbon
tail access to the hydrophobic phenylalanine clamp binding site favored chain lengths of 10
carbon versus 6 carbons for optimum interaction for the ligand at the metallocenter. We have
contemplated that more potent inhibitors could be synthesiszed with less flexible side chains.
These results seem to suggest that ligand access to the hydrophobic phenylalanine clamp
binding site is favored for optimum binding to the active site, and the α-amido cyclobutanone
moiety has the potential utility as a transition-state mimetic warhead in targeting alternative dimetalloproteins metal center in the future. Thus, targeted inhibitors utilizing cyclobutanone
derivatives could provide a rapid entry into inhibitors of other metalloenzymes enzyme for
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treatment of human disease including bacterial infection. Therefore, the cyclobutanone
functional group possesses the potential as a general molecular warhead for target di-nuclear
metalloenzyme inhibition.
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Experimental Section

1
Synthesis of N-(2-oxocyclobutyl)hexanamide (1). To a 10 mL round bottom flask fitted with a
condenser was added hexanamide (100 mg, 0.868 mmol), 1,2-bis(trimethylsilyoxy)cyclobutene
(242 μL, 0.955 mmol), dry THF (2.0 mL) and 1M HCl-ether (2.0 mL) at rt. The reaction mixture
was agitated with magnetic stirring under inert argon atmosphere and heated under reflux at 55
o

C for 3 hrs after which time HPLC and TLC (Rf = 0.2 at 4:6 ethylacetate-petroleum ether) with

PMA staining indicated consumption of hexanamide starting material. Once the reaction was
complete the solution was concentrated to dryness at 1 atm using an 80 oC heat bath. The
resulting crude syrup was dissolved in ether which was purified by passing through a 4 g silica
gel flash cartridge, using PMA stain to monitor for desired product. The product was eluted from
the column with ether-petroleum ether (1:1) mobile phase to afford the title cyclobutanone 1
(11.8 mg, 72%) as a clear oil. 1H NMR (500 MHz, CDCl3): δ 5.26 (tdd, J = 10.1, 5.9, 4.3 Hz,
1H), 4.93 – 4.79 (m, 2H), 4.30 (dq, J = 11.7, 4.5 Hz, 2H), 4.16 (ddd, J = 11.9, 5.9, 2.4 Hz, 2H),
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3.62 – 3.54 (m, 1H), 2.85 – 2.64 (m, 1H), 2.41 – 2.28 (m, 4H), 2.25 – 2.13 (m, 1H), 2.10 – 2.07
(m, 6H), 2.04 (s, 5H), 1.86 (dtt, J = 13.5, 6.4, 4.3 Hz, 4H), 1.62 (dq, J = 11.3, 7.1 Hz, 7H), 1.51
(q, J = 6.3 Hz, 10H), 0.97 – 0.83 (m, 3H).
HPLC purity = Found to be 98 % pure at 220 nm.
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2
Synthesis of N-(2-oxocyclobutyl)decanamide (2). To a 10 mL round bottom flask fitted with a
condenser was added decanamide (200 mg, 1.168 mmol), 1,2-bis(trimethylsilyoxy)cyclobutene
(326 μL, 1.284 mmol), dry THF (2.7 mL) and 1M HCl-ether (2.7 mL) at rt. The reaction mixture
was agitated with magnetic stirring under inert argon atmosphere and heated under reflux at 55
o

C for 3 hrs after which time HPLC and TLC (Rf = 0.07 at 1:1 ether-petroleum ether) with PMA

staining indicated consumption of decanamide starting material. Once the reaction was complete
the solution was concentrated to dryness at 1 atm using an 80 oC heat bath. The resulting crude
syrup was dissolved in ether and was purified by passing through a 4 g silica gel flash cartridge,
using PMA stain to monitor for desired product. The product was eluted from the column with
ether-petroleum ether (1:1) mobile phase to afford the title cyclobutanone 2 (152.6 mg, 55 %) as
a white crystalline solid. 1H NMR (500 MHz, d6-DMSO): δ 8.28 (d, J = 7.5 Hz, 1H), 4.77 (m,
1H), 3.32 (s, 2H), 2.87 (m, 1H), 2.84 (m, 1H), 2.18 (ddd, J=20, 10.5, 4.5Hz, 1H), 2.06 (t, J = 7.3
Hz, 2H), 1.96 (m, 1H), 1.46 (m, J = 7 Hz, 2H), 1.24 (bs, 12H), 0.85 (j, J = 6 Hz, 3H). 13C NMR
(500 MHz, d6-DMSO): δ 207.02, 171.82, 63.47, 41.13, 34.34, 31.24, 28.85, 28.61, 28.49, 25.05,
22.07, 18.33, 13.90. HPLC purity = Found to be 98 % pure at 220 nm. 13C NMR (500 MHz, d6DMSO): δ 207.2, 207.1, 171.8, 41.1, 39.7, 39.5, 39.3, 39.2, 39.0, 34.7, 28.5, 25.0, 13.9, 13.8.
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3
Synthesis of 4-decanamideobutanoic acid (3). γ-Aminobutyric and trimethylamine was
suspended in dry methanol in a 4 g dram vial. The reaction mixture was cooled to 0 oC over 5
min before decanoyl chloride was added to the vial in 5 portions of 38 μL over 5 min while
under continuous inert gas stream. The reaction was sealed and stirred for an additional 1 h at 0
o

C before being allowed to warm to room temperature overnight upon which HPLC indicated

consumption of starting material. The reaction mixture was concentrated to dryness before being
taken up in 10 mL of DI H2O and 10 mL of 1M HCl. The product was extracted with 3x with 10
mL chloroform which were combined and dried over sodium sulfate followed by filtration and
concentration to dryness under reduced pressure.190 The resulting white product was left to dry
overnight under high vacuum to afford the title compound 3 (226 mg, 88 %) of a white
crystalline solid. HPLC of crude product shows 98 % pure without purification. 1H NMR (500
MHz, DMSO-d6): δ 12.00 (bs, 1H), 7.76 (t, J = 5.4 Hz, I H, H-N), 3.34 (bs, solvent, H2O), 3.03
dt, J =12.8, 6.8 Hz, 2 H), 2.5 (m, solvent, DMSO), 2.19 (t, J = 7.5 Hz, 2H), 2.02 (t, J = 7.5 Hz, 2
H), 1.59 (quin, J = 7.2 Hz, 2 H), 1.46 (quin, J = 7.3 Hz, 2 H), 1.29-1.18 (m, 12 H), 0.85 (t, J = 6
Hz, 3H). 13C NMR (500 MHz, DMSO-d6): δ174.1, 172.0, 37.8, 35.4, 31.2, 31.0, 28.9, 28.7, 28.6,
25.3, 24.6, 22.1, 13.9.
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CHAPTER SIX
GCN-5-RELATED N-ACETYLTRANSFERASE (GNAT) BISUBSTRATE INHIBITORS
AND INSIGHT INTO KINETIC AND CHEMICAL MECHANISM
Abstract
The Gcn5-related N-acetyltransferase (GNAT) PA4794 from Pseudomonas aeruginosa
has been recently shown to specifically acetylate the C-terminal lysine residue of peptides,
although its native function remains unknown. As with many bacterial GNATs, their functions
have not yet been determined, which is further hampered by the lack of crystal structures of these
proteins with bound acceptor substrates. As part of our ongoing studies to functionally annotate
GNATs with unknown functions, we are using PA4794 as a model system for exploring efficient
formation of bisubstrate complexes to enhance our success rate in obtaining co-crystal structures
of GNATs with ligands bound in their acceptor sites. We have now synthesized and tested
substrate analogs of the previously identified N-phenylacetyl glycine lysine (NPAcGK) enabling
two separate three-dimensional structures of PA4794 with NPAcGK analog-derived bisubstrates
formed through direct reaction with CoA—the first through direct alkylation with a reactive
substrate, and the second through X-ray induced radical-mediated process. We also performed
docking and molecular dynamics simulations of the reverse reaction pathway from the NPAcGK
product back to formation of the tetrahedral intermediate/transition state to complement our
structural work.
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This allowed us to explore the key protein-ligand interactions within the active site of PA4794
and guide mutant synthesis and kinetics to determine the role of key residues in the active site.
Introduction
The three-dimensional structures of proteins with ligands bound in their active sites are
valuable tools because they provide a framework for determining residues available for binding
substrates or products over the course of an enzymatic reaction.194 In the present age where new
sequencing information greatly exceeds the experimental functional annotation of genes, an
additional advantage to liganded structures is that the mode of ligand binding in active sites
yields important information that can be used to more accurately predict protein function. In
collaboration with the Kuhn laboratories of San Fransisco State University (SFSU), one of the
aims of our research is to improve the structural and functional characterization of bacterial
proteins belonging to the Gcn5-related N-acetyltransferase (GNAT) superfamily. These proteins
use an activated acyl-donor (typically acetyl-coenzyme A (AcCoA)) to transfer an acyl group to
an acceptor substrate. The identity of the acceptor substrate can range from small molecules such
as polyamines, antibiotics, or arylalkylamines to peptides and proteins.195-197 Although many
proteins belonging to this family have been investigated, most of its members remain
uncharacterized with respect to substrates or function.
GNATs have two adjacent but distinct substrate-binding sites: (1) the acyl donor
substrate binding site, and (2) the acceptor substrate binding site. Many GNATs have yielded Xray structures with AcCoA/CoA bound,198 but it is less common to have ligands bound in the
acceptor substrate binding site. Furthermore, the acyl donor site is highly conserved, making
protein-CoA binding interactions in a newly-sequenced GNAT easier to predict, but the acceptor
substrate binding site, which is responsible for specificity, is quite diverse among GNATs.
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Currently, there are hundreds of structures of GNATs in the Protein Data Bank (PDB); however,
many of these do not have acceptor ligands bound in their active sites. Therefore, if the function
of the protein is unknown, it is extremely difficult to predict what possible ligands could
potentially bind, and even if the ligand is known, it is still not trivial to predict the binding mode
of ligands in this site. Obtaining structures of GNATs with bound acceptor substrates is therefore
crucial for understanding these enzymes, but has proven to be challenging, as even if the
function of the protein is known or potential acceptor substrates have been identified the
enzymes often may not bind the ligand in the crystal. Therefore, new approaches and tools are
needed to efficiently yield structures with acceptor ligands bound in order to successfully
observe and analyze binding modes of substrates.
One strategy for obtaining liganded structures has been to crystallize proteins in the
presence of bisubstrate inhibitors.199, 200 Bisubstrate inhibitors have also been employed in
medicinal chemistry in the design of more potent inhibitors, notably in the area of kinases with
both ATP and substrate binding pockets.201 The affinity of the enzyme for the bisubstrate is
typically significantly greater than that of the substrate alone; therefore, it is expected that the
enzyme will more efficiently bind the ligand in the crystal, which would enable an increase in
the number of liganded structures of those enzymes. Several GNAT structures have been
determined in the presence of bisubstrates, but they typically involve synthesis and isolation of
the full bisubstrate prior to crystallization.195-197, 202, 203 We propose a different approach for
obtaining structures of GNATs with bisubstrate inhibitors bound, where we synthesize the
analogs of the potential substrates and have the enzyme catalyze the formation of the bisubstrate
in the presence of CoA. The advantages to this approach are: (1) the synthesis and purification
procedures for acceptor ligands as opposed to full bisubstrates are simpler, (2) it reduces the
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quantity of costly CoA needed for formation of the bisubstrate, (3) many different acceptor
ligands can be tested using the same crystals, and (4) this approach can be used regardless of the
size of the substrate to be bound. This final advantage is important because the donor and
acceptor substrate binding sites of many GNATs are connected by a narrow tunnel, which would
not allow a fully formed large bisubstrate analog to thread through the active site. Allowing each
substrate to enter its respective binding site separately facilitates formation of a bisubstrate even
with a large or bulky acceptor substrate during crystal soaks or co-crystallization.
Crystal structures containing substrate, products, or intermediate-bound enzymes can be
extremely valuable tools for understanding the enzyme catalytic mechanisms; however, in many
cases it is not possible to capture and obtain a structure of an enzyme in a ligand bound form due
to factors such as rapid reaction and release of the products. Therefore, efficient methods for
obtaining crystal structures of GNATs with acceptor ligands bound are desirable. In our previous
work, we used a broad-substrate screening assay as a method to identify acceptor substrates for
an uncharacterized PA4794 GNAT enzyme from Pseudomonas aeruginosa204. Kuhn found that
PA4794 acetylates the dipeptide N-phenylacetyl glycine lysine (NPAcGK) and determined the
structure of the ternary complex with CoA and acetylated NPAcGK (PDB ID: 4L8A) as depicted
in Figure 63.205
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Figure 63. Gen5-related N-Acetyltransferase (4L8A).
Here, we have used the PA4794 enzyme as a model enzyme from the GNAT family to
develop a streamlined procedure for obtaining liganded crystal structures of GNATs. We believe
our approach is widely applicable across all members of the GNAT superfamily and will
advance the knowledge of modes of ligand binding in the acceptor site that will ideally lead to
more accurate computational methods of functional prediction or drug design. Furthermore,
substrates armed with alkylating agents can serve as covalent inhibitors with therapeutic
application, especially given the recent (re)acceptance of covalent inhibitors as drugs206 for
example as applied to protein kinases.207
Herein we describe two separate three-dimensional structures of PA4794 with NPAcGK
analog-derived bisubstrates formed in the active site through reaction with CoA, the first through
direct alkylation with a reactive substrate, and then provide evidence that the second bisubstrate
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was formed through X-ray induced radical-mediated addition to the alkene moiety of the
substrate analog. While a covalent interaction, particularly with an active site residue of an
enzyme, can trap an inhibitor in a higher energy conformation, we propose that the two different
structures reflect most of the key substrate-active site and product-active site interactions,
respectively, which is supported by molecular modeling that shows similar binding interactions
with the NPAcGK-derived acceptor molecules as in the covalently-bound bisubstrate. In
addition, molecular dynamics were employed from the NPAcGK product to simulate the reaction
pathway in reverse back to the tetrahedral intermediate/transition state and to explore the key
interactions with the active site. The key active site residues identified through the bound
bisubstrate structures and through molecular dynamics analysis were then interrogated through
the preparation and activity of synthesized mutants.
Results
Design of substrate analogs.
Majorek and Kuhn previously found that PA4794 acetylates the ε-amino group of
NPAcGK and prefers to acetylate a C-terminal lysine residue of peptides205, yet its native
function remains unknown. We chose this enzyme as a model system for exploring formation of
bisubstrates in GNATs because it is small and readily crystallizes, which makes it an ideal
protein to study mechanisms of ligand binding. To begin, we analyzed the 3D structure of the
ternary complex of PA4794 and its interactions with CoA and acetylated NPAcGK
(NPAcGAcK) peptide (PDB ID: 4L8A) and designed and synthesized reactive analogs of the
acceptor substrate that would react with CoA to form bisubstrates in the protein crystal. We
reasoned that electrophilic moieties installed near the ε-amino group of the acceptor substrate
should be capable of alkylating the thiol of free CoA to produce a bisubstrate in the active site of

230
the protein. To mimic the acetyl group transferred from CoA to the acceptor but with a reactive
moiety, we installed an α-haloacetyl group on the ε-nitrogen of the lysine. The α-haloacetyl
moiety has been utilized extensively as a group to alkylate active site residues in proteins208, and
in a similar approach, Hwang incorporated an α-haloacetyl moiety as a replacement for the acetyl
moiety of AcCoA, which was able to react with active site residues of acetyltransferases that use
AcCoA209. Our approach for synthesizing haloacetyl substrates is summarized in Scheme 13 and
was accomplished by reacting NPAcGK with chloroacetyl chloride or bromoacetyl chloride to
obtain compounds 2a and 2b, respectively. The PA4794 enzyme-mediated formation of
bisubstrate 3 occurred in the presence of CoA and these compounds in the active site.
Scheme 13. Synthesis of α-haloacetyl derivatives of NPAcGK 2a (X = Cl) and 2b (X = Br) and
enzyme-mediated formation of bisubstrate 3.

PA4794 does not O-acetylate the alcohol substrate analog.
Some GNATs are capable of both N- or O-acylating substrates210-212 and we were curious
if the PA4794 enzyme could O-acetylate NPAcGK if the ε-amino group was replaced with an
alcohol. Our strategy for synthesizing the alcohol 4 (Scheme 14) was to convert the ε-amino
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group to the transient diazonium salt with aqueous nitrous acid

213

and ultimately with sodium

nitroprusside214. As a by-product, the alkene 5 (Scheme 14) was produced via elimination, and
the mixture of 4 and 5 were inseparable by normal-phase chromatography or by small molecule
crystallization in our hands. Nonetheless, we expected the alcohol 4, as a direct analog of
NPAcGK, to serve as a potential acceptor molecule if PA4794 was indeed capable of Oacylation, whereas the alkene 5 was expected to be unreactive. Therefore, we proceeded with the
4/5 mixture for testing as a potential substrate and for co-crystallization/soaking experiments
given the bioisosteric nature of the hydroxyl for amino substitution. We found the PA4794
enzyme was not active toward the 4/5 alcohol/alkene mixture during our kinetic assays and
concluded that the enzyme was therefore specific for N-acetylation of this molecule.
Scheme 14. Formation of the alcohol/alkene mixture (4 and 5) from NPAcGK, and radicalmediated reaction of CoA with alkene 5 to form the covalent bisubstrate 6.
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Bisubstrate formation in crystals via an enzyme-mediated mechanism.
Crystals of the PA4794 protein were grown and soaked them with CoA, followed by
soaking with the 2a and 2b chloroacetyl and bromoacetyl analogs and screened crystals for
ligand binding. We found both analogs reacted with CoA to form bisubstrates 3 (Scheme 13,
Figure 66B) and exhibited identical binding modes in the structures. The bisubstrates were
formed via an enzyme-mediated mechanism whereby the enzyme active site placed the
compounds in close proximity for the SN2 displacement of the halide by the thiol of CoA.
Bisubstrate formation in crystals via a radical-mediated mechanism.
When we soaked crystals of PA4794 with CoA and the alcohol/alkene mixture (4/5), our
assumption was that the alcohol would bind preferentially in the active site of the enzyme, given
the alcohol’s ability to H-bond donate and accept, and the comparable steric volume to the amine
substrate. We were surprised to observe formation of bisubstrate 6 in the structure (Scheme 14,
Figure 66A). This was curious because both alcohol and alkene were expected to be chemically
unreactive. To determine the mechanism of bisubstrate formation between the alcohol/alkene
analog and CoA, we performed a series of tests to determine if it was produced enzymatically
from the alcohol 4 or alkene 5. Treatment of the 4/5 mixture with the PA4794 enzyme and CoA
did not give rise to any detectable bisubstrate 6 by HPLC. However, it is known that a thiol can
add to an alkene under free radical conditions,215 which could have been initiated during X-ray
data collection, so we tested whether or not the 4/5 mixture could produce a bisubstrate in the
presence of a source of radicals. Treatment of 4/5 and CoA with AIBN at 65 °C for 2 hours
showed complete consumption of the alkene 5 from the mixture and corresponding reduction in
the concentration of CoA (Figure 64).
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Figure 64. Experimental HPLC Assay Data. A) Discontinuous assay design to determine source
of C-S bond formation. Assay result HPLC Chromatogram for B) Control: Mix + Buffer, C)
Trial 1: HSCoA + Mix + Buffer, D) Trial 2: HSCoA + Mix + AIBN + Buffer.
There was no detectable effect on the concentration of alcohol 6, and the production of a
new polar peak close in retention time to CoA was shown to be bisubstrate 6 (Figure 65) by mass
spectrometry (M ¯ obs 1070.2). As a result, the formation of the bisubstrate 6 in the crystal
structure is likely due to a radical-mediated mechanism from radiation during data collection.
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Figure 65. A) MS and B) MS-MS Fragmentation Analysis of Trial 2 After Solid Phase Extraction
(SPE) Preparation.
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Two substrate analog binding modes reveal functionally important interactions.
The bisubstrate analogs formed in the present study through either an enzyme catalyzed
or radical mediated mechanism occupy both the AcCoA and acceptor substrate binding sites and
enable exploration of key interactions in both pockets. The bisubstrate 3 and 6 CoA moieties are
bound in similar conformations and through similar interactions as those of previously
determined PA4794 structures (PDB IDs pending, Figure 66A-B). Bisubstrate 6 binding is
similar to that of the acylated substrate observed in the ternary complex (PDB ID: 4L8A)
structure with NPAcGAcK (Figure 66C). In particular, the most critical charge-charge
interactions of the C-terminal carboxyl group of NPAcGAcK occur with Arg49 and the main
chain nitrogen of Asn80 as well as several water-mediated interactions. The phenylacetyl moiety
lies against a hydrophobic patch composed of residues Phe118, Phe27 and Pro31. The moiety
corresponding to the C-terminal lysine side chain of the bisubstrate 6 is shorter by four compared
to the acetylated lysine side chain of the product NPAcGAcK (Figure 66B). The bisubstrate
compound 3 (Figure 66A) in which the reactive moiety is longer, exhibits a different binding
mode compared to the acylated product shown in Figure 66C, but this can be attributed to the
longer-atom chain connecting the lysine mimetic to CoA. The modified acetyl-lysine moiety in
bisubstrate 3 is extended and is not as distorted as in the ternary complex structure. Specifically,
this is due to a movement of the C-terminal carboxyl group of the peptide that now interacts with
more surface exposed Arg141 instead of Arg49 (Figure 66A). Arg141 is located closer to the
binding pocket opening than Arg49 and allows a more extended conformation of the substrate
analog moiety, which is slightly less buried inside of the protein as compared to bisubstrate 6
(Figure 66B). In this case, additional interactions are observed between the ε-amino group and
the acetyl oxygen of the haloacetyl substrate analog derivative and the main chain oxygen of
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Ser116 and main chain nitrogens of Asn80 and Met81. The two distinct conformations of the two
bisubstrate analog moieties also induce significantly different conformations of Tyr68.

Figure 66. Comparison of binding products and bisubstrate 3 and 6 analogs. PA4794 is shown in
orange atoms with B-Factor ribbon diagram. Residues 19-37 are shown as wire-ribbons for
clarity. Ligand atoms represented as followed: CoA; dark green, NPAcGK from PDB ID:4L8A;
light green, inhibitor atoms attributed to bisubstrate 3 and 6; cyan & salmon respectively. (A)
PA4794 in complex with bisubstrate analog 6 synthesized from CoA and alcohol/alkene mixture
4/5 determined at 1.2 Å. (B) PA4794 in complex with bisubstrate analog 3 synthesized in the
active site from CoA and compound 2a determined at 1.4 Å. (C) Ternary complex structure of
PA4794 with the bound reaction products CoA and Nε-acetylated NPAcGAcK. (D) 2Fo-Fc
electron density map of the bound bisubstrate analog 6 (σ=1.0) (E) 2Fo-Fc electron density map
of the bound bisubstrate analog 3 (σ=1.0).
Importance of Arg49 and Arg141 residues of PA4794.
The binding mode of the bisubstrates revealed two arginine residues (Arg49 and Arg141)
that are implicated as playing a potentially important role in binding substrate and/or product. To
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elucidate whether these two residues were critical for activity, our collaborators in the Kuhn Lab
constructed alanine and glutamine mutants and compared their kinetic activity to the wild-type
enzyme (Figure 67). The polyhistidine tag could not be completely removed from all mutants;
therefore, the kinetic activity of all mutants and wild-type proteins were screened in the presence
of the tag for this experiment. The R49Q mutant was previously determined to display reduced
PA4794 catalytic activity, but included it here since the tag was not present previously.205 All
five mutants (R49A, R49Q, R141A, R141Q, and R49QR141Q) showed a significant decrease in
activity (between 3.5- and 23-fold decrease) compared to the wild-type enzyme, with the most
severe decrease seen for the double mutant. Replacing the more surface-exposed arginine
Arg141 with glutamine exhibited diminished activity compared to the wild-type protein, but its
replacement with alanine showed a greater decrease in activity. Arg49 mutations also led to
decreased activity relative to wild-type, but the glutamine and alanine mutants showed opposite
effects compared to the Arg141 mutants: the R49A retained greater activity relative to R49Q.
Regardless, it is clear that both of these residues are important for binding peptide, and at least
one needs to be present for catalysis to occur.
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Figure 67. Substrate saturation curves for wild-type and Arg49 and Arg141 mutants. Steady-state
enzyme kinetic experiments were performed by holding AcCoA concentration constant at 0.5
mM and varying NPAcGK peptide concentration. Standard deviations for all proteins are shown.
See Experimental procedures for details.
Product-Based Transition-State Modeling Approach.
To complement our enzyme kinetics results and elucidate potential roles of residues
during catalysis, the in silico modeling method we refer to as “Product-Based Transition-State
Modeling” (PBTSM) (See Experimental Procedures for details) was used to elucidate
hypothetical substrate and tetrahedral intermediate binding modes for PA4794. This method
proceeds in reverse chronological reaction order beginning with reaction products and
progressing back through the tetrahedral intermediate toward the original substrates. The process
is summarized in Figure 68. Crystallographic data of enzymatic reaction products (PDB ID:
4L8A) or bisubstrate 3 were used as a starting point to systematically backtrack through the
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catalytic intermediate steps to computationally guide the placement of atoms that would occur
during formation of the tetrahedral intermediate and substrate binding.

Figure 68. Product-Based Transition-State Modeling (PBTSM). Protocol for systematic
remodeling of tetrahedral intermediate and substrate binding modes from product or bisubstrate
bound crystal structures. Molecular Minimization (MM) and Molecular Dynamics (MD) stages
in the protocol are shown.
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Active site regions important along the reaction trajectory.
Using bisubstrate bound crystal structures and PBTSM, we identified a set of important
regions of the active site that may help stabilize tetrahedral intermediate formation for the
catalytic reaction to proceed. For instance, we identified a potential oxyanion hole composed of
the backbone amide hydrogen of Met81, the alpha carbon hydrogen of Cys29, and the backbone
amide hydrogen of Asn80 through a water molecule that could stabilize the negatively charged
oxygen of the tetrahedral intermediate (Figure 69A, blue circle). The water observed in the
crystal structure is present at a nearly identical site as the one observed using the PBTSM
protocol, which suggests it plays an important role in the acetyl transfer mechanism when the
system is solvated. We also observed that H-bonds were formed directly through two backbone
carbonyl oxygens of Ser116 and Leu78 or indirectly through a water molecule to stabilize the
nucleophilic approach of the ε-amino group of NPAcGK during formation of the tetrahedral
intermediate (Figure 69A, red circle). Two important arginine residues stabilize the C-terminal
carboxyl group of the NPAcGK substrate (Figure 69A, purple square). Placement of the carbonyl
oxygen atom into the oxyanion hole allowed for the accompanying elements involved in
formation of the tetrahedral transition state intermediate leading to acetyl transfer to be
recognized. A shallow hydrophobic pocket containing Leu78, Ile115, Tyr128 and Met81
residues was also observed to accommodate the methyl of the acetyl group. Finally, the model
indicates that the sulfur of CoA forms a stabilizing H-bond interaction with Tyr128 and an
ordered water molecule. This catalytic tyrosine has been predicted to play a role as a general acid
capable of reprotonating CoA after transfer of the acetyl group to the acceptor substrate has
occurred.205 This ordered water makes further interactions with the backbone carbonyl of Tyr28,
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while H-bond donation varies between the backbone amide of Phe118 and the side chain amide
of Ans121. The PBTSM generated transition state models are shown in Figure 69B and 69C.
A

B

C

Figure 69. Product-Based Transition-State Modeling Analysis. A) Schematic diagram of
tetrahedral transition state intermediate indicating major regions of substrate-enzyme interactions
in the active site, including substrate C-terminal carboxylate stabilizing interactions (black
square), oxyanion hole (blue circle), and stabilizing interactions for substrate amine approach
(red circle). PBTSM generated transition state models are shown in panels B and C. B)
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Transition state model based on PA4794 co-crystal structure with products bound (PDB ID:
4L8A) shown in light green. C) Transition state model based on PA4794 structure in complex
with bisubstrate 3 shown in cyan. The CoA moiety of the tetrahedral intermediate is shown in
dark green and protein side chains are in orange. Amino groups are in dark blue, oxygens in red,
sulfurs in yellow, and waters as red and white spheres.
Kinetic mechanism of PA4794 toward NPAcGK.
GNAT enzymes typically use either a direct transfer mechanism whereby both substrates
bind to the enzyme simultaneously and the acetyl group from AcCoA is transferred directly to
the substrate, or they use a ping-pong or double-displacement mechanism with an indirect
transfer of the acetyl group via an acetyl-enzyme intermediate. In the latter mechanism, AcCoA
binds first and transfers the acetyl group to a residue in the enzyme active site and then CoA
leaves and acceptor substrate binds and the acetyl group is transferred from the enzyme to the
acceptor substrate. Since our PBTSM modeling experiments predicted a tetrahedral intermediate,
which is indicative of a direct transfer mechanism, we performed enzyme kinetic assays and
performed kinetic model testing to experimentally determine which kinetic mechanism was
preferred for PA4794. Similar to other GNATs, Filippova and Kuhn found the PA4794 protein
indeed uses a bisubstrate steady-state kinetic 216, 217which infers an overall direct transfer of the
acetyl group to the acceptor substrate through a transition state intermediate. Thus, our in vitro
and in silico results are compatible.
Overall PA4794 reaction sequence.
Based on our combined results, we propose the sequence of substrate approach, acetyl
transfer and final product release in PA4794 occurs as follows. Our kinetic mechanism results
indicate there is no specific order for binding AcCoA or NPAcGK, thus the substrates may
approach the active site in a random order. When the NPAcGK substrate binds, its C-terminal
carboxylate interacts with Arg141 (located near the binding pocket opening) or ARG49 (located

243
closer to the catalytic center), and the lysine moiety approaches the catalytic site as a neutral
species, having been deprotonated by bulk solvent or an unidentified basic residue near the
active site.205 The nucleophilic ε-amino group of NPAcGK is guided into the correct
conformation by residues that stabilize the incipient positive ammonium species while the acetyl
oxygen takes its place in the oxyanion hole. Immediately following formation of the tetrahedral
intermediate, the bond between the carbonyl carbon and the sulfur breaks while the negative
charge on sulfur is stabilized and ultimately protonated by Tyr128. Protonation may come from
bulk solvent or from deprotonation of positively charged ammonium species. The acetylated
NPAcGKAc product and CoA would leave the active site and the catalytic cycle would continue.
The proposed PA4794 chemical mechanism for acetyltransfer is shown in Figure 70.

Figure 70. Proposed chemical mechanism for PA4794 acetyl transfer.
Discussion
We have designed two types of tools that utilize different mechanisms to form bound
bisubstrates in GNAT protein crystals: 1) chloroacetyl/bromoacetyl derivatives of an acceptor
substrate using an enzyme-mediated mechanism and 2) addition of a thiol to an alkene derivative
of acceptor substrate via a radical-mediated mechanism. We chose to use the PA4794 protein of
unknown native function from P. aeruginosa as a model system to test our bisubstrate tools since
its crystallization is highly reproducible, with fast growth of crystals that typically give high
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resolution structural data. Upon soaking crystals of PA4794 with the chloroacetyl derivative of
PhAcGK 2a in the presence of CoA followed by structure determination, we observed that the
protein enzymatically formed a covalent bisubstrate (Figure 66B) occupying both AcCoA and
acceptor substrate sites. Incubation of PA4794 crystal with bromoacetyl substrate 2b yielded an
identical bisubstrate-bound complex. Thus, either organic halide can be used to produce the same
enzyme-mediated bisubstrate binding mode.
The formation of bisubstrate 6 was unexpected, but can be attributed to radiation-induced
free-radical-mediated addition of the thiol to the alkene moiety of 5. We hypothesized that
bisubstrate 6 was not produced enzymatically, but rather through exposure to free radicals
produced by X-ray irradiation during data collection (Scheme 14). X-Ray induced chemical
modification of specific moieties is well documented, and sulfur-containing residues are
particularly susceptible.218 Scheme 14 presents a mechanistic hypothesis for the formation of
bisubstrate 6 in the active site mediated by hydroxyl radicals produced from the interaction of
radiation with ubiquitous water molecules in and around the active site. H-atom abstraction from
CoA by a hydroxyl radical would yield the thiol radical which could rapidly add to the carboncarbon double bond of alkene 5 yielding a secondary radical, which can abstract a hydrogen
atom from water or a nearby residue to obtain bisubstrate 6. The same overall mechanism is
expected in the AIBN-mediated process with H-atom abstraction from CoA by the
isobutyronitrile radical produced from loss of nitrogen from AIBN.
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Scheme 15. Mechanistic hypothesis for the formation of bisubstrate 6 from CoA and alkene 5.

The radical-mediated addition of the thiol moiety of CoA has not been previously
employed to prepare S-alkylated derivatives of CoA, and as demonstrated, this method may be
used to prepare bisubstrates of acyltransfer enzymes that employ CoA. There are several reports
of the conjugate Michael addition of the thiol moiety of CoA to enones219-221 but 1,4-addition
requires an activating group, typically a carbonyl.
The results of the enzyme-mediated and radical-mediated bisubstrates combined with
PBTSM and enzyme kinetics studies provided new information regarding key residues that are
important for PA4794 substrate binding and tetrahedral intermediate interactions. The two
different binding modes of both types of bisubstrates revealed two arginine residues that could
interact with the carboxylate of the NPAcGK substrate: ARG49 and Arg141. The alkyl side
chain of the C-terminal lysine of the substrate is less distorted in the bisubstrate 3 structure
compared to bisubstrate 6 and ternary complex (PDB ID: 4L8A) structures due to its interaction
with Arg141 compared to ARG49. The carboxylate of bisubstrate 3 interacts in this manner
because the bisubstrate is formed by attacking the alpha-CH2 of the chloroacetyl group rather
than the acyl C=O carbon for formation of bisubstrate 6, which provides an extra methylene and
lengthens the molecule. In absence of the complex structure with bisubstrate 3, we would not
have identified Arg141 as a potentially important residue for ligand binding. It appears that
either arginine residue can be present for catalysis to occur, albeit to a lesser extent, but turnover
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is dramatically decreased when both are not present. Since the native substrate of this enzyme is
not yet known, these results provide new information about the architecture of the active site that
is critical for catalysis.
Our study has expanded the tools for forming bisubstrates for GNAT structure
determination and can be applied to other acyltransferases, which indicates broad applicability
across enzyme families and types of acceptor substrates. In particular, our serendipitous radicalmediated approach for producing bisubstrates could improve the quantity of acyltransferase
crystal structures obtained in complex with specific ligands. Since PA4794 is specific for
acylating a C-terminal lysine residue, we consider it a model system for identifying the best
chemical approaches for studying and designing specific inhibitors for other lysine
acetyltransferases, such as histone acetyltransferases.
Conclusions
We have documented two methods of obtaining bisubstrate-CoA molecules in the active
site of our model GNAT, one through traditional chemical processes through a substitution
reaction of the thiol-CoA with an alpha-acetyl halide, and one through an interesting new route,
creating the bound bisubstrate molecule using an X-ray radical catalyzed mechanism to form the
Lig-C-S-CoA bond. The new bisubstrates in combination with our prior studies and the PBTSM
method have shed light on the theoretical substrate binding mode and identification of
importance of two arginine residues that can accommodate the same tetrahedral intermediate
stabilizing residues found in the active site of the protein, and expanded upon the existing
crystallographic strategies for improving ligand bound GNAT structures. We have used this data
to guide mutation studies and in silico modeling studies to answer questions regarding
mechanism of acetyl transfer in the native enzyme.
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Experimental Section
Materials.
All solvents were distilled prior to use, and all reagents were used without further
purification unless otherwise noted. All synthetic reactions were conducted under a nitrogen
atmosphere. Silica gel 60 Å, 40−75 μm (200 × 400 mesh), was used for column
chromatography. Aluminum-backed silica gel 200 μm plates were used for TLC. 1H NMR
spectra were obtained using either a 300 MHz spectrometer or a 500 MHz spectrometer with
trimethylsilane (TMS) as the internal standard. 13C NMR spectra were obtained using a 75 MHz
spectrometer or a 125 MHz spectrometer. HRMS spectra were measured on a TOF instrument by
electrospray ionization (ESI). Acetyl coenzyme A (AcCoA) and coenzyme A (CoA) trilithium
salts and N-phenylacetylglycine lysine (NPAcGK) were purchased from Sigma-Aldrich. All
other reagents for biochemical assays were purchased at the highest quality available.
Chemistry.
NPAcGK (1) was reacted with chloroacetyl chloride, and also with bromoacetyl bromide,
affording electrophilic derivatives 2a and 2b, respectively (Scheme 13). As detailed below, 2a
and 2b both yielded the same bisubstrate 3 in the active site of PA4794. We employed a classic
nitrous acid conversion of the primary ε-amine of the lysine moiety of NPAcGK to obtain a
mixture of the alcohol 4 and alkene 5, produced by reaction with water, or by elimination,
respectively (Scheme 14). We found that the diazonium reaction utilizing sodium
nitroprusside214 was milder and higher yielding than the traditional sodium nitrite and
hydrochloric acid. The mixture of 4 and 5 proved to be inseparable with normal-phase
chromatography, nevertheless this provided the mixture to test as a potential substrate for the
enzyme, as well as providing material for cocrystallization.
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2a
Synthesis of N6-(2-chloroacetyl)-N2-((2-phenylacetyl)glycyl)-L-lysine (2a). K2CO3 (46.0 mg,
0.33 mmol) was added to a solution of NPAcGK 1 (53.0 mg, 0.165 mmol) in deionized water
(0.55 mL). The reaction mixture was then cooled in an ice bath and chloroacetyl chloride (19.8
μL, 28.0 mg, 0.248 mmol) was added under nitrogen slowly over several minutes via micro
syringe, and the reaction was allowed to warm to RT over 4 hours. The pH of the reaction was
adjusted to 4 by adding 4N HCl before liquid/liquid extraction with three portions of ethyl
acetate to recover the desired product. The combined organic fractions were washed with brine
and dried over magnesium sulfate before being concentrated under reduced pressure to afford the
desired chloroacetyl derivative 2a as a colorless glass (34 mg, 52 %): 1H NMR (500 MHz, 1:3
CDCl3 + d6-DMSO): δ 12.7 (bs, 1H), 7.91 (t, J=5.5 Hz, 1H), 7.78 (t, J= 5.0, 1H), 7.65 (d, J=8
Hz, 1H), 7.32-7.21 (m, 5H), 4.37 (dt, J=8.5, 5 Hz, 1H), 3.96 (s, 2H), 3.86 (d, J=5.5 Hz, 2H), 3.56
(d, J=2 Hz, 2H), 3.16 (q, J=6.5 Hz, 2H), 1.84-1.77 (m, 1H), 1.62 (m, 1H), 1.47 (n, J=7 Hz, 2H),
1.32 (m, 2H); HRMS (MH)+ calc for C18H25ClN3O5, 398.1483; found, 398.1477.

249
A

B

250
C

D

E

Spectrum Identification Results: + Scan (0.191-0.240 min) Sub (CTR-B-29. D (2a))

251
S

a

m

p

l

e

Inj Vol

N

a

m

e

CTR-B-29

Position

20

InjPosition

P1-A3

Instrument Name
SampleType

Instrument User Name
1
IRM Calibration Status
Sample

S

Success

a

m

p

l

e

Inj Vol

N

a

m

e

CTR-B-29

Position

20

InjPosition

P1-A3

Instrument Name
SampleType

Instrument User Name
1
IRM Calibration Status
Sample

Success

Figure 71.: Spectral data for N6-(2-chloroacetyl)-N2-((2-phenylacetyl)glycyl)-L-lysine (2a). A)
predicted 1H NMD, B) unprocessed 1H NMR, C) Mnova-processed 1H NMR, D) & COSY
NMR, E) HRMS.

2b
Synthesis of N6-(2-bromoacetyl)-N2-((2-phenylacetyl)glycyl)-L-lysine (2b). In a manner
analogous to 2a, bromoacetyl derivative 2b was prepared as a colorless glass (34 mg, 16 %): 1H
NMR (500 MHz, d6-DMSO): δ 13.03 (bs, 1H), 8.27-8.23 (m, 2H), 8.08 (d, J=8Hz, 1H), 7.317.19 (m, 5H), 4.17 (dt, J=8.5, 5Hz, 1H), 3.81 (s, 2H), 3.76 (dd, J=29, 5.5Hz, 1H), 3.73 (dd, J=29,
6Hz, 1H), 3.48 (s, 2H), 3.04 (q, J=6Hz, 2H), 1.69 (m, 1H), 1.56 (m, 1H), 1.41-1.24 (m, 4H).
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Figure 72. Spectral data for N6-(2-chloroacetyl)-N2-((2-phenylacetyl)glycyl)-L-lysine (2a). A)
predicted 1H NMD, B) unprocessed 1H NMR, C) Mnova-processed 1H NMR, D) 13C NMR, E)
COSY NMR.
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Synthesis of (S)-6-hydroxy-2-(2-(2-phenylacetamido)acetamido)hexanoic acid (4) and (S)-2(2-(2-phenylacetamido)acetamido)hex-5-enoic acid (5). The NPAcGK anaologs 4/5 were
made according to scheme 16 below. NPAcGK (1) (100 mg, 0.312 mmol) was dissolved in
nano-pure H2O (4 mL) followed by 4 N NaOH (60 μL). The mixture was then heated overnight
at 60 °C. Sodium nitroprusside (115.1 mg, 0.386 mmol) was added to a separate vial and
dissolved in H2O (200 μL) with gentle heating. The nitroprusside was then added to the
NPAcGK basic solution slowly with alternating 30 μL portions of nitroprusside followed by 30
μL of 4 N NaOH over 35 min, total volume equaling 150 μL iron catalyst and 170 μL NaOH.
The sample was then allowed to stir at 60 °C overnight. The pH of the reaction was adjusted to 4
by adding 4 N HCl before liquid/liquid extraction with three portions of ethyl acetate to recover
the desired product. The combined organic fractions were washed with brine and dried over
magnesium sulfate before being concentrated under reduced pressure to afford the desired
alkene/alcohol product mixture 4/5 as a colorless oil (30.1 mg, 30%). RP LC-MS analysis on a
Surveyor Liquid Chromatography system equipped with a Symmetry Shield RP18 column (5.0
μm, 100 Ǻ) and coupled to an LCQ Advantage Mass Spectrum System (Elution with a 5 %
CH3CN (0.1 v/v TFA)-H2O [A]/ 100 % CH3CN (0.1 v/v TFA) [B] at 1 mL/min flow rate and
Ttotal = 20 min. Solvent gradient of T0 min = 90 % A / 10 % B to T15 min = 10 % A / 90 % B until
gradient switch at T15.1 min back to 90 % A / 10 % B until T20 min) was performed. The alcohol 4
retention time was 5.067 min (MS m/z calc for C16H22N2O5 obs 322 and alkene 5 retention time
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was 7.414 min (MS m/z calc for C16H20N2O4 304, obs 304). The product mixture was used
without further purification.
Scheme 16. Synthesis of (S)-6-hydroxy-2-(2-(2-phenylacetamido)acetamido)hexanoic acid (4)
and (S)-2-(2-(2-phenylacetamido)acetamido)hex-5-enoic acid (5).
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Figure 73. HPLC and LC-MS Data for 4 & 5 Sample Mixture.
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Figure 74. NMR Trituration Experiment on 4 / 5 Product Mixture.
Determination of kinetic mechanism. The most compatible model for the WT PA4794
kinetic mechanism was determined as described previously216 where a series of four NPAcGK
substrate saturation curves at set concentrations of AcCoA (0.1, 0.25, 0.5, 1 mM) were produced
using cleaved 2.1 μM WT protein while varying NPAcGK concentrations from 0-25 mM.
Substrate analog test. To determine if the PA4794 enzyme could acetylate the NPAcGK
alcohol analog, we performed the following assay using the 4/5 mixture since the two
compounds could not be separated from each other. A 50 mM stock of the 4/5 mixture was
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prepared by dissolving the compounds in 50mM Bicine pH 9.0 buffer. Substrate saturation
curves were produced in triplicate using reactions (50 μL volume) containing 50 mM Bicine pH
9.0 buffer, 0.5 mM AcCoA, and varying concentrations of the 4/5 alcohol/alkene mixture (from
0-25 mM). The reactions were initiated with 5.1 μM WT cleaved enzyme and were processed as
described previously205.
Enzyme-mediated formation of bisubstrate with alkene.
To determine if the bisubstrate formation was enzyme-mediated, we prepared a 25 mM
stock solution of the 4/5 mixture in 50 mM Bicine pH 9.0. Reactions (50 μL) contained 50 mM
Bicine pH 9.0, 5 mM CoA, and 10 mM 4/5 mixture, and were initiated using either 1.1 or 11 μM
cleaved WT enzyme and incubated at RT for 19 hrs. Control reactions included: 1) no enzyme,
2) no enzyme and no 4/5 mixture, 3) and no enzyme, no 4/5 mixture, and no CoA. The next day
150 μL of MeOH was added to each sample, centrifuged for 5 min at 21,000 x g, and transferred
to an HPLC vial for analysis. No precipitate was observed.
HPLC analysis of enzyme-mediated formation of bisubstrate with alkene.
To analyze possible PA4794 enzyme-mediated formation of the bisubstrate, highperformance liquid chromatography (HPLC) analysis was performed according to a previously
described HPLC method193 with the following modifications. Samples were analyzed on a
Hewlett Packard 1050 series HPLC system with diode array detector (DAD) set to monitor 205
nm using a Regis Little Champ II ODS guard column coupled to a SymmetryShield RP18, 3.3
μm, 100A column. Filtered samples were loaded into standard size VWR autosampler HPLC
vials fitted with 300μL conical glass inserts. Samples were eluted on a 5% acetonitrile (0.1% v/v
TFA)-H2O [A]/ 5% acetonitrile (0.1% v/v TFA) [B] at 1 mL/min flow rate. A solvent gradient
from 90% A / 10% B at time 0 to 10% A / 90% B at time 15 min was used. At time 15.1 min the
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gradient was switched to 90% A / 10% B for a re-equilibration period until the end of the method
at time 25 min. Samples were additionally analyzed on a Surveyor Liquid Chromatography
system equipped with a SymmetryShield RP18, 5.0 μm, 100A column and a UV-Vis unit set to
monitor absorbance between 200-275 nm. The LC system was coupled to an LCQ Advantage
Mass Spectrometer System monitoring both positive and negative modes under full scan.
HPLC analysis of radical-mediated AIBN formation of bisubstrate with alkene.
The radical-mediated AIBN reaction was used to test for formation of the bisubstrate
with the 4/5 mixture in the presence of coenzyme A. A sample of the 4/5 mixture (2.2 mg, ~6.8
μmol) was dissolved in HPLC grade methanol (35μl) followed by addition of AIBN (300 mg,
0.34 μmol) and CoA (5.3 mg, 6.8 μmol). The reaction was stirred at 60°C over four hours and
then diluted with 2.0 mL of methanol. HPLC analysis was performed as described above.
AIBN mediated bisubstrate sample purification & LC MS/MS analysis.
Solid-phase extraction (SPE) was performed using an AASP Vac-Elut Model AI 6000
vacuum manifold from Analytichem International and was regulated to maintain a flowrate of 35 mL/min. The desalting procedure was performed using a 200 mg Oasis HLB resin (Waters)
extraction cartridge loaded with a 3 mg sample of concentrated bisubstrate as follows: The SPE
cartridge was conditioned with 1 mL acetonitrile followed by 1 mL of 0.1M triethylammonium
acetate buffer (TEAA) at pH 7. The crude sample was dissolved in 500 μL 0.1 M TEAA and
loaded onto the SPE cartridge. The cartridge was washed with 2 x 5 mL of 0.1 M TEAA
followed by 5 mL DI H2O to remove salts from the sample. The sample was recovered using
three consecutive 500 μL elutions of 70% acetonitrile-H2O. The purified analyte was then
analyzed with direct inject mass spectroscopy on a LCQ Advantage Mass Spectrometer System
monitoring negative mode under full scan. Mass calc. for C37H56N9O20P3S 1071.26, found
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1070.21. A MS fragmentation ion spectrum was also obtained for the ion peak at 1070 with a
2

30% fragmentation power.222
Protein Crystallization.
PA4794 protein crystals were grown by Karolina Majorek using vapor diffusion and
hanging drop setups. The crystallization drops were a 1 µl : 1 µl mixture of protein solution at 9
mg/mL and the precipitant composed of 2 M ammonium sulfate and 100 mM Bis-Tris pH 6.5.
To obtain structures of the PA4794 protein in the presence of bisubstrates, apo-form crystals
were soaked first with 5mM CoA, followed by adding 10 mM of the N6-(2-chloroacetyl)-N2((2-phenylacetyl)glycyl)-L-lysine 2a or mixture of (S)-6-hydroxy-2-(2-(2phenylacetamido)acetamido)hexanoic acid (4) and (S)-2-(2-(2-phenylacetamido)acetamido)hex5-enoic acid (5). Prior to data collection, each crystal was transferred to a solution containing a
2:1 mixture of precipitant solution and ethylene glycol and immediately cryo-cooled in liquid
nitrogen. Tracking and analysis of the experiments were performed with the LabDB and XtalDB
data management system.
Data collection, structure determination and refinement.
Data collection was performed at the 21-ID-G beam line of the Life Sciences
Collaborative Access Team at the Advanced Photon Source (APS). Data were collected at a
temperature of 100 K and processed with HKL-2000223. The PA4794 structure (PDB ID: 4L8A)
was used as a model to solve the structure of PA4794 in complex with bisubstrates by molecular
replacement (MR) using HKL-3000 224 coupled with MOLREP225. Refinement was performed
using HKL-3000226,227, 228 and selected programs from the CCP4 package (Collaborative
Computional Project, 1994). The atom B-factors were refined using anisotropic refinement.
Structure validation was performed using MOLPROBITY229 and ADIT230. Structures of PA4794
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in complex with two bisubstrates were determined: (A) (3R,20S)-1-(((((((2R,3S,4R,5R)-5-(6amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-3-hydroxy-2,2-dimethyl4,8,14-trioxo-20-(2-(2-phenylacetamido)acetamido)-12-thia-5,9,15-triazahenicosan-21-oic acid
(3) and (B) (2R)-5-((2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3(phosphonooxy)tetrahydrofuran-2yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3dimethylbutanamido)propanamido)ethyl)thio)-2-(2-(2-phenylacetamido)acetamido)pentanoic
acid (6). The coordinates, structure factors, and intensities were deposited in the PDB (PDB ID:
TBD).
In Silico Modeling.
Modeling and molecular dynamics simulations were performed using Chemical
Computing Group’s M.O.E. (Molecular Operating Environment).76 To understand the critical
components of the PA4794 acetyl transfer reaction mechanism, the crystal structure of the
PA4794 ternary complex (PDB ID: 4L8A) and the bisubstrate co-crystal structure obtained from
soaking chloroacetyl derivative 2a and CoA (PDB ID: TBD) were used to model the tetrahedral
intermediate expected to be generated during the acetyl transfer reaction of AcCoA (donor) and
NPAcGK (acceptor). Two separate models were prepared as starting points using MOE’s utility
Structure-Prep.76 First, the products of the enzymatic reaction were modeled based on the
conformation of bisubstrate 3 in the crystal structure using MOE’s utility 3D Builder by first
removing the bond between the bisubstrate sulfur of CoA and the acetyl methyl carbon of
NPAcGAcK. This left NPAcGK-εNHAc and HSCoA ligands bound to the active site of the
model. The 4L8A structure205 already possessed these two products so no remodeling of the
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second model was necessary. Next, the models were solvated in a simple water box at pH of 7.4
and treated with NaCl counter ions. Periodic boundary conditions were enabled, and the
hydrogen bonding network of the model was optimized by automatic sampling of different
tautomer/protomer states using Protonate3D102. Atoms were then optimized with a short,
localized molecular minimization (MM) using the MOE utility QuickPrep with receptor atom
tether constraint strength set to 10 and atoms further then 8 Å from the ligand fixed. Refinement
proceeded until a RMS Gradient of 0.1 kcal/mol/Å was reached. Molecular Dynamics
parameters were set to globally minimize the protein, ligand and solvent atoms of the models. To
minimize variables during in the simulation, the atoms involved in H-bonding between the betaalanine to beta-cysteamine amide bond were tethered to maintain the occupancy of the CoA in
the active site during the annealing process. Simulated annealing was then performed on the
product bound models. Molecular dynamics experiments were performed using a NPA algorithm
with a Amber12:EHT force field, an initial warming from 0-311 K over 100 ps with equilibration
at 311 K over 100 ps, and a 200 ps production stage at constant temperature followed by a 100 ps
cooling stage from 300-0 K.
The two equilibrated and optimized NPAcGK-εNAc + HS-CoA product models were
then remodeled to produce tetrahedral intermediate models. Another local minimization using
QuickPrep was performed to correct the distorted atomic bonds resulting from manual ligand
modification. Molecular dynamics simulations were performed to optimize the residue
interactions responsible for stabilizing the tetrahedral intermediate. A second simulated
annealing simulation was performed as described above except a 700 ps production stage at
constant temperature followed by a 100 ps cooling stage from 300-0 K was used. Binding
affinities for the molecular dynamics results were calculated based on tetrahedral intermediates.
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Similar modeling was performed using the MOE 3D Build utility to systematically transform the
tetrahedral intermediates for each model into corresponding substrate NPAcGK + AcCoA
models. The bond between N6 and the carbon of the acetyl was deleted and the double bond of
the carbonyl was reestablished, and the carbonyl oxygen and the nitrogen atoms were given a
neutral charge. Then, a third and final molecular dynamics simulation was performed to validate
the model using the same parameters as described above except with a 200 ps equilibration stage
and 700 ps production stage at constant temperature and a 100 ps cooling stage from 300-0 K.
The differences in binding modes between the two respective models for products, tetrahedral
intermediates and substrates were compared to determine the likely residues critical for acetyl
transfer and the most reasonable substrate approach to the active site.
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The molecular model and molecular dynamics files are saved with the format: ‘ligand
name’_(additional identifier)-‘receptor name and/or pdb code’_(conformation identifier)-(system
refinement state). An example would be: Penicillin_TS-NDM1_4RAW-sol-min-md, which
indicates the model contains a transition state intermediate of penicillin bound to the NDM1
structure, pdb code 4RAW, and which has been solvated and minimized followed by a molecular
dynamics production run. MOE will by default save every file in lower case so dashes and
underscores are used to communicate relating information and breaks in component train.
Underscores denote entries that are related while dashes indicate a break in relation. This is a
semi-cryptic method for saving, but very helpful for keeping track of in silico experiments in a
large library of rapidly generated files. It is recommended that refined and finished model
systems be saved often. Errors in experimental setup will happen often and it is easier to start
from a stable system when solutions cannot be found. It is also good to start from a common
starting point when performing variations of experiments on identical systems.

APPENDIX B
HIGH PERFORMANCE LIQUID CHROMOTOGRAPHY
ANALYTICAL METHODS
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Method CTV1.
Samples were analyzed on a Hewlett Packard 1050 series HPLC system with diode array
detector (DAD) monitoring wave lengths of 205 nm, 220 nm, 245 nm and 275 nm coupled with
a Zorbax SB-CN, 5.0 μm, 100 Å column. Filtered samples were loaded into standard size VWR
autosampler HPLC vials, injected, and eluted using 5 % acetonitrile (0.1 % v/v TFA)-H2O [A] &
5 % acetonitrile (0.1 % v/v TFA) [B] at 1 mL/min flow rate. Solvents eluted with gradient from
90 % A / 10 % B at time 0 to 10 % A / 90 % B at time 15 min was used. At time 15.1 min the
gradient was switched to 90 % A / 10% B for a re-equilibration period until the end of the
method at time 20 min.
Method CB254.
Samples were analyzed on a Hewlett Packard 1100 series HPLC system with Photo
Diode Array (PDA) detector monitoring 245 nm wavelength coupled with a SymmetryShield
RP18, 5.0 μm, 100 Å column. Filtered samples were loaded into standard size VWR autosampler
HPLC vials, injected, and eluted using 5 % acetonitrile (0.1 % v/v TFA)-H2O [A] & 5 %
acetonitrile (0.1 % v/v TFA) [B] at 1 mL/min flow rate. Solvents eluted with gradient from 90 %
A / 10 % B at time 0 to 10 % A / 90 % B at time 15 min was used. At time 15.1 min the gradient
was switched to 90 % A / 10% B for a re-equilibration period until the end of the method at time
20 min.
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